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ABSTRACT
Regulator of G Protein Signaling-12 (RGS12) in dopaminergic and kappa opioid receptordependent signaling and behavior

Joshua David Gross
Dopaminergic neurotransmission is critically involved in the etiology and treatment of
many psychiatric and neurological disorders. One modulator of dopaminergic neurotransmission
is the kappa opioid receptor (KOR) -- a G protein-coupled receptor (GPCR) that is densely
expressed within dopaminergic neurons and circuits. GPCRs are tightly regulated by a variety of
intracellular signaling molecules, including Regulator of G Protein Signaling (RGS) proteins.
Canonically, RGS proteins act as GTPase accelerating proteins (GAPs) on GTP-bound Ga
subunits following GPCR activation, thereby hastening the rate at which GPCR-mediated G
protein signaling is terminated. However, some RGS proteins exhibit more complex mechanisms
of action on cellular signaling. One such example is RGS12, which harbors the capacity to
regulate both G protein-dependent and -independent signaling cascades. RGS12 is widely
expressed across the developing and adult brain; we show that expression levels are notably high
within dopamine- and KOR-enriched regions. We also observed that Rgs12 mRNA exhibits
marked expression overlap with Oprk1 mRNA encoding KOR, which potently regulates
dopaminergic neurotransmission following environmental stress and pharmacological challenge
with psychostimulants. We revealed that genetic ablation of Rgs12 in mice upregulates dopamine
transporter (DAT) function and attenuates behavioral responses to psychostimulants via KORdependent mechanisms. Moreover, we showed that RGS12 differentially regulates G proteindependent versus G protein-independent signaling and behavior downstream of KOR activation.
We also demonstrated that RGS12 displays region-specific effects in the striatum, and that
RGS12 selectivity modulates KOR over other opioid receptors. Further studies are required to
more completely elucidate the complex interaction between RGS12 and KOR, as well as to
identify precisely the neuronal cell populations and brain regions mediating the effect of RGS12
on dopaminergic and KOR-dependent signal transduction and behavior.
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CHAPTER 1
General Introduction
1.1 - G Protein-Coupled Receptor Signal Transduction
1.1.1 - Background
All organisms must convert extracellular stimuli into intracellular signals to enable
physiological adaptation to the environment. A primary mechanism by which organisms transduce
extracellular cues into cellular responses is via membrane-bound, cell surface-expressed
receptor proteins (Gilman, 1987; Bockaert and Pin, 1999; Unwin, 1993; Ullrich and Schlessinger,
1990). The largest class of receptor proteins is G protein-coupled receptors (GPCRs), which
constitute more than 1% of the protein-coding human genome (Bockaert and Pin, 1999;
Fredriksson et al., 2003). GPCRs are ubiquitously expressed throughout the body, and they
respond to a diverse array of external stimuli, including neurotransmitters, hormones, ions, and
sensory cues, such as light and odor (Rosenbaum et al., 2009; Lagerstrom and Schioth, 2008;
Krishnan and Schioth, 2015). Accordingly, GPCRs represent the largest pharmacological drug
target class (Hauser et al., 2017; Santos et al., 2017).
GPCRs (also referred to as 7TMRs) contain seven transmembrane a-helices, with an
extracellular N-terminus, three extracellular loops, three intracellular loops, and an intracellular Cterminus (Geppetti et al., 2015; Rosenbaum et al., 2009). Inactive GPCRs couple to intracellular
heterotrimeric G protein complexes composed of a GDP-bound Ga subunit and an obligate Gbg
dimer (Hepler and Gilman, 1992; Gilman, 1987). Binding of a GPCR agonist (activating ligand)
induces conformational changes in the GPCR that promote the exchange of GDP for GTP (the
latter nucleotide in higher cytosolic concentrations) on Ga subunits, thereby acting as a guanine
nucleotide exchange factor (GEF). GTP-bound Ga subunits exhibit reduced affinity for the Gbg
heterodimer and, thus, Ga·GTP dissociates from Gbg heterodimers (Lambright et al., 1994; Neer,
1995; Oldham and Hamm, 2008). Heterotrimeric G protein complex dissociation reflects the ‘on’
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state of the receptor, as freed Ga·GTP subunits and Gbg heterodimers interact with various
intracellular effectors, including adenylyl cyclase, isoforms of phospholipase C, ion channels, and
many others. The engagement of specific effectors is predicated on the subtype of Ga subunit
(Freissmuth et al., 1989; Simon et al., 1991; Hart et al., 1998; Siehler, 2009). For example, Gas
activates adenylyl cyclase, resulting in the formation of cyclic adenosine monophosphate (cAMP)
(i.e., stimulatory activity) (Hausdorff et al., 1989), whereas Gai/o blocks this process (i.e., exerts
inhibitory activity) (Gilman, 1984). Effector signaling leads to a wide array of biological responses
over

short-

and

long-term

timespans,

including

neuronal

excitation/inhibition,

neurotransmitter/hormone release, and gene transcription (Clapham and Neer, 1997; Carman et
al., 1999; Simonds, 1999; Kammermeier et al., 2000; Lutz et al., 2007). Free Ga·GTP and Gbg
subunits continue to impact intracellular effector molecules until GTP is hydrolyzed back to GDP
via intrinsic GTPase catalytic activity of the Ga subunit (Cassel et al., 1979; Vuong and Chabre,
1991). Ga·GDP has a higher affinity for Gbg heterodimers, thus GTP hydrolysis drives restoration
of heterotrimeric complex formation and receptor coupling (i.e., the 'off’ state) until subsequent
GPCR activation (Neubig and Siderovski, 2002; Kimple et al., 2011; Siderovski DP, 2008)

1.2 - GPCR Regulation
1.2.1 - Regulators of G Protein Signaling
The termination of GPCR signaling is tightly regulated by intracellular signaling molecules
across a wide temporal scale (i.e., seconds to minutes to hours) (Berman and Gilman, 1998;
Kimple et al., 2011; Smith and Rajagopal, 2016a). Although Ga subunits harbor intrinsic GTP
hydrolysis activity, the spontaneous rate of this reaction is too slow to account for the physiological
processes engendered by GPCR activation (Vuong and Chabre, 1991; Angleson and Wensel,
1993; Breitwieser and Szabo, 1988). Regulators of G protein signaling (RGS) proteins serve as
the primary mechanism by which GTP is rapidly hydrolyzed from active Ga subunits and thereby
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act as the chief short-term negative regulators of G protein signaling in the cell. RGS proteins
exhibit GTPase-accelerating protein (GAP) activity on GTP-bound Ga subunits via a conserved
~120 amino acid RGS domain (Berman and Gilman, 1998; McCudden et al., 2005; Dohlman and
Thorner, 1997; Soundararajan et al., 2008). The RGS domain exhibits strong affinity for the
enzymatic transition state of Ga·GTP along its path of GTP hydrolysis. Once bound, RGS
proteins stabilize the positioning of an essential glutamate residue within the intrinsic Ga
catalytic region, thereby accelerating the rate of GTP hydrolysis to GDP + Pi (Kimple et al., 2011).
An extensive literature has demonstrated that loss of RGS protein expression in mice (e.g.,
RGS2, RGS4, RGS9-2) engenders increased GPCR sensitivity to agonist stimulation (e.g.,
(Heximer et al., 2003; Ruiz de Azua et al., 2010; Han et al., 2010; Zachariou et al., 2003;
Psifogeorgou et al., 2007), thus highlighting the importance of RGS proteins in vivo.
There are 20 classical RGS proteins, and these can be partitioned into smaller subfamilies
(R4, R7, R12, RZ) on the basis of sequence and protein domain homology. Notably, many other
protein classes contain an RGS domain, including G protein-coupled receptor kinases (GRKs),
nexins, ankyrins, AKAPs, and Rho-GEFs, but these are considered non-canonical RGS proteins,
as most of them do not exhibit Ga-directed GAP activity (Neubig and Siderovski, 2002; Sjogren,
2017). The largest (in number) and simplest RGS protein subfamily is the R4 family (e.g., RGS2,
RGS4, RGS21), which contains only a central RGS domain between the N- and C-termini.
Members of the RZ family exhibit a similar domain architecture, except that they each contain an
N-terminal post-cysteine segment that undergoes reversible palmitoylation. Members of other
RGS subfamilies contain multi-domain architectures capable of mediating protein-protein
interactions with adaptor proteins or regulating G protein-independent signaling. For example,
stable expression of RGS proteins within the R7 subfamily (i.e., RGS6, RGS7, RGS9, RGS11)
requires an obligatory physical interaction with Gb5 subunits via the N-terminal GGL (Gb-like)
domain (Chen et al., 2003; Snow et al., 1998b). In contrast, RGS12 (a member of the R12 family)
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contains an N-terminal PDZ domain that enables physical interactions with GPCRs expressing
C-terminal PDZ recognition motifs (Snow et al., 2002; Snow et al., 1998a). Another
distinguishable feature of R12 family members (e.g., RGS12, RGS14) is that these proteins are
capable of modulating G protein-independent signal transduction. Specifically, RGS12 and
RGS14 both contain tandem Ras-binding

domains (RBDs), which affect mitogen-activated

protein kinase/extracellular-signaling regulated kinase (MAPK/ERK) cascades (Willard et al.,
2009; Willard et al., 2007); furthermore, RGS12 (but not RGS14) contains an N-terminal
phosphotyrosine-binding domain that can modulate receptor-tyrosine kinase (RTK)-mediated
signaling (Willard et al., 2007). For a deeper discussion on the molecular mechanisms and
physiological outcomes of RGS12-dependent signaling, please see 1.2.1c - RGS12 and Its Role
in the CNS below. Comprehensive reviews on the sequence and biochemical differences between
RGS protein subfamily members can be found elsewhere (Siderovski and Willard, 2005; Neubig
and Siderovski, 2002; Siderovski DP, 2013).
RGS proteins can exhibit specificity for GPCRs on multiple levels. First, the RGS domain
displays Ga subunit specificity, although some can act upon multiple Ga subunit subtypes (Xu et
al., 1999; Soundararajan et al., 2008). However, to date, there are no identified RGS proteins
capable of acting as a functional GAP on Gas subunits (cf., (Zheng et al., 2001). Second, RGS
proteins can exhibit specificity for particular GPCRs via compatible amino acid sequences
between the RGS protein and its cognate GPCR. For example, RGS12 contains a PDZ binding
domain on its N-terminus that enables selective GPCR interactions via direct physical association
with GPCRs containing a C-terminal PDZ recognition motif (Snow et al., 1998a; Martemyanov et
al., 2003; Snow et al., 2002; Sambi et al., 2006). Lastly, RGS proteins can exert specificity for
GPCRs through differential and selective expression distributions across physiological systems
and tissues. A stark example of this phenomenon is the RGS9 splice variants RGS9-1 and
RGS9-2. The RGS9-1 isoform is exclusively expressed in rod and cone photoreceptors, where
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it serves as the critical GAP for rhodopsin (He et al., 1998), whereas RGS9-2 is almost
exclusively expressed in the striatum, where it acts on neurotransmitter GPCRs (Mancuso et
al., 2010).

1.2.1a - RGS Proteins in Neuronal Physiology
RGS proteins are widely expressed in the mammalian central nervous system (CNS)
(Gold et al., 1997; Larminie et al., 2004) and have been extensively linked to a wide variety of
neurological and psychiatric conditions (Rivero et al., 2012; Mirnics et al., 2001; Erdely et al.,
2006; Tekumalla et al., 2001). The functional role of RGS proteins in neuronal physiology has
been predominantly elucidated through the use of transgenic mice. Classically, constitutive and
conditional RGS knockout mice provided a method by which to investigate the role of specific
RGS proteins in vivo (Grillet et al., 2005; Zachariou et al., 2003; Oliveira-Dos-Santos et al., 2000;
Lee et al., 2010). These efforts have been augmented by the development and use of RGSinsensitive Ga subunit knockin mice. In these mice, specific Ga subunits (Gao, Gai2) are incapable
of functional coupling to RGS proteins (DiBello et al., 1998; Lan et al., 1998; Fu et al., 2004; Kaur
et al., 2011; Lamberts et al., 2013). Studies utilizing these techniques have revealed the integral
roles for RGS proteins in the modulation of GPCR signaling-driven neuroplasticity and behaviors
via action within a variety of neuronal cell populations and circuits (Gerber et al., 2016; Roman
and Traynor, 2011). A comprehensive summary of the mechanisms by which all CNS-expressed
RGS proteins affect neuronal physiology is beyond the scope of this thesis. Therefore, I will focus
specifically on the extant findings that strongly support a role for RGS proteins in the modulation
of opioidergic signaling and behavior.

1.2.1b - RGS Proteins and Opioidergic Signaling and Behavior
Several groups have demonstrated that RGS proteins are critical determinants of
opioidergic signaling and behavior (Traynor, 2012; Zachariou et al., 2003; Wang et al., 2009; Xie
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et al., 2007). There are three classical opioid receptors, the mu (MOR), delta (DOR), and kappa
(KOR) opioid GPCRs (Waldhoer et al., 2004; Snyder and Pasternak, 2003). Historically, most
work has focused on characterizing the functional relationship between several different RGS
proteins and the MOR, which is the molecular target of opioid analgesics and drugs of abuse,
such as morphine, hydrocodone, oxycodone, and heroin (Contet et al., 2004). Extensive prior
work has demonstrated that RGS4 and RGS9-2 are required for the molecular and behavioral
effects of MOR-directed drugs (for a comprehensive review, see (Traynor, 2012)).
RGS4 is one of the smallest RGS proteins, consisting only of a single RGS domain that
promiscuously acts as a GAP on Gai/o and Gaq subunits (Zheng et al., 1999; Zhong and Neubig,
2001). RGS4 is co-expressed with MOR in many brain regions, and Rgs4 mRNA is upregulated
following spinal injury in rodents (Garnier et al., 2003; Mansour et al., 1995). In heterologous
systems, RGS4 co-immunoprecipitates with MOR and acts as a GAP on MOR-mediated G protein
signaling (Leontiadis et al., 2009; Georgoussi et al., 2006; Talbot et al., 2010). Although
constitutive RGS4 knockout mice only display mild MOR-specific phenotypes, specific knockdown
of Rgs4 in the nucleus accumbens (NAc -- a subregion of the ventral striatum) using lentiviral
shRNA manifests more marked effects on MOR-induced reward (Han et al., 2010), suggesting
that germline deletion of RGS4 may be compensated for by other related RGS proteins.
Moreover, RGS4 has been shown to interact with DOR (Wang et al., 2009), supporting that
permissive action of RGS4 on MOR-mediated signaling and behavior in vivo may relate to its
redundant interactions with other opioid receptors.
In contrast to the relatively mild role that RGS4 plays in MOR-dependent outcomes,
several groups have demonstrated that RGS9-2 exhibits considerably more robust and specific
actions on MOR-mediated signaling and behavior (Xie and Palmer, 2005; Traynor, 2012).
RGS9-2 is an alternative splice variant of the RGS9 gene that is nearly exclusively expressed in
the striatum, but also exhibits low expression in the periaqueductal gray -- both brain regions
being crucial for the effects of opioidergic drugs (Cowan et al., 1998; Granneman et al., 1998;
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Rahman et al., 1999). Extensive in vitro and in vivo findings indicate that RGS9-2 potently affects
MOR-mediated signal transduction and clinically relevant behavioral outcomes, including
analgesia, reward, and drug tolerance (Rahman et al., 2003; Zachariou et al., 2003; Traynor et
al., 2009; Traynor, 2012). Like RGS4, RGS9-2 acts as a potent GAP for MOR agonist-mediated
G protein signaling in over-expression systems (Psifogeorgou et al., 2011). Consistent with
RGS9-2 as a negative regulator of MOR-mediated signaling, prior studies with constitutive RGS9
knockout mice demonstrated that RGS9 loss results in hypersensitivity to the rewarding and
analgesic properties of morphine (Zachariou et al., 2003). These effects could be reversed upon
virally mediated re-expression of RGS9 in the NAc (Zachariou et al., 2003), supporting a causal
role for RGS9 in this striatal subregion in the regulation of morphine-induced reward. Further
studies using antisense oligonucleotide-mediated knockdown of RGS9, or the obligate RGS9
partner Gb5, recapitulated the enhanced analgesia and reward in response to morphine and
DAMGO (a selective MOR agonist) observed with constitutive RGS9 knockout mice (SanchezBlazquez et al., 2003). Notably, RGS9 exerts opposing effects on DOR, with knockdown of RGS9
resulting in reduced DOR agonist-mediated analgesia (Sanchez-Blazquez et al., 2003). These
findings, in contrast with prior findings using RGS4 loss, support that RGS proteins can exhibit
selectivity for one opioid receptor over another. Furthermore, acute morphine administration to
wildtype mice upregulates RGS9 protein in several analgesia- and reward-related brain regions,
whereas chronic morphine downregulates RGS9 protein in these areas. Accordingly, RGS9
knockout mice display enhanced analgesia as induced by acute morphine treatment, despite
expressing attenuated tolerance to chronic administrations of morphine (Zachariou et al., 2003).
Given that the acute and chronic effects of MOR-directed agonists are mediated by independent
signaling mechanisms ((Bohn et al., 2003; Bohn et al., 2000) -- for further discussion see 1.2.2a
b-arrestins in Neuronal Physiology below), these findings and others (Psifogeorgou et al., 2007)
support that RGS proteins can exert distinct effects on signal transduction cascades downstream
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of their cognate GPCRs and, consequently, perturbation of RGS protein expression can result in
separable behavioral outcomes in response to opioidergic drug administration.

1.2.1c - RGS12 and Its Role in the CNS
RGS12 is a Gai/o-selective RGS protein originally cloned in 1997 by the Siderovski group
from cultures of the rat C6 glioblastoma cell line treated with morphine (Snow et al., 1997).
RGS12 is relatively widely expressed throughout mammalian tissues, although it does exhibit
some cellular and regional specificity within certain physiological systems, especially the brain
(Snow et al., 1998a; Lopez-Aranda et al., 2006). RGS12 is unique among RGS proteins in that
it exhibits a complex domain architecture capable of independently modulating and coordinating
across several signaling pathways beyond canonical RGS domain-mediated GAP activity;
accordingly, RGS12 is considered a “signaling scaffold” (Willard et al., 2007; Sambi et al., 2006;
Wang et al., 2017; Huang et al., 2014). RGS12 possesses an N-terminal PDZ domain, a
phosphotyrosine binding domain (PTB), a central Gai/o-specific RGS domain, tandem Ras
binding domains (RBDs), and a C-terminal GoLoco motif (Siderovski and Willard, 2005). The
GoLoco motif of RGS12 acts as a guanine nucleotide dissociation inhibitor (GDI) by
sequestering inactive Ga subunits, thereby prolonging Gbg signaling (Kimple et al., 2001). Thus,
RGS12 uniquely contains two Gai-interaction domains, the RGS domain and the GoLoco motif,
which differentially affect Gai-dependent signaling. Moreover, RGS12 harbors Gai-independent
domains that are common among signaling adaptors and scaffolds (e.g., PDZ, PTB, RBDs)
(Romero et al., 2011; Yaffe, 2002; Willard et al., 2007). Together, the diverse domain
architecture and biochemical properties of RGS12 support the notion that it coordinates
complex and integrative regulation of signal transduction initiated by both G protein-dependent
and -independent pathways.
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Two primary isoforms of RGS12 exist: a full-length variant containing N-terminal PDZ
and PTB domains, and a truncated variant lacking these N-terminal domains. The truncated
variant of RGS12 exhibits a domain architecture identical to another R12 family member,
RGS14 (Snow et al., 1997; Snow et al., 1998a). However, the expression distributions of RGS12
and RGS14 in the developing and adult brain differ considerably (Martin-McCaffrey et al., 2005;
Lopez-Aranda et al., 2006), suggesting there is likely little, if any, genetic compensation of
RGS14 upon transgenic deletion of RGS12.
RGS12 is required for nerve growth factor-mediated axonogenesis by dorsal root
ganglion neurons via PTB domain-dependent mitogen-activated protein kinase (MAPK)
scaffolding (Willard et al., 2007). These findings highlight at least one way in which RGS
proteins can perform integral physiological functions independent of their canonical GAPmediated termination of G protein signaling. Consistent with its effects on neurodevelopmental
processes, such as axonogenesis, RGS12 is highly expressed in CNS progenitor cell
populations during early stages of brain development (Martin-McCaffrey et al., 2005), although
the functional implications of this temporal and spatial expression pattern in the developing CNS
remain to be determined. Consistent with the notion that RGS12 is important for
neurodevelopmental processes, studies in both mice and humans have identified changes in
RGS12

protein

expression

and

mutations

in

the

RGS12

gene,

respectively,

in

neurodevelopmental disease models/states. In a whisker-trimming animal model of
somatosensory cortical development, RGS12 was significantly down-regulated under
conditions of early-life sensory deprivation (Butko et al., 2013). In a rat model of schizophrenia
in which a non-mutant variant of the human disrupted-in-schizophrenia (DISC1) gene is overexpressed, RGS12 was found to be down-regulated in the striatum (Sialana et al., 2018). These
findings are strengthened by exome sequencing analyses of humans diagnosed with
schizoaffective disorder and schizophrenia (considered neurodevelopmental disorders of the
CNS; (Owen et al., 2011; Birnbaum and Weinberger, 2017)), in which two independent groups
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identified de novo missense mutations in RGS12 (Xu et al., 2011; Guipponi et al., 2014).
Collectively, these studies suggest that RGS12 likely plays a crucial role in neurodevelopmental
processes and that perturbation of its function could manifest neurobiological disruptions
consistent with psychiatric diseases, such as schizophrenia.

1.2.2 - b-arrestin
In addition to the homeostatic feedback exerted by RGS proteins, GPCRs are also
negatively regulated by another class of proteins called b-arrestins (barrs) (Pierce et al., 2002;
Lohse et al., 1990). barrs are ubiquitously expressed and exist in two relatively homologous (78%
sequence homology) but distinct isoforms within the CNS, barr1 and barr2 (Lohse et al., 1990;
Attramadal et al., 1992). Initial work identified barrs as an essential mediator of GPCR
desensitization following intense, repeated and/or prolonged receptor stimulation (Wilden et al.,
1986; Lohse et al., 1990). However, a considerable number of studies since these initial
observations have demonstrated that barrs also are essential modulators of other processes,
such as GPCR internalization (i.e., receptor endocytosis), GPCR degradation/downregulation,
signaling crosstalk/receptor transactivation (e.g., with RTKs), and that these proteins can even
act as scaffolds of signal transduction cascades (e.g., MAPK/ERK signaling) independent of
canonical G protein signaling. For comprehensive reviews on the myriad functional outcomes of
GPCR-mediated barr signaling, see (Kang et al., 2014; Lefkowitz and Whalen, 2004; Shenoy and
Lefkowitz, 2011; Smith and Rajagopal, 2016b).
barr-dependent signaling is engaged following GPCR activation by an agonist/activating
ligand, or under conditions in which the GPCR is constitutively active (Scheerer and Sommer,
2017). Following receptor activation, cytosolic G protein receptor kinases (GRKs) are recruited to
the GPCR, resulting in phosphorylation of serine/threonine residues on the receptor C-terminus
or intracellular loop regions (Benovic et al., 1986a; Benovic et al., 1986b; Gurevich and Gurevich,
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2019). To date, there have been seven independent GRK isoforms identified (GRK1-7), and these
are separated into subclasses based on sequence homology and function. GRK1 and GRK7
(GRK1-like subfamily) are found only in the visual system. The GRK4-like subfamily includes
GRK4, which is expressed predominantly in the testes, as well as GRK5 and GRK6, which exhibit
more ubiquitous expression. The GRK2-like subfamily includes GRK2 and GRK3, which are also
ubiquitously expressed (Pitcher et al., 1998; Gainetdinov et al., 2004). The mechanisms by which
GRKs are recruited to GPCRs varies across GRK subtypes/subfamilies (Gurevich and Gurevich,
2019). Given that the GRK2/3 subfamily has been the most extensively characterized in the brain
(Gainetdinov et al., 2004; Evron et al., 2012), I will focus on outlining only GRK2/3-initated
signaling cascades. Classical models indicate that GRK activation is directly stimulated by free
Gbg subunits, which interact with the pleckstrin homology (PH) domain of the GRK molecule
(Koch et al., 1993; Touhara et al., 1994). However, more recent evidence suggests that GRK
signaling can be initiated independent of Gbg (i.e., G protein)-mediated mechanisms (Pack et al.,
2018). GRK-mediated GPCR phosphorylation mobilizes cytoplasmic barr to the 2nd or 3rd
intracellular loop regions of the GPCR, leading to functional uncoupling of the GPCR and
heterotrimeric G protein complex by steric hindrance, thereby preventing further signaling (i.e.,
desensitization) (DeGraff et al., 2002; Marion et al., 2006). Additionally, barrs act as cellular
scaffolds of AP-2, resulting in GPCR internalization via dynamin-dependent endocytosis in
clathrin-coated pits (Ferguson et al., 1996; Kang et al., 2013; Claing et al., 2001). Internalized
GPCRs either recycle back to the plasma membrane (via recycling endosomes) or undergo
degradation/downregulation (via sorting into late endosomes targeted to lysosomes) (Kang et al.,
2014; Oakley et al., 2000). Lastly, the scaffolding properties of barrs enable the nucleation of
cellular signal transduction cascades, most notably of the MAPK/ERK family, that are distinct from
signaling engendered by G proteins (Luttrell et al., 1999; Luo et al., 2008; Sun et al., 2002;
Bruchas et al., 2006; Breitman et al., 2012). For example, some GPCRs will induce MAPK/ERK
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signaling in early (e.g., ~5 minutes) and late (e.g., ~30 minutes) phases via distinct G protein- and
barr-dependent mechanisms (Gesty-Palmer et al., 2006; McLennan et al., 2008). Moreover,
GPCR-mediated p38 MAPK activation has been shown to be barr-, but not G protein-, dependent
(Bruchas et al., 2006), further highlighting that barr-mediated signaling cascades can be
engendered independently of those evoked by G proteins following receptor activation.

1.2.2a - b-arrestins in Neuronal Physiology
The physiological importance of barrs has been elucidated predominantly through the use
of transgenic knockout mice. Double knockout of barr1 and barr2 is embryonically lethal (DeWire
et al., 2007), thus barrs play a prominent developmental role. However, knockout of either barr1
or barr2 produces viable offspring that display grossly normal phenotypic profiles, suggesting that
loss of a single barr isoform can result in, at least some, physiological compensation by the
alternate barr. Despite relatively normal baseline phenotypes in barr1 and barr2 knockout mice,
these strains often display perturbed physiological responses to environmental stressors or
pharmacological challenge (Conner et al., 1997; Bohn et al., 1999).
1.2.2b - b-arrestins and Opioidergic Signaling and Behavior
One of the most widely recognized examples of the physiological importance of barr
function is work performed by the Caron group, which demonstrated that constitutive barr2
knockout mice exhibit enhanced and prolonged morphine-induced analgesia (Bohn et al., 1999),
despite marked reductions in morphine-induced tolerance and physical dependence (Bohn et al.,
2000; Bohn et al., 2002). These findings were among the first to confirm that barrs play an
important role in agonist-induced desensitization and/or internalization/downregulation of CNSexpressed GPCRs in vivo and suggested that specific behavioral outcomes (e.g., analgesia)
could be mediated by distinct signal transduction cascades. Further work demonstrated that
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MOR-induced analgesia is lost following pertussis toxin (PTX) treatment (Parolaro et al., 1990;
Bodnar et al., 1990), which abolishes Gai/o signaling via irreversible ADP-ribosylation (Moss and
Vaughan, 1988). These findings, when considered along with the aforementioned studies utilizing
barr2 knockout mice, support that MOR-induced analgesia is mediated specifically by G i/o protein
signaling. Continued work by Bohn, Caron, and others highlighted that barr2 loss also blunts some
of the negative side effects produced by morphine and other MOR-directed opioids, including
respiratory depression and constipation (Raehal et al., 2005; Raehal et al., 2011). Taken together,
these seminal studies revealed that G protein and barr signaling downstream of opioidergic
GPCRs can differentially determine behavioral outcomes.

1.2.3 - GPCR Functional Selectivity (also known as Biased Agonism)
More recent work has focused on applying the mechanistic insight obtained from barr
knockout mice toward designing and characterizing novel pharmacological compounds that
exhibit the capacity to differentially or preferentially engage G protein- or barr-dependent signaling
downstream of GPCRs (Urban et al., 2007; Violin and Lefkowitz, 2007). In classical models of
ligand-receptor interactions, ligands possess two properties: affinity and efficacy. Affinity reflects
how tightly a ligand binds to a receptor, whereas efficacy refers to the capacity of the ligand to
produce a biological response following receptor binding (Stephenson, 1956; Kenakin, 2004).
Thus, classical models suggested that GPCRs exist in either an active or inactive conformation,
contingent on whether an agonist was bound (active conformation) or unbound (inactive
conformation) (De Lean et al., 1980; Violin and Lefkowitz, 2007). These models permitted the
classification of ligands as full agonists, partial agonists, neutral antagonists, or inverse agonists
across a continuum of affinities. Specifically, full agonists produce maximal biological responses
(i.e., maximal efficacy) via stabilization of an active state conformation of the GPCR. Partial
agonists also stabilize an active state conformation of the GPCR, but exhibit submaximal efficacy
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relative to full agonists. Inverse agonists stabilize an inactive state of the GPCR and exert an
inhibitory effect on signal transduction that results from constitutive activity of the receptor (i.e.,
receptor activity that is independent of agonist binding). Lastly, ligands can be neutral antagonists,
which prevent binding of other ligands and do not exhibit any efficacy at the receptor (Ariens,
1954; Kenakin, 1995). While these categories accurately described many ligands, classical
models of ligand-receptor pharmacology did not account for the aberrant property of some GPCRdirected ligands to exhibit differential efficacy for distinct signal transduction cascades (e.g., G
protein and barr signaling) within the same cellular system (Wei et al., 2003; Gesty-Palmer et al.,
2006), a process previously described as "imbalanced efficacy." For example, a ligand can act as
an antagonist of one signaling pathway (e.g., barr signaling), while simultaneously acting as an
agonist at a distinct signaling pathway (e.g., G protein signaling), despite identical expression of
signal transduction machinery (e.g., RGSs, GRKs, barrs) within that particular cellular milieu
(Allen et al., 2011). This concept is now more commonly known as functional selectivity or biased
agonism (Urban et al., 2007; Reiter et al., 2012; Kenakin, 2011). Under this principle, an agonist
(full, partial, or inverse) may stabilize a conformation of its cognate GPCR that preferentially or,
in some cases, exclusively drive G protein (a 'G protein-biased' agonist) or barr (a 'barr-biased'
agonist) signaling cascades.
The use of biased agonists in animal models has provided an additional strategy (i.e.,
along with transgenic manipulation) by which to further elucidate of how G protein or barr signaling
mediates specific physiological or behavioral outcomes. Perhaps more importantly, biased
agonists permit the opportunity to design a drug that can, in theory, produce enhanced therapeutic
efficacy and/or mitigate disadvantageous side effects if these physiological/behavioral outcomes
are independently induced by G protein versus barr signaling (Whalen et al., 2011). For example,
the aforementioned work on the effects of morphine in barr2 knockout mice led to speculation that
a MOR-selective G protein-biased agonist would be expected to preserve and/or enhance
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analgesia, while reducing or eliminating clinically undesired side effects, such as tolerance,
dependence, respiratory depression, and constipation (Schmid et al., 2017; Madariaga-Mazon et
al., 2017). Indeed, MOR-selective G protein biased agonists have been synthesized and are
considered to display a more clinically advantageous behavioral profile relative to unbiased,
conventional MOR agonists, such as morphine (Manglik et al., 2016; DeWire et al., 2013; Koblish
et al., 2017; Urits et al., 2019). These studies have led to a clinical trial of a MOR-selective G
protein biased agonist called TRV-130 (oliceridine, brand name Olinvo) for severe pain (Singla et
al., 2017), but the candidate compound failed due to weak efficacy and safety concerns related
to QT interval prolongation, addiction, and tolerance liability (Research, 2018). Nonetheless, the
design and characterization of biased agonists (directed against a wide variety of GPCRs)
remains an encouraging and highly active pursuit that seeks to both deepen our mechanistic
understanding of how GPCR signaling mediates a diverse array of physiological outcomes, as
well as provide novel therapeutic candidates for clinical application across many different
diseases and pathologies.

1.3 - Kappa Opioid Receptor (KOR) Signaling and Behavior
1.3.1 - Background: Opioid Receptor Signal Transduction
Each opioid receptor (MOR, DOR, and KOR) is a Gi/o-coupled GPCR and thus activation
leads to adenylyl cyclase inhibition and reduced cAMP production (Al-Hasani and Bruchas, 2011).
Via freed Gbg subunits, opioid receptor activation also leads to the activation of G protein inwardly
rectifying potassium channels (GIRKs) (Luscher and Slesinger, 2010; Nockemann et al., 2013)
and inhibition of P/Q-, N-, and L-type Ca2+ channels (Wang et al., 2010; Tedford and Zamponi,
2006),

thereby

reducing

neuronal

excitation

(via

hyperpolarization)

and

decreasing

neurotransmitter/neuropeptide release, respectively. Opioid receptors also recruit barr via
activation-dependent receptor phosphorylation by GRK2/3, primarily at the C-terminal tail of the
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receptor; thus, opioid receptors undergo barr-dependent desensitization and internalization in an
agonist-dependent manner (Al-Hasani and Bruchas, 2011). The recruitment of barr also promotes
G protein-independent signaling cascades, including the activation of kinases, such as ERK1/2,
MAPK p38, and c-Jun N-terminal kinase (JNK) (Appleyard et al., 1999; Bruchas et al., 2006;
McDonald et al., 2000; Wagley et al., 2013). MOR, DOR, and KOR show approximately 50-70%
sequence similarity (Katritch et al., 2013), but display distinct neuroanatomical distributions and
behavioral outcomes upon activation (Pan, 1998; Al-Hasani and Bruchas, 2011). In this section,
I will focus on the mechanisms by which KOR signal transduction manifests specific behavioral
outcomes following endogenous or exogenous activation.
1.3.2 - KOR Expression in the Mouse Brain
The endogenous ligands of KOR are dynorphins, a class of neuropeptides derived from
the precursor preprodynorphin (Sohn et al., 2014; Draisci and Iadarola, 1989). Dynorphin is
released under conditions of stress and mediates a variety of acutely adaptive behavioral
responses that chiefly serve to enable escape, and later avoidance, of environmental threats
and/or aversive stimuli. Specifically, dynorphin-stimulated KOR activation can produce behavioral
states of dysphoria (displeasure and unease), anhedonia (reduced responses to rewarding
stimuli), anxiety, cognitive disruption, psychosis, analgesia, neuroendocrine dysfunction, and
withdrawal following drug abuse (Chavkin and Koob, 2016). Continued or severe acute exposure
to stressors upregulates dynorphin and often produces hypersensitization of the dynorphin/KOR
system, which can promote the manifestation of disease-related physiological and behavioral
states (Van't Veer and Carlezon, 2013; Vien et al., 2009; Karkhanis et al., 2016; Yorgason et al.,
2016). As one would expect based on this notion, KOR expression is densely distributed
throughout the stress-sensitive limbic system of the brain, including the mesolimbic dopamine
(DA) system (the reward system; the VTA and NAc), the dorsal raphe nucleus (DRN; the site of
most serotonergic neurons innervating the forebrain), the prefrontal cortex (PFC), the amygdala
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(AMY), the hippocampus (HPC), and the hypothalamus (Yasuda et al., 1993; Crowley and Kash,
2015; Lalanne et al., 2014). A comprehensive review of the known actions of KOR activation
within each of these brain regions can be found elsewhere (Crowley and Kash, 2015; Knoll and
Carlezon, 2010; Van't Veer and Carlezon, 2013) and is beyond the scope of this thesis. Given the
critical importance of KOR in regulating the mesolimbic DA system and the robust expression of
RGS12 within mesolimbic substructures, I will focus on the specific mechanisms by which KOR
affects mesolimbic DAergic neurotransmission and behavior.

1.3.3 - KOR and Dopaminergic Neurotransmission
1.3.3a - Background: KOR in the Mesolimbic DA System
KOR is enriched on presynaptic terminals of the NAc (a subregion of the ventral striatum
[vSTR]), which originate from VTA DAergic projection neurons (Crowley and Kash, 2015;
Bruijnzeel, 2009; Britt and McGehee, 2008). KORs are also expressed on VTA cell bodies, but
these receptors preferentially regulate subpopulations of DAergic neurons that project to the
prefrontal cortex (the mesocortical DA tract) (Margolis et al., 2006). Under conditions of elevated
synaptic DA tone in the NAc, extracellular DA stimulates post-synaptic DA receptors (e.g.,
dopamine D1 receptor [D1R] and dopamine D2 receptor [D2R]) expressed on the cell bodies of
GABAergic medium spiny neurons (MSNs), which comprise ~95% of the cells making up the
striatum (Gerfen et al., 1990). Activation of D1R-expressing MSNs stimulates the release of
dynorphin in a retrograde fashion to act upon presynaptic KORs expressed on DAergic terminals,
leading to reductions in extracellular DA. Thus, KOR serves an important role in the negative
feedback of mesolimbic DAergic neurotransmission (Trifilieff and Martinez, 2013). KOR-mediated
decreases in DA occur by two primary, PTX-sensitive (i.e., Gi/o heterotrimer signaling-dependent),
mechanisms; (1) inhibition of exocytotic DA release (Di Chiara and Imperato, 1988; Donzanti et
al., 1992) and (2) increased dopamine transporter (DAT)-mediated DA uptake (Thompson et al.,
2000; Kivell et al., 2014). KOR-mediated reductions in DAergic neurotransmission are proposed

18
to underlie the dysphorigenic effects of KOR agonists in mice and humans (Pfeiffer et al., 1986;
Shippenberg et al., 1993) and, accordingly, conditioned place aversion produced in mice by KOR
agonists is lost upon ablation of KORs in DAergic neurons (Chefer et al., 2013). Furthermore,
many drugs of abuse exert their rewarding effects by increasing mesolimbic DA (Nestler, 2001);
thus, either acute administration of KOR agonists or endogenous activation of KOR by dynorphin
effectively reduces behavioral responses to addictive substances (e.g., such psychostimulants as
amphetamine and cocaine), and this reduction is dependent on KOR action in vSTR (Thompson
et al., 2000; Gray et al., 1999).

1.3.3b - Dopamine Release
Extensive prior evidence supports the notion that activation of KOR on presynaptic
mesolimbic DA neurons reduces exocytotic DA release. Systemic administration of KOR agonists
(e.g., U50,488, U69,593), or their direct infusion into the NAc, reduces extracellular DA in vivo
(Spanagel et al., 1992; Chefer et al., 2005). Moreover, direct application of KOR agonists to NAccontaining brain slices attenuates electrically-evoked, depolarization-dependent release of
exogenously applied [3H]DA and endogenous DA stores (Heijna et al., 1990; Grilli et al., 2009;
Rose et al., 2016). More recent studies using optogenetics demonstrate that the inhibitory effect
of KOR on DA is preserved following the selective activation of DA terminals (i.e., absent the
recruitment of local striatal microcircuitry, such as GABAergic MSNs or cholinergic interneurons)
(Melchior and Jones, 2017), supporting the idea that KOR reduces DA release via a direct, cellautonomous mechanism. KOR-mediated inhibition of DA release is PTX- and Ca2+-sensitive (Grilli
et al., 2009; Dalman and O'Malley, 1999), supporting the notion that reduced DA exocytosis by
KOR activation is Gi/o heterotrimer signaling-dependent and likely mediated by Gbg-dependent
inhibition of Ca2+ channels. KOR is also expressed, albeit at relatively low levels, in local striatal
cholinergic interneurons. Cholinergic interneurons constitute only ~1% of the cell populations
making up the striatum; however, they densely innervation DAergic terminals and serve an
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integral role in the modulation of DA release via stimulatory release of acetylcholine (ACh) (Bolam
et al., 1984; Contant et al., 1996). Accordingly, prior work supports that KOR-dependent
regulation of DA release is, in part, related to the activation of KORs on striatal cholinergic
interneurons (Threlfell and Cragg, 2011; Karkhanis et al., 2017). Perhaps the most compelling
support for the notion that KOR regulates DA release via action within cholinergic interneurons
comes from work by the Jones lab, which has demonstrated that KOR activation more potently
inhibits DA release in the NAc following electrical stimulation (which directly recruits cholinergic
interneurons) than after selective DAergic terminal activation (using optogenetics) (Rose et al.,
2016; Melchior and Jones, 2017). The most parsimonious explanation for these findings is that
the activation of DA terminal-expressed KORs is necessary, but not sufficient, to account for the
inhibitory effect that KOR exerts on striatal DA release and that cholinergic interneuron-expressed
KORs contribute, in part, to this effect.

1.3.3c - The Dopamine Transporter (DAT)
A central determinant of striatal DA tone (extracellular DA concentration) is the dopamine
transporter (DAT). DAT is a 12-transmembrane protein with cytosolic N- and C-termini and is
expressed exclusively within presynaptic and somatodendritic compartments of DAergic neurons
(Chen and Reith, 2000; Ciliax et al., 1995). Under normal physiological conditions, DAT
recaptures released DA back into DA neurons via a Na+/Cl--dependent mechanism, thereby
terminating DAergic neurotransmission (Kuhar et al., 1990; Amara and Sonders, 1998). DAT can
also display reverse transport, and thereby elevate extracellular DA via the non-exocytotic efflux
of free cytosolic DA, in response to several psychostimulants (e.g., amphetamine [AMPH],
methamphetamine [METH]), which are aptly characterized as releasing agents (Rothman et al.,
2001). Releasing agents are substrates for DAT; thus, in addition to their action as releasers, they
also increase extracellular DA levels via competitive reuptake inhibition with endogenous DA
(Rothman et al., 2001). In contrast, psychostimulants such as cocaine and methylphenidate
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(RitalinTM) are not DAT substrates: they bind directly to the extracellular face of DAT and preclude
the reuptake of DA, thereby augmenting extracellular DA levels predominantly via noncompetitive DAT inhibition (Beuming et al., 2008). Mice genetically engineered to lack DAT
expression (i.e., DAT KO mice) exhibit markedly elevated extracellular DA tone at baseline and
display remarkable levels of spontaneous hyperactivity; moreover, these mice do not exhibit
locomotor activation or DA release to such psychostimulant drugs as AMPH and cocaine (Giros
et al., 1996), highlighting the integral role that DAT plays in mediating the effects of
psychostimulant drugs (Gainetdinov et al., 2002). Under both basal and psychostimulantstimulated conditions, DAT expression, subcellular trafficking, and uptake/efflux functions are all
tightly regulated by a host of direct and indirect interactants, including receptors (e.g., GPCRs),
kinases, and scaffolds (Torres et al., 2003; Vaughan and Foster, 2013).
KORs are robustly expressed on the plasma membrane of NAc DA neurons in direct
apposition to DAT (Svingos et al., 2001), and KOR forms an oligomeric complex with DAT in
transfected cells (Kivell et al., 2014). Activation of KOR leads to increased DAT-mediated DA
uptake (Thompson et al., 2000; Kivell et al., 2014), likely by increasing the translocation of DAT
to the plasma membrane (Kivell et al., 2014). However, at least one report found that KOR
agonism (using the KOR agonist mesyl Sal B) induced an augmentation of DAT-mediated DA
uptake with no change in cell surface DAT levels (Simonson et al., 2015). Thus, the effects of
KOR activation on DAT, particularly with respect to DAT trafficking, are likely ligand-dependent.
KOR activation-mediated increases in DA uptake are PTX-sensitive, supporting that these
processes are mediated by a Gi/o heterotrimer signaling-dependent mechanism (Kivell et al.,
2014). DAT expression and function are both altered following either acute or chronic KOR
activation (Chefer et al., 2005), thereby providing, at least in part, a mechanistic explanation for
the observation that both acute and prolonged stress (e.g., via environmental stress-induced
dynorphin upregulation or pharmacological activation of KOR) results in mesolimbic hypoDAergia
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and disrupted responses to DAT-dependent psychostimulants (Walker and Koob, 2008;
Karkhanis et al., 2016).

1.3.3d - Psychostimulants
Ample prior evidence supports that KOR activation strongly regulates the behavioral and
biochemical responses to psychostimulants such as AMPH and cocaine. Acute administration of
the KOR-selective agonist U69,593 attenuates AMPH-induced behavioral activation and AMPHinduced elevations in ventral striatal DA, while local application of the KOR-selective antagonist
nor-BNI into the vSTR reverses these effects (Gray et al., 1999). These data strongly support that
KOR signaling within the vSTR is able to regulate the DA-dependent behavioral effects of AMPH.
However, repeated administration of U69,593 has no effect on locomotor sensitization to AMPH
following repeated administration (Escobar Adel et al., 2012), suggesting that KOR signaling may
play a more important role in modulating the acute effects of AMPH. Indeed, acute administration
of AMPH potently stimulates the release of endogenous dynorphin, which can result in the
desensitization of striatal KORs (Xia et al., 2008). These findings provide at least one explanation
for why KORs may not be as important under conditions of chronically administered AMPH.
Considerably more work has been performed to elucidate the role that KOR plays in the
behavioral and biochemical effects of cocaine. Administration of KOR agonists blocks acute
cocaine-induced locomotor activation (Heidbreder et al., 1993; Vanderschuren et al., 2000). In
contrast to AMPH, some work has shown that KOR agonists also blunt locomotor sensitization
and conditioned place preference to cocaine (Heidbreder et al., 1993; Shippenberg et al., 1996;
Zhang et al., 2004), measures of repeated/chronic cocaine administration. Moreover, chronic
cocaine adminstration upregulates KOR protein levels (Collins et al., 2002). Together, prior
evidence supports that cocaine and KOR exhibit a reciprocally functional interaction, particularly
within the mesolimbic DA system (Trifilieff and Martinez, 2013).
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However, some work has shown that KOR agonists do not affect cocaine-induced
locomotor sensitization (Vanderschuren et al., 2000), and the effect of KOR on cocaine selfadministration is similarly mixed (Karkhanis et al., 2017). More recent work convincingly
reconciles these mixed findings by demonstrating the nuanced temporal dependence of KOR
activity on the chronic effects of cocaine. For example, the Chavkin group has shown that
systemic administration of the KOR-selective agonist U50,488 15 minutes prior to cocaine
administration in a conditioned place preference paradigm decreases cocaine preference, and
these effects correlate with traditionally observed KOR-mediated reductions in the elevation of
extracellular DA (in the NAc) evoked by cocaine (Zhang et al., 2004). However, when U50,488 is
administered 60 minutes prior to cocaine administration, cocaine preference is markedly
increased with concomitantly augmented DA levels in the NAc relative to baseline conditions. The
authors conclude that 60-minute pretreatment with a KOR agonist initially results in reduced
synaptic DA levels, thereby resetting baseline DAergic tone to a lower starting point, and thus
permitting a greater effect of cocaine (i.e., an enhanced effect size of cocaine-stimulated DAergic
tone relative to baseline) (Ehrich et al., 2014). Notably, potentiation of cocaine-induced CPP is
also observed following chronic stress (using a chronic forced swim paradigm), a process that
increases dynorphin release and KOR activation (McLaughlin et al., 2006; Schindler et al., 2010;
Ehrich et al., 2014). This biphasic, time-dependent effect of KOR activation on cocaine-induced
DA tone has been observed by other groups, even when employing different KOR agonists and
behavioral paradigms (Chartoff et al., 2016). Together, these findings support that KOR
dynamically responds to, and can determine, the overall effects of cocaine and perturbations in
mesolimbic DA neurotransmission.
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1.4 - 'Functionally Selective' Behavioral Outcomes of KOR Activation
1.4a - Background
Consistent with the aforementioned studies demonstrating that functional selectivity at
MOR can produce profoundly distinct molecular and behavioral outcomes (Bohn et al., 1999;
Bohn et al., 2000; Bohn et al., 2002), recent work has shown that similar processes occur with
KOR (Bohn and Aube, 2017; Schmid et al., 2013; White et al., 2015; Brust et al., 2016; Dunn et
al., 2018). KOR activation results in a wide array of clinically relevant effects, including analgesia
(Kivell and Prisinzano, 2010), anti-addiction/reward (Bruijnzeel, 2009), anxiety/depressive-like
behaviors (Van't Veer and Carlezon, 2013), anti-pruritus (anti-itch) (Brust et al., 2016), diuresis
(DeHaven-Hudkins and Dolle, 2004), sedation (Vonvoigtlander et al., 1983), dysphoria/aversion
(Ehrich et al., 2015), and psychotomimesis (Pfeiffer et al., 1986). Clearly, a subset of these
outcomes are clinically advantageous (e.g., analgesia, anti-itch, anti-reward), while others are
disadvantageous (anxiety/depression, dysphoria, psychotomimesis). To date, the only approved
KOR-directed ligand, nalfurafine (Remitch), is used in Japan for the treatment of intractable itch
in patients with uremic pruritus related to chronic kidney disease (Kumagai et al., 2010). However,
most work with animal models has focused on leveraging the notion that KOR agonists produce
analgesia, but lack addictive potential; thus, many have proposed that KOR agonists could
represent a viable replacement (or adjuvant) for highly addictive MOR-directed pain relievers
(e.g., oxycodone, hydrocodone, etc.) (Bohn and Aube, 2017; Vanderah, 2010).
The clinical viability of KOR agonists has been largely hampered by an inability to identify
KOR-selective drugs that preserve clinically beneficial outcomes, while mitigating (or abolishing)
detrimental outcomes. This issue may be addressable by exploiting functional selectivity at KOR,
as the prevailing notion in the literature supports that the analgesic properties of KOR agonists
are mediated by G protein signaling-dependent mechanisms, whereas the dysphoric/aversive
effects of KOR agonists are mediated by barr-dependent processes (Bruchas et al., 2007; Brust
et al., 2016). Considerably less work has sought to identify the functional selectivity underlying
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other clinically relevant KOR-mediated behaviors (e.g., anxiety/depression). Therefore, in this
section, I will focus on the extant findings related to the G protein- and barr-dependent
mechanisms underlying KOR-induced analgesia and dysphoria/aversion.

1.4b - KOR-induced Analgesia
KOR is expressed within many ascending sensory and descending inhibitory painassociated cell types/regions within the spinal cord and brain (Mansour et al., 1994; Ji et al.,
1995). Accordingly, KOR activation in both the CNS and periphery reduces inflammatory, visceral,
neuropathic, and acute pain (Kivell and Prisinzano, 2010; Vanderah, 2010; Simonin et al., 1998;
Cunha et al., 2012). The upregulation of dynorphin and/or KOR is an important mechanism
underlying the negative affective response experienced under conditions of chronic pain (Cahill
et al., 2014; Liu et al., 2019; Massaly et al., 2019), further highlighting the diverse and integrative
role that KOR signaling plays in pain processing. The signaling mechanisms underlying KORmediated analgesia have largely been elucidated using assays of supraspinal (hot plate assay)
and spinal (tail immersion/withdrawal assay) analgesia in rodents. Using these assays, it has
been shown that KOR agonist-induced analgesia is abolished with PTX pretreatment (Hernandez
et al., 1995) and is unaffected in mice lacking GRK3 or barr expression (McLaughlin et al., 2004;
White et al., 2015). Moreover, several G protein-biased KOR agonists retain analgesic efficacy
comparable to conventional unbiased agonists (White et al., 2015; Brust et al., 2016; Schattauer
et al., 2017). Collectively, these findings strongly support that KOR agonist-induced supraspinal
analgesia is mediated by G protein signaling downstream of receptor activation. Similar
mechanistic underpinnings have been ascribed to the anti-pruritic effects of KOR agonists
(Morgenweck et al., 2015; Brust et al., 2016), although these effects are mediated by KORs within
the dorsal root ganglion (DRG) (Kardon et al., 2014). Under conditions of chronic pain (e.g.,
neuropathic injury), dynorphin and KOR are upregulated, enabling an analgesic compensation in
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response to injury (Xu et al., 2004; Wagner et al., 1993; Wang et al., 2001). However, prolonged
dynorphin release desensitizes KOR via a GRK/barr-dependent mechanism (Xu et al., 2004),
thereby reducing the analgesic effects of KOR activation. Thus, the acute analgesic effects of
KOR activation are mediated via G protein-dependent signaling, whereas the efficacy of KORmediated analgesia in chronic pain states may rely predominantly on barr-dependent signaling.

1.4c - KOR-induced Dysphoria/Aversion
Early investigation into the effects of KOR agonists in humans revealed KOR activation
can result in profound dysphoria and psychotomimesis (Pfeiffer et al., 1986). The dysphoric and
hallucinogenic effects in humans have been derived predominantly from observations with the
KOR-selective agonist salvinorin A, the psychoactive constituent of the plant Salvia divinorum.
The Mazatec peoples of Oaxaca, Mexico have traditionally used Salvia divinorum for religious
practices, while the general recreational use of salvinorin A extracts has become more
widespread over the last few decades (Roth et al., 2002; Mahendran et al., 2016). Salvinorin A
administration produces profound effects of mind-body dissociation and cognitive disruption
(MacLean et al., 2013; Maqueda et al., 2015), although participants do not always rate these
experiences as dysphoric or anxiety-inducing (Johnson et al., 2011; Ranganathan et al., 2012;
MacLean et al., 2013). However, some speculate that the absence of dysphoria or negative affect
in some participants may be confounded by prior use of other hallucinogens/psychedelics and/or
expectation(s) of experience (Gonzalez et al., 2006).
In contrast to the mixed affective responses observed in humans, KOR agonists
administered to rodents very reliably induce aversion, a behavioral response considered to be a
measure of dysphoria (Al-Hasani and Bruchas, 2011; Valentino and Volkow, 2018). The standard
assay employed for measuring aversion in rodents is the conditioned place aversion (CPA)
paradigm, which employs Pavlovian conditioning to determine the aversive properties of drugs
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and/or the actions of neural circuits or neurotransmitter systems. Early work (Shippenberg and
Herz, 1986) identified KOR agonists as potently aversive agents using the CPA paradigm. The
dysphoric effects of KOR agonists were later reinforced by independent results from behavioral
tasks less reliant on learning, such as intracranial self-stimulation (ICSS) (Todtenkopf et al.,
2004). Aversion produced by systemic KOR agonist administration is abolished following 6hydroxydopamine (6-OHDA)-induced lesioning of DAergic neurons or pharmacological DA
receptor inhibition in the mesolimbic (i.e., NAc), but not mesocortical (i.e., PFC), system
(Shippenberg et al., 1993). Moreover, microinjection of the KOR agonist U50,488 into the NAc is
sufficient to produce CPA, and this behavioral outcome correlates with KOR agonist-induced
reductions in DAergic tone (Bals-Kubik et al., 1993). Additionally, more recent work demonstrated
that KOR agonist-induced CPA is lost upon DA neuron-specific knockout of KOR (Chefer et al.,
2013). Together, these findings support the idea that KOR agonist-induced aversion is mediated
by reductions in DA within the NAc, a biological process consistent with a state of negative affect.
However, not all studies support this model. For example, DA-deficient mice still exhibit KOR
agonist-induced CPA (Land et al., 2009). Although this finding is compelling, it is confounded by
the fact that CPA assays with DA-deficient mice required caffeine administration (Land et al.,
2009) in order to reverse the marked inactivity exhibited by these mice at baseline. Perhaps more
convincing are experiments demonstrating that selective inactivation of KOR expressed within
serotonergic dorsal raphe nucleus (DRN) neurons (specifically those projecting to the NAc)
prevents KOR agonist-induced CPA; moreover, selective re-expression of KOR within
serotonergic DRN neurons of KOR knockout mice was sufficient to produce KOR agonist-induced
aversion (Land et al., 2009). Thus, in contrast to prior studies supporting KOR's effects on
mesolimbic DA as being required for agonist-induced aversion, this study supports an integral
role of serotonin in these processes.
The intracellular signaling determinants underlying KOR-induced aversion have also been
controversial, although the traditional theory within the field supports that the dysphoric/aversive
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properties of KOR agonists are mediated by barr-dependent processes. This notion is
predominantly predicated on extensive work by the Chavkin group utilizing pharmacologic and
genetic manipulations of upstream (GRK3) and downstream (p38 MAPK) signaling molecules of
barr following KOR activation (Bruchas et al., 2006; Ehrich et al., 2015; Al-Hasani and Bruchas,
2011). The dependence of barr in mediating KOR-induced aversion is further bolstered by the
lack of dysphoria/aversion produced by some G protein-biased KOR agonists (Brust et al., 2016;
Kivell et al., 2018). However, a study by the Roth group (White et al., 2015) provided conflicting
evidence to this theory when the authors evaluated KOR agonist-induced CPA in barr-2 knockout
mice. These experiments showed that the CPA induced by the conventional KOR agonist
U69,593 was unaffected in mice constitutively lacking barr-2. Notably, the authors recognize the
possibility that compensation of barr-1 could underlie these results, especially given their
overlapping expression (White et al., 2015). Moreover, barr-2 plays an integral role in
neurodevelopmental processes (Philipp et al., 2013); thus, it is highly plausible that constitutive
loss of barr-2 from conception could engender disruptions to neuronal cell and circuit function,
thereby confounding a determination of whether KOR agonist-induced aversion is mediated by a
direct barr-2-dependent mechanism. Future studies employing selective ablation of barr within
KOR neurons (e.g., progeny from KOR::Cre mice crossed with Barr2 floxed mice) may provide
the best model to determine whether barr is absolutely required for KOR agonist-induced
aversion, as this would obviate issues of genetic compensation and off-target effects (i.e., loss of
barr in non-KOR-expressing cell populations).

28
1.5 - References

Al-Hasani R and Bruchas MR. (2011) Molecular mechanisms of opioid receptor-dependent
signaling and behavior. Anesthesiology 115: 1363-1381.
Allen JA, Yost JM, Setola V, et al. (2011) Discovery of beta-arrestin-biased dopamine D2 ligands
for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl
Acad Sci U S A 108: 18488-18493.
Amara SG and Sonders MS. (1998) Neurotransmitter transporters as molecular targets for
addictive drugs. Drug Alcohol Depend 51: 87-96.
Angleson JK and Wensel TG. (1993) A GTPase-accelerating factor for transducin, distinct from its
effector cGMP phosphodiesterase, in rod outer segment membranes. Neuron 11: 939949.
Appleyard SM, Celver J, Pineda V, et al. (1999) Agonist-dependent desensitization of the kappa
opioid receptor by G protein receptor kinase and beta-arrestin. J Biol Chem 274: 2380223807.
Ariens EJ. (1954) Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems
and theory. Arch Int Pharmacodyn Ther 99: 32-49.
Attramadal H, Arriza JL, Aoki C, et al. (1992) Beta-arrestin2, a novel member of the arrestin/betaarrestin gene family. J Biol Chem 267: 17882-17890.
Bals-Kubik R, Ableitner A, Herz A, et al. (1993) Neuroanatomical sites mediating the motivational
effects of opioids as mapped by the conditioned place preference paradigm in rats. J
Pharmacol Exp Ther 264: 489-495.
Benovic JL, Mayor F, Jr., Somers RL, et al. (1986a) Light-dependent phosphorylation of rhodopsin
by beta-adrenergic receptor kinase. Nature 321: 869-872.
Benovic JL, Strasser RH, Caron MG, et al. (1986b) Beta-adrenergic receptor kinase: identification
of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor.
Proc Natl Acad Sci U S A 83: 2797-2801.
Berman DM and Gilman AG. (1998) Mammalian RGS proteins: barbarians at the gate. J Biol Chem
273: 1269-1272.
Beuming T, Kniazeff J, Bergmann ML, et al. (2008) The binding sites for cocaine and dopamine in
the dopamine transporter overlap. Nat Neurosci 11: 780-789.
Birnbaum R and Weinberger DR. (2017) Genetic insights into the neurodevelopmental origins of
schizophrenia. Nat Rev Neurosci 18: 727-740.
Bockaert J and Pin JP. (1999) Molecular tinkering of G protein-coupled receptors: an evolutionary
success. EMBO J 18: 1723-1729.
Bodnar RJ, Paul D, Rosenblum M, et al. (1990) Blockade of morphine analgesia by both pertussis
and cholera toxins in the periaqueductal gray and locus coeruleus. Brain Res 529: 324328.
Bohn LM and Aube J. (2017) Seeking (and Finding) Biased Ligands of the Kappa Opioid Receptor.
ACS Med Chem Lett 8: 694-700.
Bohn LM, Gainetdinov RR, Lin FT, et al. (2000) Mu-opioid receptor desensitization by betaarrestin-2 determines morphine tolerance but not dependence. Nature 408: 720-723.

29
Bohn LM, Gainetdinov RR, Sotnikova TD, et al. (2003) Enhanced rewarding properties of
morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci 23: 1026510273.
Bohn LM, Lefkowitz RJ and Caron MG. (2002) Differential mechanisms of morphine
antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci 22:
10494-10500.
Bohn LM, Lefkowitz RJ, Gainetdinov RR, et al. (1999) Enhanced morphine analgesia in mice lacking
beta-arrestin 2. Science 286: 2495-2498.
Bolam JP, Wainer BH and Smith AD. (1984) Characterization of cholinergic neurons in the rat
neostriatum. A combination of choline acetyltransferase immunocytochemistry, Golgiimpregnation and electron microscopy. Neuroscience 12: 711-718.
Breitman M, Kook S, Gimenez LE, et al. (2012) Silent scaffolds: inhibition OF c-Jun N-terminal
kinase 3 activity in cell by dominant-negative arrestin-3 mutant. J Biol Chem 287: 1965319664.
Breitwieser GE and Szabo G. (1988) Mechanism of muscarinic receptor-induced K+ channel
activation as revealed by hydrolysis-resistant GTP analogues. J Gen Physiol 91: 469-493.
Britt JP and McGehee DS. (2008) Presynaptic opioid and nicotinic receptor modulation of
dopamine overflow in the nucleus accumbens. J Neurosci 28: 1672-1681.
Bruchas MR, Land BB, Aita M, et al. (2007) Stress-induced p38 mitogen-activated protein kinase
activation mediates kappa-opioid-dependent dysphoria. J Neurosci 27: 11614-11623.
Bruchas MR, Macey TA, Lowe JD, et al. (2006) Kappa opioid receptor activation of p38 MAPK is
GRK3- and arrestin-dependent in neurons and astrocytes. J Biol Chem 281: 18081-18089.
Bruijnzeel AW. (2009) kappa-Opioid receptor signaling and brain reward function. Brain Res Rev
62: 127-146.
Brust TF, Morgenweck J, Kim SA, et al. (2016) Biased agonists of the kappa opioid receptor
suppress pain and itch without causing sedation or dysphoria. Sci Signal 9: ra117.
Butko MT, Savas JN, Friedman B, et al. (2013) In vivo quantitative proteomics of somatosensory
cortical synapses shows which protein levels are modulated by sensory deprivation. Proc
Natl Acad Sci U S A 110: E726-735.
Cahill CM, Taylor AM, Cook C, et al. (2014) Does the kappa opioid receptor system contribute to
pain aversion? Front Pharmacol 5: 253.
Carman CV, Parent JL, Day PW, et al. (1999) Selective regulation of Galpha(q/11) by an RGS
domain in the G protein-coupled receptor kinase, GRK2. J Biol Chem 274: 34483-34492.
Cassel D, Eckstein F, Lowe M, et al. (1979) Determination of the turn-off reaction for the
hormone-activated adenylate cyclase. J Biol Chem 254: 9835-9838.
Chartoff EH, Ebner SR, Sparrow A, et al. (2016) Relative Timing Between Kappa Opioid Receptor
Activation and Cocaine Determines the Impact on Reward and Dopamine Release.
Neuropsychopharmacology 41: 989-1002.
Chavkin C and Koob GF. (2016) Dynorphin, Dysphoria, and Dependence: the Stress of Addiction.
Neuropsychopharmacology 41: 373-374.
Chefer VI, Backman CM, Gigante ED, et al. (2013) Kappa opioid receptors on dopaminergic
neurons are necessary for kappa-mediated place aversion. Neuropsychopharmacology
38: 2623-2631.

30
Chefer VI, Czyzyk T, Bolan EA, et al. (2005) Endogenous kappa-opioid receptor systems regulate
mesoaccumbal dopamine dynamics and vulnerability to cocaine. J Neurosci 25: 50295037.
Chen CK, Eversole-Cire P, Zhang H, et al. (2003) Instability of GGL domain-containing RGS proteins
in mice lacking the G protein beta-subunit Gbeta5. Proc Natl Acad Sci U S A 100: 66046609.
Chen N and Reith ME. (2000) Structure and function of the dopamine transporter. Eur J
Pharmacol 405: 329-339.
Ciliax BJ, Heilman C, Demchyshyn LL, et al. (1995) The dopamine transporter: immunochemical
characterization and localization in brain. J Neurosci 15: 1714-1723.
Claing A, Chen W, Miller WE, et al. (2001) beta-Arrestin-mediated ADP-ribosylation factor 6
activation and beta 2-adrenergic receptor endocytosis. J Biol Chem 276: 42509-42513.
Clapham DE and Neer EJ. (1997) G protein beta gamma subunits. Annu Rev Pharmacol Toxicol 37:
167-203.
Collins SL, Kunko PM, Ladenheim B, et al. (2002) Chronic cocaine increases kappa-opioid receptor
density: lack of effect by selective dopamine uptake inhibitors. Synapse 45: 153-158.
Conner DA, Mathier MA, Mortensen RM, et al. (1997) beta-Arrestin1 knockout mice appear
normal but demonstrate altered cardiac responses to beta-adrenergic stimulation. Circ
Res 81: 1021-1026.
Contant C, Umbriaco D, Garcia S, et al. (1996) Ultrastructural characterization of the acetylcholine
innervation in adult rat neostriatum. Neuroscience 71: 937-947.
Contet C, Kieffer BL and Befort K. (2004) Mu opioid receptor: a gateway to drug addiction. Curr
Opin Neurobiol 14: 370-378.
Cowan CW, Fariss RN, Sokal I, et al. (1998) High expression levels in cones of RGS9, the
predominant GTPase accelerating protein of rods. Proc Natl Acad Sci U S A 95: 5351-5356.
Crowley NA and Kash TL. (2015) Kappa opioid receptor signaling in the brain: Circuitry and
implications for treatment. Prog Neuropsychopharmacol Biol Psychiatry 62: 51-60.
Cunha TM, Souza GR, Domingues AC, et al. (2012) Stimulation of peripheral kappa opioid
receptors
inhibits
inflammatory
hyperalgesia
via
activation
of
the
PI3Kgamma/AKT/nNOS/NO signaling pathway. Mol Pain 8: 10.
Dalman FC and O'Malley KL. (1999) kappa-Opioid tolerance and dependence in cultures of
dopaminergic midbrain neurons. J Neurosci 19: 5750-5757.
De Lean A, Stadel JM and Lefkowitz RJ. (1980) A ternary complex model explains the agonistspecific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J
Biol Chem 255: 7108-7117.
DeGraff JL, Gurevich VV and Benovic JL. (2002) The third intracellular loop of alpha 2-adrenergic
receptors determines subtype specificity of arrestin interaction. J Biol Chem 277: 4324743252.
DeHaven-Hudkins DL and Dolle RE. (2004) Peripherally restricted opioid agonists as novel
analgesic agents. Curr Pharm Des 10: 743-757.
DeWire SM, Ahn S, Lefkowitz RJ, et al. (2007) Beta-arrestins and cell signaling. Annu Rev Physiol
69: 483-510.

31
DeWire SM, Yamashita DS, Rominger DH, et al. (2013) A G protein-biased ligand at the mu-opioid
receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction
compared with morphine. J Pharmacol Exp Ther 344: 708-717.
Di Chiara G and Imperato A. (1988) Opposite effects of mu and kappa opiate agonists on
dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving
rats. J Pharmacol Exp Ther 244: 1067-1080.
DiBello PR, Garrison TR, Apanovitch DM, et al. (1998) Selective uncoupling of RGS action by a
single point mutation in the G protein alpha-subunit. J Biol Chem 273: 5780-5784.
Dohlman HG and Thorner J. (1997) RGS proteins and signaling by heterotrimeric G proteins. J Biol
Chem 272: 3871-3874.
Donzanti BA, Althaus JS, Payson MM, et al. (1992) Kappa agonist-induced reduction in dopamine
release: site of action and tolerance. Res Commun Chem Pathol Pharmacol 78: 193-210.
Draisci G and Iadarola MJ. (1989) Temporal analysis of increases in c-fos, preprodynorphin and
preproenkephalin mRNAs in rat spinal cord. Brain Res Mol Brain Res 6: 31-37.
Dunn AD, Reed B, Guariglia C, et al. (2018) Structurally Related Kappa Opioid Receptor Agonists
with Substantial Differential Signaling Bias: Neuroendocrine and Behavioral Effects in
C57BL6 Mice. Int J Neuropsychopharmacol 21: 847-857.
Ehrich JM, Messinger DI, Knakal CR, et al. (2015) Kappa Opioid Receptor-Induced Aversion
Requires p38 MAPK Activation in VTA Dopamine Neurons. J Neurosci 35: 12917-12931.
Ehrich JM, Phillips PE and Chavkin C. (2014) Kappa opioid receptor activation potentiates the
cocaine-induced increase in evoked dopamine release recorded in vivo in the mouse
nucleus accumbens. Neuropsychopharmacology 39: 3036-3048.
Erdely HA, Tamminga CA, Roberts RC, et al. (2006) Regional alterations in RGS4 protein in
schizophrenia. Synapse 59: 472-479.
Escobar Adel P, Cornejo FA, Andres ME, et al. (2012) Repeated treatment with the kappa opioid
receptor agonist U69593 reverses enhanced K+ induced dopamine release in the nucleus
accumbens, but not the expression of locomotor sensitization in amphetamine-sensitized
rats. Neurochem Int 60: 344-349.
Evron T, Daigle TL and Caron MG. (2012) GRK2: multiple roles beyond G protein-coupled receptor
desensitization. Trends Pharmacol Sci 33: 154-164.
Ferguson SS, Downey WE, 3rd, Colapietro AM, et al. (1996) Role of beta-arrestin in mediating
agonist-promoted G protein-coupled receptor internalization. Science 271: 363-366.
Fredriksson R, Lagerstrom MC, Lundin LG, et al. (2003) The G-protein-coupled receptors in the
human genome form five main families. Phylogenetic analysis, paralogon groups, and
fingerprints. Mol Pharmacol 63: 1256-1272.
Freissmuth M, Casey PJ and Gilman AG. (1989) G proteins control diverse pathways of
transmembrane signaling. FASEB J 3: 2125-2131.
Fu Y, Zhong H, Nanamori M, et al. (2004) RGS-insensitive G-protein mutations to study the role
of endogenous RGS proteins. Methods Enzymol 389: 229-243.
Gainetdinov RR, Premont RT, Bohn LM, et al. (2004) Desensitization of G protein-coupled
receptors and neuronal functions. Annu Rev Neurosci 27: 107-144.
Gainetdinov RR, Sotnikova TD and Caron MG. (2002) Monoamine transporter pharmacology and
mutant mice. Trends Pharmacol Sci 23: 367-373.

32
Garnier M, Zaratin PF, Ficalora G, et al. (2003) Up-regulation of regulator of G protein signaling 4
expression in a model of neuropathic pain and insensitivity to morphine. J Pharmacol Exp
Ther 304: 1299-1306.
Georgoussi Z, Leontiadis L, Mazarakou G, et al. (2006) Selective interactions between G protein
subunits and RGS4 with the C-terminal domains of the mu- and delta-opioid receptors
regulate opioid receptor signaling. Cell Signal 18: 771-782.
Geppetti P, Veldhuis NA, Lieu T, et al. (2015) G Protein-Coupled Receptors: Dynamic Machines
for Signaling Pain and Itch. Neuron 88: 635-649.
Gerber KJ, Squires KE and Hepler JR. (2016) Roles for Regulator of G Protein Signaling Proteins in
Synaptic Signaling and Plasticity. Mol Pharmacol 89: 273-286.
Gerfen CR, Engber TM, Mahan LC, et al. (1990) D1 and D2 dopamine receptor-regulated gene
expression of striatonigral and striatopallidal neurons. Science 250: 1429-1432.
Gesty-Palmer D, Chen M, Reiter E, et al. (2006) Distinct beta-arrestin- and G protein-dependent
pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem
281: 10856-10864.
Gilman AG. (1984) G proteins and dual control of adenylate cyclase. Cell 36: 577-579.
Gilman AG. (1987) G proteins: transducers of receptor-generated signals. Annu Rev Biochem 56:
615-649.
Giros B, Jaber M, Jones SR, et al. (1996) Hyperlocomotion and indifference to cocaine and
amphetamine in mice lacking the dopamine transporter. Nature 379: 606-612.
Gold SJ, Ni YG, Dohlman HG, et al. (1997) Regulators of G-protein signaling (RGS) proteins: regionspecific expression of nine subtypes in rat brain. J Neurosci 17: 8024-8037.
Gonzalez D, Riba J, Bouso JC, et al. (2006) Pattern of use and subjective effects of Salvia divinorum
among recreational users. Drug Alcohol Depend 85: 157-162.
Granneman JG, Zhai Y, Zhu Z, et al. (1998) Molecular characterization of human and rat RGS 9L,
a novel splice variant enriched in dopamine target regions, and chromosomal localization
of the RGS 9 gene. Mol Pharmacol 54: 687-694.
Gray AM, Rawls SM, Shippenberg TS, et al. (1999) The kappa-opioid agonist, U-69593, decreases
acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of
dopamine and glutamate in the ventral striatum. J Neurochem 73: 1066-1074.
Grillet N, Pattyn A, Contet C, et al. (2005) Generation and characterization of Rgs4 mutant mice.
Mol Cell Biol 25: 4221-4228.
Grilli M, Neri E, Zappettini S, et al. (2009) Salvinorin A exerts opposite presynaptic controls on
neurotransmitter exocytosis from mouse brain nerve terminals. Neuropharmacology 57:
523-530.
Guipponi M, Santoni FA, Setola V, et al. (2014) Exome sequencing in 53 sporadic cases of
schizophrenia identifies 18 putative candidate genes. PLoS One 9: e112745.
Gurevich VV and Gurevich EV. (2019) GPCR Signaling Regulation: The Role of GRKs and Arrestins.
Front Pharmacol 10: 125.
Han MH, Renthal W, Ring RH, et al. (2010) Brain region specific actions of regulator of G protein
signaling 4 oppose morphine reward and dependence but promote analgesia. Biol
Psychiatry 67: 761-769.
Hart MJ, Jiang X, Kozasa T, et al. (1998) Direct stimulation of the guanine nucleotide exchange
activity of p115 RhoGEF by Galpha13. Science 280: 2112-2114.

33
Hausdorff WP, Bouvier M, O'Dowd BF, et al. (1989) Phosphorylation sites on two domains of the
beta 2-adrenergic receptor are involved in distinct pathways of receptor desensitization.
J Biol Chem 264: 12657-12665.
Hauser AS, Attwood MM, Rask-Andersen M, et al. (2017) Trends in GPCR drug discovery: new
agents, targets and indications. Nat Rev Drug Discov 16: 829-842.
He W, Cowan CW and Wensel TG. (1998) RGS9, a GTPase accelerator for phototransduction.
Neuron 20: 95-102.
Heidbreder CA, Goldberg SR and Shippenberg TS. (1993) The kappa-opioid receptor agonist U69593 attenuates cocaine-induced behavioral sensitization in the rat. Brain Res 616: 335338.
Heijna MH, Padt M, Hogenboom F, et al. (1990) Opioid receptor-mediated inhibition of dopamine
and acetylcholine release from slices of rat nucleus accumbens, olfactory tubercle and
frontal cortex. Eur J Pharmacol 181: 267-278.
Hepler JR and Gilman AG. (1992) G proteins. Trends Biochem Sci 17: 383-387.
Hernandez A, Soto-Moyano R, Mestre C, et al. (1995) Intrathecal pertussis toxin but not cyclic
AMP blocks kappa opioid-induced antinociception in rat. Int J Neurosci 81: 193-197.
Heximer SP, Knutsen RH, Sun X, et al. (2003) Hypertension and prolonged vasoconstrictor
signaling in RGS2-deficient mice. J Clin Invest 111: 1259.
Huang J, Nalli AD, Mahavadi S, et al. (2014) Inhibition of Galphai activity by Gbetagamma is
mediated by PI 3-kinase-gamma- and cSrc-dependent tyrosine phosphorylation of
Galphai and recruitment of RGS12. Am J Physiol Gastrointest Liver Physiol 306: G802-810.
Ji RR, Zhang Q, Law PY, et al. (1995) Expression of mu-, delta-, and kappa-opioid receptor-like
immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. J
Neurosci 15: 8156-8166.
Johnson MW, MacLean KA, Reissig CJ, et al. (2011) Human psychopharmacology and dose-effects
of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.
Drug Alcohol Depend 115: 150-155.
Kammermeier PJ, Ruiz-Velasco V and Ikeda SR. (2000) A voltage-independent calcium current
inhibitory pathway activated by muscarinic agonists in rat sympathetic neurons requires
both Galpha q/11 and Gbeta gamma. J Neurosci 20: 5623-5629.
Kang DS, Tian X and Benovic JL. (2013) beta-Arrestins and G protein-coupled receptor trafficking.
Methods Enzymol 521: 91-108.
Kang DS, Tian X and Benovic JL. (2014) Role of beta-arrestins and arrestin domain-containing
proteins in G protein-coupled receptor trafficking. Curr Opin Cell Biol 27: 63-71.
Kardon AP, Polgar E, Hachisuka J, et al. (2014) Dynorphin acts as a neuromodulator to inhibit itch
in the dorsal horn of the spinal cord. Neuron 82: 573-586.
Karkhanis A, Holleran KM and Jones SR. (2017) Dynorphin/Kappa Opioid Receptor Signaling in
Preclinical Models of Alcohol, Drug, and Food Addiction. Int Rev Neurobiol 136: 53-88.
Karkhanis AN, Rose JH, Weiner JL, et al. (2016) Early-Life Social Isolation Stress Increases Kappa
Opioid Receptor Responsiveness and Downregulates the Dopamine System.
Neuropsychopharmacology 41: 2263-2274.
Katritch V, Cherezov V and Stevens RC. (2013) Structure-function of the G protein-coupled
receptor superfamily. Annu Rev Pharmacol Toxicol 53: 531-556.

34
Kaur K, Kehrl JM, Charbeneau RA, et al. (2011) RGS-insensitive Galpha subunits: probes of Galpha
subtype-selective signaling and physiological functions of RGS proteins. Methods Mol Biol
756: 75-98.
Kenakin T. (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends
Pharmacol Sci 16: 232-238.
Kenakin T. (2004) Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25: 186-192.
Kenakin T. (2011) Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336:
296-302.
Kimple AJ, Bosch DE, Giguere PM, et al. (2011) Regulators of G-protein signaling and their Galpha
substrates: promises and challenges in their use as drug discovery targets. Pharmacol Rev
63: 728-749.
Kimple RJ, De Vries L, Tronchere H, et al. (2001) RGS12 and RGS14 GoLoco motifs are G alpha(i)
interaction sites with guanine nucleotide dissociation inhibitor Activity. J Biol Chem 276:
29275-29281.
Kivell B and Prisinzano TE. (2010) Kappa opioids and the modulation of pain.
Psychopharmacology (Berl) 210: 109-119.
Kivell B, Uzelac Z, Sundaramurthy S, et al. (2014) Salvinorin A regulates dopamine transporter
function via a kappa opioid receptor and ERK1/2-dependent mechanism.
Neuropharmacology 86: 228-240.
Kivell BM, Paton KF, Kumar N, et al. (2018) Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates
Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in
Rodents. Molecules 23.
Knoll AT and Carlezon WA, Jr. (2010) Dynorphin, stress, and depression. Brain Res 1314: 56-73.
Koblish M, Carr R, 3rd, Siuda ER, et al. (2017) TRV0109101, a G Protein-Biased Agonist of the
micro-Opioid Receptor, Does Not Promote Opioid-Induced Mechanical Allodynia
following Chronic Administration. J Pharmacol Exp Ther 362: 254-262.
Koch WJ, Inglese J, Stone WC, et al. (1993) The binding site for the beta gamma subunits of
heterotrimeric G proteins on the beta-adrenergic receptor kinase. J Biol Chem 268: 82568260.
Krishnan A and Schioth HB. (2015) The role of G protein-coupled receptors in the early evolution
of neurotransmission and the nervous system. J Exp Biol 218: 562-571.
Kuhar MJ, Sanchez-Roa PM, Wong DF, et al. (1990) Dopamine transporter: biochemistry,
pharmacology and imaging. Eur Neurol 30 Suppl 1: 15-20.
Kumagai H, Ebata T, Takamori K, et al. (2010) Effect of a novel kappa-receptor agonist, nalfurafine
hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized,
double-blind, placebo-controlled study. Nephrol Dial Transplant 25: 1251-1257.
Lagerstrom MC and Schioth HB. (2008) Structural diversity of G protein-coupled receptors and
significance for drug discovery. Nat Rev Drug Discov 7: 339-357.
Lalanne L, Ayranci G, Kieffer BL, et al. (2014) The kappa opioid receptor: from addiction to
depression, and back. Front Psychiatry 5: 170.
Lamberts JT, Smith CE, Li MH, et al. (2013) Differential control of opioid antinociception to
thermal stimuli in a knock-in mouse expressing regulator of G-protein signalinginsensitive Galphao protein. J Neurosci 33: 4369-4377.

35
Lambright DG, Noel JP, Hamm HE, et al. (1994) Structural determinants for activation of the
alpha-subunit of a heterotrimeric G protein. Nature 369: 621-628.
Lan KL, Sarvazyan NA, Taussig R, et al. (1998) A point mutation in Galphao and Galphai1 blocks
interaction with regulator of G protein signaling proteins. J Biol Chem 273: 12794-12797.
Land BB, Bruchas MR, Schattauer S, et al. (2009) Activation of the kappa opioid receptor in the
dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking.
Proc Natl Acad Sci U S A 106: 19168-19173.
Larminie C, Murdock P, Walhin JP, et al. (2004) Selective expression of regulators of G-protein
signaling (RGS) in the human central nervous system. Brain Res Mol Brain Res 122: 24-34.
Lee SE, Simons SB, Heldt SA, et al. (2010) RGS14 is a natural suppressor of both synaptic plasticity
in CA2 neurons and hippocampal-based learning and memory. Proc Natl Acad Sci U S A
107: 16994-16998.
Lefkowitz RJ and Whalen EJ. (2004) beta-arrestins: traffic cops of cell signaling. Curr Opin Cell Biol
16: 162-168.
Leontiadis LJ, Papakonstantinou MP and Georgoussi Z. (2009) Regulator of G protein signaling 4
confers selectivity to specific G proteins to modulate mu- and delta-opioid receptor
signaling. Cell Signal 21: 1218-1228.
Liu SS, Pickens S, Burma NE, et al. (2019) Kappa Opioid Receptors Drive a Tonic Aversive
Component of Chronic Pain. J Neurosci.
Lohse MJ, Benovic JL, Codina J, et al. (1990) beta-Arrestin: a protein that regulates betaadrenergic receptor function. Science 248: 1547-1550.
Lopez-Aranda MF, Acevedo MJ, Carballo FJ, et al. (2006) Localization of the GoLoco motif carrier
regulator of G-protein signalling 12 and 14 proteins in monkey and rat brain. Eur J
Neurosci 23: 2971-2982.
Luo J, Busillo JM and Benovic JL. (2008) M3 muscarinic acetylcholine receptor-mediated signaling
is regulated by distinct mechanisms. Mol Pharmacol 74: 338-347.
Luscher C and Slesinger PA. (2010) Emerging roles for G protein-gated inwardly rectifying
potassium (GIRK) channels in health and disease. Nat Rev Neurosci 11: 301-315.
Luttrell LM, Ferguson SS, Daaka Y, et al. (1999) Beta-arrestin-dependent formation of beta2
adrenergic receptor-Src protein kinase complexes. Science 283: 655-661.
Lutz S, Shankaranarayanan A, Coco C, et al. (2007) Structure of Galphaq-p63RhoGEF-RhoA
complex reveals a pathway for the activation of RhoA by GPCRs. Science 318: 1923-1927.
MacLean KA, Johnson MW, Reissig CJ, et al. (2013) Dose-related effects of salvinorin A in humans:
dissociative, hallucinogenic, and memory effects. Psychopharmacology (Berl) 226: 381392.
Madariaga-Mazon A, Marmolejo-Valencia AF, Li Y, et al. (2017) Mu-Opioid receptor biased
ligands: A safer and painless discovery of analgesics? Drug Discov Today 22: 1719-1729.
Mahendran R, Lim HA, Tan JY, et al. (2016) Salvia divinorum: An overview of the usage, misuse,
and addiction processes. Asia Pac Psychiatry 8: 23-31.
Mancuso JJ, Qian Y, Long C, et al. (2010) Distribution of RGS9-2 in neurons of the mouse striatum.
J Neurochem 112: 651-661.
Manglik A, Lin H, Aryal DK, et al. (2016) Structure-based discovery of opioid analgesics with
reduced side effects. Nature 537: 185-190.

36
Mansour A, Fox CA, Burke S, et al. (1995) Immunohistochemical localization of the cloned mu
opioid receptor in the rat CNS. J Chem Neuroanat 8: 283-305.
Mansour A, Fox CA, Burke S, et al. (1994) Mu, delta, and kappa opioid receptor mRNA expression
in the rat CNS: an in situ hybridization study. J Comp Neurol 350: 412-438.
Maqueda AE, Valle M, Addy PH, et al. (2015) Salvinorin-A Induces Intense Dissociative Effects,
Blocking External Sensory Perception and Modulating Interoception and Sense of Body
Ownership in Humans. Int J Neuropsychopharmacol 18.
Margolis EB, Lock H, Chefer VI, et al. (2006) Kappa opioids selectively control dopaminergic
neurons projecting to the prefrontal cortex. Proc Natl Acad Sci U S A 103: 2938-2942.
Marion S, Oakley RH, Kim KM, et al. (2006) A beta-arrestin binding determinant common to the
second intracellular loops of rhodopsin family G protein-coupled receptors. J Biol Chem
281: 2932-2938.
Martemyanov KA, Hopp JA and Arshavsky VY. (2003) Specificity of G protein-RGS protein
recognition is regulated by affinity adapters. Neuron 38: 857-862.
Martin-McCaffrey L, Hains MD, Pritchard GA, et al. (2005) Differential expression of regulator of
G-protein signaling R12 subfamily members during mouse development. Dev Dyn 234:
438-444.
Massaly N, Copits BA, Wilson-Poe AR, et al. (2019) Pain-Induced Negative Affect Is Mediated via
Recruitment of The Nucleus Accumbens Kappa Opioid System. Neuron 102: 564-573
e566.
McCudden CR, Hains MD, Kimple RJ, et al. (2005) G-protein signaling: back to the future. Cell Mol
Life Sci 62: 551-577.
McDonald PH, Chow CW, Miller WE, et al. (2000) Beta-arrestin 2: a receptor-regulated MAPK
scaffold for the activation of JNK3. Science 290: 1574-1577.
McLaughlin JP, Land BB, Li S, et al. (2006) Prior activation of kappa opioid receptors by U50,488
mimics repeated forced swim stress to potentiate cocaine place preference conditioning.
Neuropsychopharmacology 31: 787-794.
McLaughlin JP, Myers LC, Zarek PE, et al. (2004) Prolonged kappa opioid receptor
phosphorylation mediated by G-protein receptor kinase underlies sustained analgesic
tolerance. J Biol Chem 279: 1810-1818.
McLennan GP, Kiss A, Miyatake M, et al. (2008) Kappa opioids promote the proliferation of
astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways. J
Neurochem 107: 1753-1765.
Melchior JR and Jones SR. (2017) Chronic ethanol exposure increases inhibition of optically
targeted phasic dopamine release in the nucleus accumbens core and medial shell ex vivo.
Mol Cell Neurosci 85: 93-104.
Mirnics K, Middleton FA, Stanwood GD, et al. (2001) Disease-specific changes in regulator of Gprotein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 6: 293-301.
Morgenweck J, Frankowski KJ, Prisinzano TE, et al. (2015) Investigation of the role of
betaarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus.
Neuropharmacology 99: 600-609.
Moss J and Vaughan M. (1988) ADP-ribosylation of guanyl nucleotide-binding regulatory proteins
by bacterial toxins. Adv Enzymol Relat Areas Mol Biol 61: 303-379.

37
Neer EJ. (1995) Heterotrimeric G proteins: organizers of transmembrane signals. Cell 80: 249257.
Nestler EJ. (2001) Molecular neurobiology of addiction. Am J Addict 10: 201-217.
Neubig RR and Siderovski DP. (2002) Regulators of G-protein signalling as new central nervous
system drug targets. Nat Rev Drug Discov 1: 187-197.
Nockemann D, Rouault M, Labuz D, et al. (2013) The K(+) channel GIRK2 is both necessary and
sufficient for peripheral opioid-mediated analgesia. EMBO Mol Med 5: 1263-1277.
Oakley RH, Laporte SA, Holt JA, et al. (2000) Differential affinities of visual arrestin, beta arrestin1,
and beta arrestin2 for G protein-coupled receptors delineate two major classes of
receptors. J Biol Chem 275: 17201-17210.
Oldham WM and Hamm HE. (2008) Heterotrimeric G protein activation by G-protein-coupled
receptors. Nat Rev Mol Cell Biol 9: 60-71.
Oliveira-Dos-Santos AJ, Matsumoto G, Snow BE, et al. (2000) Regulation of T cell activation,
anxiety, and male aggression by RGS2. Proc Natl Acad Sci U S A 97: 12272-12277.
Owen MJ, O'Donovan MC, Thapar A, et al. (2011) Neurodevelopmental hypothesis of
schizophrenia. Br J Psychiatry 198: 173-175.
Pack TF, Orlen MI, Ray C, et al. (2018) The dopamine D2 receptor can directly recruit and activate
GRK2 without G protein activation. J Biol Chem 293: 6161-6171.
Pan ZZ. (1998) mu-Opposing actions of the kappa-opioid receptor. Trends Pharmacol Sci 19: 9498.
Parolaro D, Patrini G, Giagnoni G, et al. (1990) Pertussis toxin inhibits morphine analgesia and
prevents opiate dependence. Pharmacol Biochem Behav 35: 137-141.
Pfeiffer A, Brantl V, Herz A, et al. (1986) Psychotomimesis mediated by kappa opiate receptors.
Science 233: 774-776.
Philipp M, Evron T and Caron MG. (2013) The role of arrestins in development. Prog Mol Biol
Transl Sci 118: 225-242.
Pierce KL, Premont RT and Lefkowitz RJ. (2002) Seven-transmembrane receptors. Nat Rev Mol
Cell Biol 3: 639-650.
Pitcher JA, Freedman NJ and Lefkowitz RJ. (1998) G protein-coupled receptor kinases. Annu Rev
Biochem 67: 653-692.
Psifogeorgou K, Papakosta P, Russo SJ, et al. (2007) RGS9-2 is a negative modulator of mu-opioid
receptor function. J Neurochem 103: 617-625.
Psifogeorgou K, Terzi D, Papachatzaki MM, et al. (2011) A unique role of RGS9-2 in the striatum
as a positive or negative regulator of opiate analgesia. J Neurosci 31: 5617-5624.
Raehal KM, Schmid CL, Groer CE, et al. (2011) Functional selectivity at the mu-opioid receptor:
implications for understanding opioid analgesia and tolerance. Pharmacol Rev 63: 10011019.
Raehal KM, Walker JK and Bohn LM. (2005) Morphine side effects in beta-arrestin 2 knockout
mice. J Pharmacol Exp Ther 314: 1195-1201.
Rahman Z, Gold SJ, Potenza MN, et al. (1999) Cloning and characterization of RGS9-2: a striatalenriched alternatively spliced product of the RGS9 gene. J Neurosci 19: 2016-2026.
Rahman Z, Schwarz J, Gold SJ, et al. (2003) RGS9 modulates dopamine signaling in the basal
ganglia. Neuron 38: 941-952.

38
Ranganathan M, Schnakenberg A, Skosnik PD, et al. (2012) Dose-related behavioral, subjective,
endocrine, and psychophysiological effects of the kappa opioid agonist Salvinorin A in
humans. Biol Psychiatry 72: 871-879.
Reiter E, Ahn S, Shukla AK, et al. (2012) Molecular mechanism of beta-arrestin-biased agonism at
seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 52: 179-197.
Research FDADACfDE. (2018) Oliceridine Briefing Document. FDA.
Rivero G, Gabilondo AM, Garcia-Fuster MJ, et al. (2012) Differential regulation of RGS proteins in
the prefrontal cortex of short- and long-term human opiate abusers. Neuropharmacology
62: 1044-1051.
Roman DL and Traynor JR. (2011) Regulators of G protein signaling (RGS) proteins as drug targets:
modulating G-protein-coupled receptor (GPCR) signal transduction. J Med Chem 54: 74337440.
Romero G, von Zastrow M and Friedman PA. (2011) Role of PDZ proteins in regulating trafficking,
signaling, and function of GPCRs: means, motif, and opportunity. Adv Pharmacol 62: 279314.
Rose JH, Karkhanis AN, Chen R, et al. (2016) Supersensitive Kappa Opioid Receptors Promotes
Ethanol Withdrawal-Related Behaviors and Reduce Dopamine Signaling in the Nucleus
Accumbens. Int J Neuropsychopharmacol 19.
Rosenbaum DM, Rasmussen SG and Kobilka BK. (2009) The structure and function of G-proteincoupled receptors. Nature 459: 356-363.
Roth BL, Baner K, Westkaemper R, et al. (2002) Salvinorin A: a potent naturally occurring
nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 99: 11934-11939.
Rothman RB, Baumann MH, Dersch CM, et al. (2001) Amphetamine-type central nervous system
stimulants release norepinephrine more potently than they release dopamine and
serotonin. Synapse 39: 32-41.
Ruiz de Azua I, Scarselli M, Rosemond E, et al. (2010) RGS4 is a negative regulator of insulin
release from pancreatic beta-cells in vitro and in vivo. Proc Natl Acad Sci U S A 107: 79998004.
Sambi BS, Hains MD, Waters CM, et al. (2006) The effect of RGS12 on PDGFbeta receptor
signalling to p42/p44 mitogen activated protein kinase in mammalian cells. Cell Signal 18:
971-981.
Sanchez-Blazquez P, Rodriguez-Diaz M, Lopez-Fando A, et al. (2003) The GBeta5 subunit that
associates with the R7 subfamily of RGS proteins regulates mu-opioid effects.
Neuropharmacology 45: 82-95.
Santos R, Ursu O, Gaulton A, et al. (2017) A comprehensive map of molecular drug targets. Nat
Rev Drug Discov 16: 19-34.
Schattauer SS, Kuhar JR, Song A, et al. (2017) Nalfurafine is a G-protein biased agonist having
significantly greater bias at the human than rodent form of the kappa opioid receptor.
Cell Signal 32: 59-65.
Scheerer P and Sommer ME. (2017) Structural mechanism of arrestin activation. Curr Opin Struct
Biol 45: 160-169.
Schindler AG, Li S and Chavkin C. (2010) Behavioral stress may increase the rewarding valence of
cocaine-associated cues through a dynorphin/kappa-opioid receptor-mediated

39
mechanism without affecting associative learning or memory retrieval mechanisms.
Neuropsychopharmacology 35: 1932-1942.
Schmid CL, Kennedy NM, Ross NC, et al. (2017) Bias Factor and Therapeutic Window Correlate to
Predict Safer Opioid Analgesics. Cell 171: 1165-1175 e1113.
Schmid CL, Streicher JM, Groer CE, et al. (2013) Functional selectivity of 6'-guanidinonaltrindole
(6'-GNTI) at kappa-opioid receptors in striatal neurons. J Biol Chem 288: 22387-22398.
Shenoy SK and Lefkowitz RJ. (2011) beta-Arrestin-mediated receptor trafficking and signal
transduction. Trends Pharmacol Sci 32: 521-533.
Shippenberg TS, Bals-Kubik R and Herz A. (1993) Examination of the neurochemical substrates
mediating the motivational effects of opioids: role of the mesolimbic dopamine system
and D-1 vs. D-2 dopamine receptors. J Pharmacol Exp Ther 265: 53-59.
Shippenberg TS and Herz A. (1986) Differential effects of mu and kappa opioid systems on
motivational processes. NIDA Res Monogr 75: 563-566.
Shippenberg TS, LeFevour A and Heidbreder C. (1996) kappa-Opioid receptor agonists prevent
sensitization to the conditioned rewarding effects of cocaine. J Pharmacol Exp Ther 276:
545-554.
Sialana FJ, Wang AL, Fazari B, et al. (2018) Quantitative Proteomics of Synaptosomal Fractions in
a Rat Overexpressing Human DISC1 Gene Indicates Profound Synaptic Dysregulation in
the Dorsal Striatum. Front Mol Neurosci 11: 26.
Siderovski DP KA. (2013) Regulator of G-Protein Signaling (RGS) Protein Family. In: S C (ed)
Encyclopedia of signaling molecules. . New York, New York: Springer, 3.
Siderovski DP KA, Willard FS. . (2008) Large G-Proteins. . In: Begley TP e (ed) Wiley Encyclopedia
of Chemical Biology. . Hoboken, New Jersey: John Wiley & Sons, Inc.
Siderovski DP and Willard FS. (2005) The GAPs, GEFs, and GDIs of heterotrimeric G-protein alpha
subunits. Int J Biol Sci 1: 51-66.
Siehler S. (2009) Regulation of RhoGEF proteins by G12/13-coupled receptors. Br J Pharmacol
158: 41-49.
Simon MI, Strathmann MP and Gautam N. (1991) Diversity of G proteins in signal transduction.
Science 252: 802-808.
Simonds WF. (1999) G protein regulation of adenylate cyclase. Trends Pharmacol Sci 20: 66-73.
Simonin F, Valverde O, Smadja C, et al. (1998) Disruption of the kappa-opioid receptor gene in
mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of
the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 17:
886-897.
Simonson B, Morani AS, Ewald AW, et al. (2015) Pharmacology and anti-addiction effects of the
novel kappa opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of
salvinorin A. Br J Pharmacol 172: 515-531.
Singla N, Minkowitz HS, Soergel DG, et al. (2017) A randomized, Phase IIb study investigating
oliceridine (TRV130), a novel micro-receptor G-protein pathway selective (mu-GPS)
modulator, for the management of moderate to severe acute pain following
abdominoplasty. J Pain Res 10: 2413-2424.
Sjogren B. (2017) The evolution of regulators of G protein signalling proteins as drug targets - 20
years in the making: IUPHAR Review 21. Br J Pharmacol 174: 427-437.

40
Smith JS and Rajagopal S. (2016a) The beta-Arrestins: Multifunctional Regulators of G Proteincoupled Receptors. 291: 8969-8977.
Smith JS and Rajagopal S. (2016b) The beta-Arrestins: Multifunctional Regulators of G Proteincoupled Receptors. J Biol Chem 291: 8969-8977.
Snow BE, Antonio L, Suggs S, et al. (1997) Molecular cloning and expression analysis of rat Rgs12
and Rgs14. Biochem Biophys Res Commun 233: 770-777.
Snow BE, Brothers GM and Siderovski DP. (2002) Molecular cloning of regulators of G-protein
signaling family members and characterization of binding specificity of RGS12 PDZ
domain. Methods Enzymol 344: 740-761.
Snow BE, Hall RA, Krumins AM, et al. (1998a) GTPase activating specificity of RGS12 and binding
specificity of an alternatively spliced PDZ (PSD-95/Dlg/ZO-1) domain. J Biol Chem 273:
17749-17755.
Snow BE, Krumins AM, Brothers GM, et al. (1998b) A G protein gamma subunit-like domain
shared between RGS11 and other RGS proteins specifies binding to Gbeta5 subunits. Proc
Natl Acad Sci U S A 95: 13307-13312.
Snyder SH and Pasternak GW. (2003) Historical review: Opioid receptors. Trends Pharmacol Sci
24: 198-205.
Sohn J, Hioki H, Okamoto S, et al. (2014) Preprodynorphin-expressing neurons constitute a large
subgroup of somatostatin-expressing GABAergic interneurons in the mouse neocortex. J
Comp Neurol 522: 1506-1526.
Soundararajan M, Willard FS, Kimple AJ, et al. (2008) Structural diversity in the RGS domain and
its interaction with heterotrimeric G protein alpha-subunits. Proc Natl Acad Sci U S A 105:
6457-6462.
Spanagel R, Herz A and Shippenberg TS. (1992) Opposing tonically active endogenous opioid
systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A 89:
2046-2050.
Stephenson RP. (1956) A modification of receptor theory. Br J Pharmacol Chemother 11: 379393.
Sun Y, Cheng Z, Ma L, et al. (2002) Beta-arrestin2 is critically involved in CXCR4-mediated
chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem
277: 49212-49219.
Svingos AL, Chavkin C, Colago EE, et al. (2001) Major coexpression of kappa-opioid receptors and
the dopamine transporter in nucleus accumbens axonal profiles. Synapse 42: 185-192.
Talbot JN, Roman DL, Clark MJ, et al. (2010) Differential modulation of mu-opioid receptor
signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in
permeabilised C6 cells is Galpha subtype dependent. J Neurochem 112: 1026-1034.
Tedford HW and Zamponi GW. (2006) Direct G protein modulation of Cav2 calcium channels.
Pharmacol Rev 58: 837-862.
Tekumalla PK, Calon F, Rahman Z, et al. (2001) Elevated levels of DeltaFosB and RGS9 in striatum
in Parkinson's disease. Biol Psychiatry 50: 813-816.
Thompson AC, Zapata A, Justice JB, Jr., et al. (2000) Kappa-opioid receptor activation modifies
dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. J
Neurosci 20: 9333-9340.

41
Threlfell S and Cragg SJ. (2011) Dopamine signaling in dorsal versus ventral striatum: the dynamic
role of cholinergic interneurons. Front Syst Neurosci 5: 11.
Todtenkopf MS, Marcus JF, Portoghese PS, et al. (2004) Effects of kappa-opioid receptor ligands
on intracranial self-stimulation in rats. Psychopharmacology (Berl) 172: 463-470.
Torres GE, Gainetdinov RR and Caron MG. (2003) Plasma membrane monoamine transporters:
structure, regulation and function. Nat Rev Neurosci 4: 13-25.
Touhara K, Inglese J, Pitcher JA, et al. (1994) Binding of G protein beta gamma-subunits to
pleckstrin homology domains. J Biol Chem 269: 10217-10220.
Traynor J. (2012) mu-Opioid receptors and regulators of G protein signaling (RGS) proteins: from
a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend 121:
173-180.
Traynor JR, Terzi D, Caldarone BJ, et al. (2009) RGS9-2: probing an intracellular modulator of
behavior as a drug target. Trends Pharmacol Sci 30: 105-111.
Trifilieff P and Martinez D. (2013) Kappa-opioid receptor signaling in the striatum as a potential
modulator of dopamine transmission in cocaine dependence. Front Psychiatry 4: 44.
Ullrich A and Schlessinger J. (1990) Signal transduction by receptors with tyrosine kinase activity.
Cell 61: 203-212.
Unwin N. (1993) Neurotransmitter action: opening of ligand-gated ion channels. Cell 72 Suppl:
31-41.
Urban JD, Clarke WP, von Zastrow M, et al. (2007) Functional selectivity and classical concepts of
quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13.
Urits I, Viswanath O, Orhurhu V, et al. (2019) The Utilization of Mu-Opioid Receptor Biased
Agonists: Oliceridine, an Opioid Analgesic with Reduced Adverse Effects. Curr Pain
Headache Rep 23: 31.
Valentino RJ and Volkow ND. (2018) Untangling the complexity of opioid receptor function.
Neuropsychopharmacology 43: 2514-2520.
Van't Veer A and Carlezon WA, Jr. (2013) Role of kappa-opioid receptors in stress and anxietyrelated behavior. Psychopharmacology (Berl) 229: 435-452.
Vanderah TW. (2010) Delta and kappa opioid receptors as suitable drug targets for pain. Clin J
Pain 26 Suppl 10: S10-15.
Vanderschuren LJ, Schoffelmeer AN, Wardeh G, et al. (2000) Dissociable effects of the kappaopioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and
long-term behavioral sensitization induced by amphetamine and cocaine.
Psychopharmacology (Berl) 150: 35-44.
Vaughan RA and Foster JD. (2013) Mechanisms of dopamine transporter regulation in normal
and disease states. Trends Pharmacol Sci 34: 489-496.
Vien TN, Gleason CA, Hays SL, et al. (2009) Effects of neonatal stress and morphine on kappa
opioid receptor signaling. Neonatology 96: 235-243.
Violin JD and Lefkowitz RJ. (2007) Beta-arrestin-biased ligands at seven-transmembrane
receptors. Trends Pharmacol Sci 28: 416-422.
Vonvoigtlander PF, Lahti RA and Ludens JH. (1983) U-50,488: a selective and structurally novel
non-Mu (kappa) opioid agonist. J Pharmacol Exp Ther 224: 7-12.
Vuong TM and Chabre M. (1991) Deactivation kinetics of the transduction cascade of vision. Proc
Natl Acad Sci U S A 88: 9813-9817.

42
Wagley Y, Hwang CK, Lin HY, et al. (2013) Inhibition of c-Jun NH2-terminal kinase stimulates mu
opioid receptor expression via p38 MAPK-mediated nuclear NF-kappaB activation in
neuronal and non-neuronal cells. Biochim Biophys Acta 1833: 1476-1488.
Wagner R, DeLeo JA, Coombs DW, et al. (1993) Spinal dynorphin immunoreactivity increases
bilaterally in a neuropathic pain model. Brain Res 629: 323-326.
Waldhoer M, Bartlett SE and Whistler JL. (2004) Opioid receptors. Annu Rev Biochem 73: 953990.
Walker BM and Koob GF. (2008) Pharmacological evidence for a motivational role of kappaopioid systems in ethanol dependence. Neuropsychopharmacology 33: 643-652.
Wang HB, Zhao B, Zhong YQ, et al. (2010) Coexpression of delta- and mu-opioid receptors in
nociceptive sensory neurons. Proc Natl Acad Sci U S A 107: 13117-13122.
Wang Q, Liu-Chen LY and Traynor JR. (2009) Differential modulation of mu- and delta-opioid
receptor agonists by endogenous RGS4 protein in SH-SY5Y cells. J Biol Chem 284: 1835718367.
Wang Y, Wang J, Zhang L, et al. (2017) RGS12 Is a Novel Tumor-Suppressor Gene in African
American Prostate Cancer That Represses AKT and MNX1 Expression. Cancer Res 77:
4247-4257.
Wang Z, Gardell LR, Ossipov MH, et al. (2001) Pronociceptive actions of dynorphin maintain
chronic neuropathic pain. J Neurosci 21: 1779-1786.
Wei H, Ahn S, Shenoy SK, et al. (2003) Independent beta-arrestin 2 and G protein-mediated
pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2.
Proc Natl Acad Sci U S A 100: 10782-10787.
Whalen EJ, Rajagopal S and Lefkowitz RJ. (2011) Therapeutic potential of beta-arrestin- and G
protein-biased agonists. Trends Mol Med 17: 126-139.
White KL, Robinson JE, Zhu H, et al. (2015) The G protein-biased kappa-opioid receptor agonist
RB-64 is analgesic with a unique spectrum of activities in vivo. J Pharmacol Exp Ther 352:
98-109.
Wilden U, Wust E, Weyand I, et al. (1986) Rapid affinity purification of retinal arrestin (48 kDa
protein) via its light-dependent binding to phosphorylated rhodopsin. FEBS Lett 207: 292295.
Willard FS, Willard MD, Kimple AJ, et al. (2009) Regulator of G-protein signaling 14 (RGS14) is a
selective H-Ras effector. PLoS One 4: e4884.
Willard MD, Willard FS, Li X, et al. (2007) Selective role for RGS12 as a Ras/Raf/MEK scaffold in
nerve growth factor-mediated differentiation. EMBO J 26: 2029-2040.
Xia YF, He L, Whistler JL, et al. (2008) Acute amphetamine exposure selectively desensitizes
kappa-opioid receptors in the nucleus accumbens. Neuropsychopharmacology 33: 892900.
Xie GX and Palmer PP. (2005) RGS proteins: new players in the field of opioid signaling and
tolerance mechanisms. Anesth Analg 100: 1034-1042.
Xie Z, Li Z, Guo L, et al. (2007) Regulator of G protein signaling proteins differentially modulate
signaling of mu and delta opioid receptors. Eur J Pharmacol 565: 45-53.
Xu B, Roos JL, Dexheimer P, et al. (2011) Exome sequencing supports a de novo mutational
paradigm for schizophrenia. Nat Genet 43: 864-868.

43
Xu M, Petraschka M, McLaughlin JP, et al. (2004) Neuropathic pain activates the endogenous
kappa opioid system in mouse spinal cord and induces opioid receptor tolerance. J
Neurosci 24: 4576-4584.
Xu X, Zeng W, Popov S, et al. (1999) RGS proteins determine signaling specificity of Gq-coupled
receptors. J Biol Chem 274: 3549-3556.
Yaffe MB. (2002) Phosphotyrosine-binding domains in signal transduction. Nat Rev Mol Cell Biol
3: 177-186.
Yasuda K, Raynor K, Kong H, et al. (1993) Cloning and functional comparison of kappa and delta
opioid receptors from mouse brain. Proc Natl Acad Sci U S A 90: 6736-6740.
Yorgason JT, Calipari ES, Ferris MJ, et al. (2016) Social isolation rearing increases dopamine uptake
and psychostimulant potency in the striatum. Neuropharmacology 101: 471-479.
Zachariou V, Georgescu D, Sanchez N, et al. (2003) Essential role for RGS9 in opiate action. Proc
Natl Acad Sci U S A 100: 13656-13661.
Zhang Y, Butelman ER, Schlussman SD, et al. (2004) Effect of the kappa opioid agonist R-84760
on cocaine-induced increases in striatal dopamine levels and cocaine-induced place
preference in C57BL/6J mice. Psychopharmacology (Berl) 173: 146-152.
Zheng B, De Vries L and Gist Farquhar M. (1999) Divergence of RGS proteins: evidence for the
existence of six mammalian RGS subfamilies. Trends Biochem Sci 24: 411-414.
Zheng B, Ma YC, Ostrom RS, et al. (2001) RGS-PX1, a GAP for GalphaS and sorting nexin in
vesicular trafficking. Science 294: 1939-1942.
Zhong H and Neubig RR. (2001) Regulator of G protein signaling proteins: novel multifunctional
drug targets. J Pharmacol Exp Ther 297: 837-845.

44
CHAPTER TWO
RGS12 modulates the dopamine transporter in ventral striatum and locomotor
responses to psychostimulants
Original Article - Journal of Psychopharmacology (2018) vol. 32, issue 2, pgs 191-203
Joshua D. Gross 1, Shane W. Kaski 1, Adam B. Schroer 1, Kimberley A. Wix 1,
David P. Siderovski 1, Vincent Setola 1,2
1

Department of Physiology, Pharmacology & Neuroscience, and
2 Department of Behavioral Medicine & Psychiatry,
West Virginia School of Medicine, One Medical Center Drive, PO Box 9229,
Morgantown WV 26506-9229 USA

45
2.1 - Abstract
Regulators of G protein Signaling (RGS) are proteins that accelerate the termination of
effector stimulation after G protein-coupled receptor (GPCR) activation. Many RGS
proteins are highly expressed in the brain and therefore considered potential drug
discovery targets for CNS pathologies; for example, here we show that RGS12 is highly
expressed in microdissected mouse ventral striatum. Given a role for the ventral striatum
in psychostimulant-induced locomotor activity, we tested whether Rgs12 genetic ablation
affected behavioral responses to amphetamine and cocaine. RGS12 loss significantly
decreased hyperlocomotion to lower doses of both amphetamine and cocaine; however,
other outcomes of administration (sensitization and conditioned place preference) were
unaffected, suggesting that RGS12 does not function in support of the rewarding
properties of these psychostimulants. To test whether observed response changes upon
RGS12 loss were caused by changes to dopamine transporter (DAT) expression and/or
function, we prepared crude membranes from the brains of wild type and RGS12-null
mice and measured DAT-selective [3H]WIN 35428 binding, revealing an increase in DAT
levels in the ventral—but not dorsal—striatum of RGS12-null mice. To address DAT
function, we prepared striatal synaptosomes and measured [3H]dopamine uptake.
Consistent with increased [3H]WIN 35428 binding, DAT-specific [3H]dopamine uptake in
RGS12-null ventral striatal synaptosomes was found to be increased. Decreased
amphetamine-induced locomotor activity and increased [3H]WIN 35428 binding were
recapitulated with an independent RGS12-null mouse strain. Thus, we propose that
RGS12 regulates DAT expression and function in the ventral striatum, affecting
amphetamine- and cocaine-induced increases in dopamine levels that specifically elicit
acute hyperlocomotor responses.
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2.2 - Introduction
Psychostimulant drugs of abuse such as (+)-amphetamine (AMPH) and cocaine are
among the most widely abused substances in the United States (Quality., 2015). These
psychostimulants impose severe liabilities of high abuse potential, capacity to induce
psychoses, considerable neurotoxicity, and mortality (Heal et al., 2013; Ciccarone, 2011).
The locomotor-activating and rewarding properties of these psychostimulants are
dependent on the mesolimbic dopamine (DA) system of the brain (Adinoff, 2004; Kauer
and Malenka, 2007; Thomas et al., 2008; Nutt et al., 2015), defined as the projections
from DAergic cell bodies in the ventral tegmental area (VTA) to presynaptic terminals in
the nucleus accumbens (NAc) of the ventral striatum (vSTR). Dopaminergic signaling
within the vSTR is central to psychostimulant-induced locomotor activity (Ikemoto, 2002):
lesioning of DAergic terminals within the NAc—but not in the dorsal striatum (dSTR)—by
local injection of 6-hydroxydopamine markedly reduces the hyperlocomotor responses to
the dopaminergic indirect agonists AMPH and cocaine (Kelly and Iversen, 1976).
Similarly, microinjections of AMPH or cocaine into the NAc—but not dSTR—increase
locomotion and rearing behavior in rodents (Staton and Solomon, 1984; Carr and White,
1987; Kelley et al., 1989; Delfs et al., 1990).
AMPH and cocaine exert their effects by increasing extracellular DA levels in the vSTR
via their action at the dopamine transporter (DAT; refs. (Giros et al., 1996; Federici et al.,
2014)), which acts to translocate released DA back into the presynaptic DA terminal, thus
terminating neurotransmission at post-synaptic DA receptors. However, the mechanisms
by which AMPH and cocaine modulate DAT are mechanistically distinct. AMPH acts as
an indirect dopaminergic agonist in two ways: first, the drug acts as a substrate for (and
hence, a competitive inhibitor of) DAT (Sitte and Freissmuth, 2010), whose role is to reuptake dopamine after its release (Ramsey et al., 2008). Upon entry into dopaminergic
terminals, AMPH also acts as a substrate for the vesicular monoamine transporter, whose
role is to transport synaptoplasmic dopamine into vesicles for release (Sulzer, 2011).
Once inside dopaminergic vesicles, AMPH causes release, through reverse transport of
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the vesicular monoamine transporter, of free dopamine into the synaptoplasm (Sitte and
Freissmuth, 2010). In addition, amphetamine causes release of that free dopamine
through DAT, thereby increasing synaptic levels of dopamine (Sitte and Freissmuth,
2010). Cocaine acts more simply: it is not a DAT substrate rather, it is a competitive
inhibitor of the protein (Rothman, 1990). Cocaine blocks the ability of DAT to re-uptake
released dopamine, thereby increasing levels of dopamine in the synapse (Nestler, 2005).
Thus, each drug (AMPH and cocaine) ultimately yields increased levels of synaptic
dopamine in dopaminergic (dopamine transporter-expressing) synapses. These
increased levels of dopamine in response to AMPH or cocaine act on post-synaptic,
dopamine-responsive, G protein-coupled receptors (GPCRs) to elicit responses postsynaptically (Schultz, 2002).
DAT expression, subcellular trafficking, and DA uptake function are all tightly
regulated by a host of protein interactants (Torres, 2006), such as receptors, kinases, and
scaffolds. In particular, several groups have identified presynaptic GPCRs and scaffolding
proteins that directly and/or functionally interact with DAT (Torres, 2006), suggesting that
GPCR-dependent, multiprotein networks are critical to DAT function. RGS12, a member
of the ‘Regulator of G protein Signaling’ (RGS) protein superfamily (Snow et al., 1998; Snow
et al., 1997), has not previously been associated with DAT regulation. RGS proteins are known
to accelerate the inactivation of GPCR-activated Ga subunits (i.e., GTP-bound Ga
subunits) by stimulating their intrinsic GTPase activity (Berman et al., 1996). This
inactivation is followed by the reassociation of GDP-bound (i.e., inactive) Ga subunits
with Gbg subunits, thereby terminating signaling originally evoked by free GTP-bound Ga
subunits (e.g., inhibition of adenylyl cyclase; (Clark and Traynor, 2004)) and/or free Gbg
subunits (e.g., stimulation of G protein-coupled inwardly rectifying potassium (GIRK)
channels; (Zhou et al., 2012)).
As many RGS proteins are expressed in the CNS (e.g., ref. (Gold et al., 1997)), they are
suspected to play key roles in neuronal function and behavior (Neubig and Siderovski, 2002).
For example, RGS14, the closest related paralog to RGS12, is integral to hippocampal
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synaptic plasticity underlying learning and memory (Lee et al., 2010). Several RGS
proteins, including RGS12 and RGS14, are endowed with functional domains other than
the RGS domain (Kimple et al., 2011). In addition to being a Ga-directed GTPaseaccelerating protein (GAP) (Snow et al., 1998), RGS12 contains four additional functional
motifs: a PDZ binding domain (common among scaffolding proteins), a phosphotyrosine
binding domain, tandem Ras binding domains, and a GoLoco motif (which sequesters
GDP-bound Ga subunits) (Kimple et al., 2002; Snow et al., 1998; Willard et al., 2007).
Thus, the function of RGS12 in vivo need not be restricted to Ga-directed GAP activity in
opposition to GPCR activation; for example, we have shown that RGS12 acts as a
scaffold for Ras, Raf, and MEK in prolonging NGF-stimulated ERK signaling and
stimulating axonogenesis by dorsal root ganglion neurons, as detailed in (Willard et al.,
2007).
To explore more deeply the potential roles for RGS12 function in the CNS, we created
both conventional and conditional mouse knockout strains and conducted subsequent
behavioral (locomotion, sensitization, conditioned place preference) and biochemical
(tissue radioligand binding, synaptosome uptake and release) studies. Based on our
findings, we propose that RGS12 modulates the expression and function of DAT in the
ventral striatum, thus explaining decreased hyperlocomotor responses in RGS12-null
mice to AMPH or cocaine compared with wild type littermates. Our findings are
compatible with a robust literature indicating that DAT function is modulated by a number
of accessory proteins/enzymes (Torres, 2006). Thus, we have identified RGS12 as a
novel regulator of DAT and suggest that the locomotor-activating effects of
psychostimulants are dependent, in part, on RGS12 function.
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2.3 Methods
2.3.1 - Animals
Generation of two independent strains of RGS12-null mice (constitutive Rgs12Δ5-8/Δ5-8 and
Cre-dependent Rgs12Δ5-6/Δ5-6) is described in Figure 1 and Supplementary Figure S1.
Both mouse strains are in the C57BL/6J background. Mice were housed under standard
temperature, humidity, and lighting conditions (12 hours light / 12 hours dark). All
behavioral experiments performed during the light cycle using mice between 8-10 weeks
of age. All mice were provided food and water ad libitum. All experiments were conducted
in accordance with West Virginia University Animal Care and Use Committee and
followed the National Institute of Health guidelines for use of animals in research. The
procedures of the behavioral assays are described below and were conducted according
to previously published methods (as cited); mice were used for only one behavioral assay
involving either acute or chronic drug dosing (i.e., all drug-based studies were performed
with drug-naïve mice; there is no sequence of multiple, drug-based experimental trials to
define for individual mice used in this study).

2.3.2 - In situ hybridization
In situ hybridization with an antisense riboprobe directed against Rgs12 was performed
in order to assess the distribution of Rgs12 mRNA in brain. cDNA from the mouse Rgs12
open reading frame (full-length) was subcloned into a pBluescript II SK vector by
restriction enzyme digestion. In vitro transcription with T7 RNA polymerase was
conducted to produce a digoxigenin-labeled antisense riboprobe. In situ hybridization was
then performed by the University of North Carolina Neuroscience Center In Situ
Hybridization Core using standardized protocols (UNC-Chapel Hill).

2.3.3 - Immunoblots
Immunoblot analyses of microdissected dopaminergic brain regions (frontal cortex, dorsal
and ventral striatum, and midbrain) were performed in order to identify which regions
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contained RGS12 protein, to compare the relative abundances of RGS12 protein across
selected regions, and to verify complete knockout of RGS12 protein in Rgs12Δ5-8/Δ5-8 mice.
Mice were injected with a lethal dose of pentobarbital (200 mg/kg, ip), decapitated, rapidly
dissected, and frozen on dry ice. Dorsal striatum, ventral striatum, and midbrain were
sonicated in 10 volumes of RIPA buffer containing 25 mM Tris-HCl (pH 7.6), 150 mM
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS (Pierce) supplemented with
protease inhibitors (HaltTM protease inhibitor cocktail, Thermo Fisher). Lysates were
cleaned by centrifugation at 20,800 g for 20 min and pellets were discarded. Proteins
were then separated by SDS-PAGE on a gradient 4-15% gel (BioRad), electrotransferred
to nitrocellulose membranes, and incubated overnight (4°C) with a monoclonal primary
antibody directed against the N-terminus of RGS12 (generated in-house) or beta-actin
(Thermo Fisher). Blots were then probed with HRP-conjugated goat anti-mouse
secondary antibodies and visualized by chemiluminescence (Pierce). Data were derived
from a sample size of n = 6-9 per genotype per experiment.
2.3.4 - Locomotor assays
AMPH- or cocaine-induced locomotor activity assessments were carried out in order to
evaluate behavioral phenotypes in RGS12-null mice. Open field locomotor activity was
evaluated in a 16 x 16 photobeam activity system (PAS) under standard environmental
conditions (San Diego Instruments, San Diego, CA). Horizontal locomotor activity was
measured as the sum of the total X and Y coordinate beam breaks collected every 5
minutes. Acute psychostimulant-induced locomotor activity experiments were carried out
over 3 days. On day 1, mice were habituated to locomotor chambers over 150 minutes to
reduce the influence of novelty. On day 2, all mice we allowed to habituate to locomotor
chambers for 30 min before intraperitoneal (ip) administration of saline (0.9% NaCl) at a
volume 10 mL/kg and locomotor activity was measured over 110 minutes.
On day 3, mice were habituated to locomotor chambers for 30 min and then injected with
d-amphetamine (1, 3, or 5 mg/kg, ip) (Salahpour et al., 2008; Tzschentke, 2007) or
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cocaine (10, 20, or 40 mg/kg, ip) (Ramsey et al., 2008; Jung et al., 2013) dissolved in
saline (ip, at a final volume of 10 mL/kg). Psychostimulant-induced hyperlocomotion was
then measured over 110 minutes. All drugs were obtained from Sigma-Aldrich (St. Louis,
MO). Data were derived from a sample size of n = 7-23 per genotype per experiment.
2.3.5 - Psychostimulant-induced locomotor sensitization
Sensitization experiments were performed in order to assess whether RGS12-null mice
exhibited reduced responsiveness to repeated administration of AMPH or cocaine as was
observed with acute hyperlocomotion induced by these psychostimulants. Experiments
were performed as previously described (Steinkellner et al., 2014) with minor
modifications. Briefly, mice were habituated to locomotor chambers on day 1 and 2 as
described in acute psychostimulant-induced locomotor activity experiments. Mice were
then administered d-amphetamine (2 mg/kg, ip) or cocaine (20 mg/kg, ip) (Ramsey et al.,
2008) for 6 consecutive days (d1-d6) to induce sensitization under the conditions
described for day 3 of acute psychostimulant-induced locomotor activity experiments.
After the sixth day of psychostimulant administration, drug was withdrawn for 14 days.
Following washout (d20), mice were challenged with d-amphetamine (2 mg/kg, ip) or
cocaine (20 mg/kg, ip) and horizontal locomotor activity was evaluated. Data were
analyzed by two-way, repeated measures ANOVA. Data were derived from a sample size
of n = 6-9 per genotype per experiment.
2.3.6 - Conditioned place preference (CPP)
CPP was conducted with RGS12-null mice in order to evaluate whether RGS12
influences the rewarding properties of AMPH or cocaine. CPP studies were performed in
a two-chambered apparatus (Med Associates, ENV-3013-2, Georgia, VA) with the
paradigm described by Ramsey and colleagues (Ramsey et al., 2008) with minor
modifications. The two chambers of the CPP apparatus contained distinguishable floor
grating (grid floor vs rod floor) and colored walls (white vs black). Each experiment
consisted of habituation, preconditioning, conditioning, and post-conditioning phases.
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Habituation (day 1) was carried out to reduce the influence of apparatus novelty. Mice
were allowed free access to either chamber for 30 min and measurements of time spent
in each chamber was measured. For the preconditioning phase (day 2), mice were again
allowed free access to either chamber for 30 min and time spent in each chamber was
measured to determine the least-preferred chamber of each mouse. Preference on days
1 and 2 were comparable (data not shown). The next day (day 3) began the conditioning
phase. Mice were injected with either d-amphetamine (2 mg/kg, ip) or cocaine (20 mg/kg,
ip) and were restricted to the least preferred chamber for 30 min. On day 4, mice were
injected with saline (0.9% NaCl, ip) and restricted to the other chamber for 30 min. The
remainder of the conditioning phase consisted of two more repetitions of alternating drug
(days 5 and 7) and saline (days 6 and 8). For the postconditioning test phase, conditioned
place preference was determined by allowing mice free access to either chamber and
measuring the time spent for 30 min. No differences in chamber preference were
identified between habituation (day 1) and preconditioning day (day 2). Preconditioning
and postconditioning were calculated by subtracting the time spent (seconds) in the
preferred chamber (as determined on day 2) from the least preferred chamber (as
determined on day 2). Data were analyzed by two-way, repeated measures ANOVA. Data
were derived from a sample size of n = 7-8 per genotype per experiment.

2.3.7 - Preparation of brain sections and immunohistochemistry for c-Fos
Psychostimulant-induced c-Fos immunohistochemistry was performed in order to
determine whether RGS12-null mice showed a reduction in neural activity specifically
within the NAc of the vSTR. Mice received ip injection of saline or d-amphetamine (3
mg/kg). Following 90 min, mice were anesthetized with pentobarbital (200 mg/kg) and
transcardially perfused with 4% paraformaldehyde. Perfused brains were post-fixed
overnight and then placed in 30% sucrose solution until brains sank. Cryoprotected brains
were then frozen overnight at -80°C and 40-μm free-floating sections were prepared.
Sections were incubated with a polyclonal anti-c-Fos primary antibody (1:100; Santa
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Cruz, Dallas, TX) overnight at 4°C, followed by incubation of a flurophore-conjugated goat
anti-rabbit secondary antibody (Thermo Fisher Sci.) for 2 hr at RT. Psychostimulantinduced c-Fos expression was visualized on an Evos epifluorescent microscope and cFos-positive nuclei were counted in a 0.16-mm2 field of dorsal and ventral striatum.
Anatomical landmarks, such as the anterior commissure, corpus callosum, and septum,
were utilized to demarcate the dorsal and ventral striatum. Three independent sections
separated by 200 μm were counted per mouse, and presented data were determined by
computing the average number of c-Fos-positive nuclei per field in 3-4 mice per genotype.

2.3.8 - Preparation of synaptosomes and measurement of [3H]dopamine uptake and
release These biochemical experiments were performed to assess whether the observed
reductions in acute psychostimulant-induced hyperlocomotion were correlated with
changes in DA uptake and/or AMPH-induced DA release. For [3H]dopamine uptake
experiments, dorsal and ventral striatal synaptosomes were prepared by homogenizing
brain tissue from 3-4 mice per genotype in 10 volumes ice-cold sucrose buffer (10%
sucrose, 5 mM HEPES, pH 7.4) with a Potter-Elvehjem homogenizer (10 strokes).
Homogenates were then centrifuged at 1,000 g for 10 min and supernatants containing
crude synaptosomes were maintained on ice. Synaptosomes were then added to tubes
containing Krebs-Ringer uptake buffer (120 mM NaCl, 20 mM Tris-HCl, 5 mM KCl, 1.2
mM MgSO4, 2.5 mM CaCl2, 10 mM glucose, 1 mM ascorbic acid, and 0.1 mM pargyline)
plus [3H]dopamine (33.5 μCi, Perkin-Elmer, Bridgeville, PA) and incubated for 10 min at
RT for uptake to occur. Non-specific [3H]dopamine uptake was determined in the
presence of 10 μM cocaine and subtracted from total uptake. Uptake was terminated by
rapid filtration (Brandel harvester) through 0.1% PEI-soaked Whatman GF/B filters with
ice-cold Krebs-Ringer buffer and washed three times before radioactivity measurement
via liquid scintillation counting. Data were analyzed with nonlinear fitting software
(GraphPad Prism 7) to determine Vmax and Km. AMPH-induced [3H]dopamine release
assays were performed as previously described (Rothman et al., 2001) with minor
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modifications. Briefly, dorsal and ventral striatal synaptosomes were prepared as
described above but with ice-cold sucrose buffer supplemented with 1 μM reserpine.
Synaptosomes were then incubated to steady-state with 5 nM [3H]dopamine (30 min) in
Krebs-Ringer buffer supplemented with 1 μM reserpine. Following incubation, 900 μL of
preloaded synaptosomes were added to 12 x 75 mm polystyrene tubes containing damphetamine (1 x 10-8.5 to 1 x 10-5 M) in Krebs-Ringer buffer. The release reaction
proceeded for 5 min, then terminated by rapid filtration over Whatman GF/B filters with
ice-cold Krebs-Ringer buffer, washed three times, and radioactivity was measured via
liquid scintillation counting. Data were analyzed with nonlinear fitting software (GraphPad
Prism 7) to determine EC50. Data were derived from a sample size of n = 6-12 per
genotype per experiment.

2.3.9 - Preparation of brain tissue and measurement of [3H]WIN 35428 binding
DAT saturation binding experiments were conducted in order to determine whether the
increased DA uptake in RGS12-null mice was associated with elevated DAT protein
levels. Dorsal and ventral striatal brain regions were rapidly dissected and frozen on dry
ice. Tissue was then homogenized with a Polytron homogenizer with 10 volumes of
transporter binding buffer (50 mM Tris-HCl, 120 mM NaCl, and 5 mM MgCl2, pH 7.4).
Homogenates were then centrifuged at 20,800 g for 20 min. The resulting pellet was then
resuspended in transporter binding buffer and added to tubes containing [3H]WIN 35428
(1.75 to 52.5 nM) and incubated for 1 hr at RT. Nonspecific binding was determined in
the presence of 10 GBR12909. Binding was terminated by rapid filtration over Whatman
GF/B filters with ice-cold transporter binding buffer, washed three times, and radioactivity
was measured via liquid scintillation counting. Data were analyzed with nonlinear fitting
software (GraphPad Prism 7) to determine Bmax and Kd. Data were derived from a sample
size of n = 6-9 per genotype per experiment.
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2.3.10 - High-performance liquid chromatography (HPLC) with dual-cell electrochemical
detection
HPLC on microdissected dopaminergic brain regions was carried out to assess whether
tissular DA levels differed between RGS12-null and wild type mice. Dorsal and ventral
striatal brain regions were rapidly dissected and frozen on dry ice. Tissue was then
sonicated in 10 volumes of 0.3 N perchloric acid and homogenates were centrifuged at
12,000 x g for 15 min. Supernatants were collected, passed through a 0.22 µm filter, and
dopamine levels in the homogenates were determined by HPLC with dual-cell
electrochemical detection. Cleared lysates underwent automated direct injection of 10 µL
into a Dionex Ultimate 3000 HPLC system equipped with a pump (ISO-3100BM, Thermo
Scientific, Waltham, WA) linked to an autosampler (WPS-3000TBRS, Thermo Scientific),
ESA HPLC column (MD-150 x 3.2) and dual coulometric/amperometric electrochemical
detectors (ECD-3000RS, Thermo Scientific) set at -170 mV and +400 mV, respectively.
Mobile phase (MD-TM; Thermo Scientific) was pumped at a flow rate of 0.6 mL/min.
Chromatograms were analyzed using Chromeleon software and dopamine peak height
(concentration) was determined from a standard curve. The identity of the dopamine peak
in the sample was confirmed by standard addition.

2.3.11 - Statistics
All data are presented as the mean ± SEM. Statistical significance was set at p < 0.05
for all experiments, and data were analyzed by student’s t-test or two-way ANOVA
followed by Sidak’s post hoc test where appropriate.

56
2.4 Results

2.4.1 - RGS12 protein is abundantly expressed in the ventral striatum of the mouse CNS
Our study was initiated by the generation of two independent strains of RGS12-null
mice on the C57BL/6J background (Figure 1A-C). Rgs12 mRNA was detected within the
brain by in situ hybridization in wild type, but not in RGS12-null, mice (Figure 1D-E). Rgs12 is
expressed in the ventral tegmental area (VTA) and the substantia nigra pars compacta
(SNc) (Figure 1D); there was also clear labeling of Rgs12 in the dentate gyrus and the
CA regions of the hippocampus (HPC). As shown in Figure 1E, there was also diffuse
labeling of Rgs12 in the striatum (STR) and cortex (CTX), as well as marked labeling of
Rgs12 in the claustrum (CLA). RGS12 protein immunoreactivity was detected in the
midbrain (the seat of the VTA and SNc) (Figure 1F); however, midbrain RGS12 protein
content was low in comparison to the high abundance of Rgs12 mRNA. There was also
detectable RGS12 immunoreactivity in the frontal cortex and dorsal striatum (dSTR)
(Figure 1F). RGS12 immunoreactivity was greater in the ventral striatum (vSTR) than in
frontal cortex, dSTR, or midbrain (Figure 1G). Quantification of immunoblots is presented
as the mean ± SEM (n = 6 per group), and statistical significance was assessed by oneway ANOVA with Tukey’s multiple comparisons post-hoc analysis: e.g., frontal cortex vs
dSTR (*, P < 0.05); dSTR vs vSTR (**, P < 0.01); midbrain vs dSTR (ns, P = 0.72). Despite
dense RGS12 immunoreactivity, Rgs12 mRNA labeling in the ventral striatum is quite
sparse (Figure 1E).

2.4.2 - RGS12 loss blunts hyperlocomotion to low doses of amphetamine and cocaine
Given marked RGS12 expression in the vSTR, and an established role for the vSTR
in psychostimulant actions, as a next step we evaluated RGS12-null mice in
psychostimulant-induced behavioral assays. Both RGS12-null mouse strains exhibited a
markedly reduced response to a standard hyperlocomotive-inducing dose (3 mg/kg) of
AMPH compared with wild type littermates (Figure 2A-C). Data indicating lack of a saline

57
effect (Fig. 2A) are displayed as the mean ± SEM (n = 7-8 per group) and analyzed by
two-way ANOVA: genotype effect, F (1,13) = 0.04, P = 0.84; time, F (21,273) = 5.4, P <
0.0001; genotype x time, F (21,273) = 1.1, P = 0.40. Data indicating reduced
hyperlocomotion of conditional RGS12-null mice to 3 mg/kg AMPH (Fig. 2B) are displayed
as the mean ± SEM (n = 7-8 per group) and analyzed by two-way ANOVA: genotype
effect, F (1,12) = 8.9, P = 0.011; time, F (21,252) = 11.3, P < 0.0001; genotype x time, F
(21,252) = 3.2, P < 0.0001. Data indicating reduced hyperlocomotion of constitutive
RGS12-null mice (Fig. 2C) are the mean ± SEM (n = 9-23 per group) and analyzed by
two-way

ANOVA:

genotype

effect,

F

(1,41)

=

18.6,

P

<

0.0001;

time,

F (21,861) = 42.3, P < 0.0001; genotype x time, F (21,861) = 9.6, P < 0.0001.
An initial dose of 3 mg/kg AMPH was selected because it has been extensively
characterized as eliciting robust locomotor responses in wild type C57BL/6 mice
(Salahpour et al., 2008; Ramsey et al., 2008; Medvedev et al., 2013). We next assessed
whether RGS12-null mice exhibit reduced locomotor responses to lower doses of AMPH.
We found that AMPH at 1 mg/kg was sufficient to observe hyperlocomotion in wild type
mice relative to saline injection (Figure 2D); however, there was only a trend towards
reduced AMPH-stimulated hyperlocomotion in RGS12-null mice at this lower dose (Figure
2D). At a high dose of AMPH (5 mg/kg), the hyperlocomotive responses of wild type and
Rgs12-null mice were identical (Figure 2D). Data from these additional AMPH doses are
displayed as the mean ± SEM (n = 8-23 per group) and analyzed by multiple t-test
analysis: saline, P = 0.52; 1 mg/kg, P = 0.057; 3 mg/kg, P < 0.0001 (****); 5 mg/kg: P =
0.086.
Having obtained the described results with AMPH, we proceeded to determine
whether the response to another dopaminergic psychostimulant, cocaine, was similarly
affected upon RGS12 loss. As shown in Figure 2E, 10 mg/kg cocaine elicited a
hyperlocomotive response in wild type mice that was markedly reduced in Rgs12-null
mice. Data indicating reduced hyperlocomotion to cocaine in RGS12-null mice are
displayed as the mean ± SEM (n = 9-10 per group) and analyzed by two-way ANOVA:
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genotype effect, F (1,17) = 17.2, P = 0.016; time, F (21,357) = 8.8, P < 0.0001; genotype
x time, F (21,357) = 2.4, P = 0.0006. In follow-up studies with 20 mg/kg and 40 mg/kg of
cocaine, doses established by others’ studies (Salahpour et al., 2008; Ramsey et al.,
2008; Elliot, 2002; Reith et al., 1991), we observed no genotype-dependent differences
in drug-induced hyperlocomotion (Figure 2F). Data from these additional cocaine doses
are displayed as the mean ± SEM (n = 7-20 per group) and analyzed by multiple t-test
analysis: saline, P = 0.99; 10 mg/kg, P = 0.02, **, P < 0.01); 20 mg/kg, P = 0.84; 40
mg/kg, P = 0.72.
Both AMPH and cocaine are well known to exert their actions via the neurotransmitter
dopamine (Ciccarone, 2011). One possible explanation for these observations of reduced
hyperlocomotion is that, in RGS12-null mice, post-synaptic dopamine receptor sensitivity
is decreased. SKF 81927 is a selective D1-like (D1/D5) dopamine receptor full agonist
(Weed et al., 1993; Desai et al., 2005), which has been extensively characterized as
eliciting robust horizontal locomotor activity in mice (Desai et al., 2005; Scott et al., 2005;
Medvedev et al., 2013). However, we found no differences in hyperlocomotion between
the two genotypes at each of the three different doses of SKF 81927 tested (Figure 2G),
suggesting a pre-synaptic, rather than a post-synaptic, effect of RGS12 loss on
dopaminergic psychostimulant action. Data on SKF 81927-mediated hyperlocomotion are
displayed as the mean ± SEM (n = 8 per group) and analyzed by multiple t-test analysis:
saline, P = 0.73; 1 mg/kg, P = 0.64; 3 mg/kg, P = 0.59; 5 mg/kg, P = 0.71.

2.4.3 - RGS12 loss does not affect sensitization nor conditioned place preference
Having established a phenotype based on acute administration of AMPH or cocaine,
we next tested the effects of repeated dosings of these psychostimulants on RGS12-null
mice with doses known to elicit robust sensitization in wild type C57BL/6 mice (Ramsey
et al., 2008; Eisener-Dorman et al., 2011). Despite recapitulating the reduced acute
locomotor responses to AMPH by RGS12-null mice (Figure 3A), sensitization to repeated
administration of AMPH—a measure of neuronal plasticity of the mesolimbic dopamine
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system (Steketee and Kalivas, 2011; Berg and Olsson, 2004)—was intact in RGS12-null
mice compared to wild type littermates (Figure 3B-C). Locomotion observations from the
first day of acute 2 mg/kg AMPH administration (Fig. 3A) were analyzed by two-way
ANOVA: genotype effect, F (1,308) = 10.3, P = 0.002 (**); time, F (21,308) = 1.7, P =
0.03; genotype x time, F (21,308) = 7.6, P = 0.75. Locomotion observations from the sixth
day of acute 2 mg/kg AMPH administration (Fig. 3B) were analyzed by two-way ANOVA:
genotype effect, F (1, 14) = 0.45, P = 0.52; time, F (21, 294) = 36.2, P < 0.0001; genotype
x time, F (21, 294) = 1.1, P = 0.36. AMPH sensitization time-course data (Fig. 3C) were
analyzed by two-way, repeated-measures ANOVA: genotype effect, F (1,14) = 2.7, P =
0.6; time, F (6, 84) = 25.4, P < 0.0001; genotype x time, F (6, 84) = 25.4, P = 0.95.
Similarly, sensitization to cocaine was not affected in RGS12-null mice (Figure 3D-F).
Locomotion observations from the first day of acute 20 mg/kg cocaine administration (Fig.
3D) were analyzed by two-way ANOVA: genotype effect, F (1, 10) = 0.31, P = 0.59; time,
F (21, 210) = 14.2, P < 0.0001; genotype x time, F (21, 210) = 3.6, P < 0.0001. Locomotion
observations from the sixth day of acute 20 mg/kg cocaine administration (Fig. 3E) were
analyzed by two-way ANOVA: genotype effect, F (1, 10) = 0.08, P = 0.78; time, F (21,
210) = 17.7, P < 0.0001; genotype x time, F (21, 210) = 0.61, P = 0.91. Cocaine
sensitization time-course data (Fig. 3F) were analyzed by two-way, repeated-measures
ANOVA: genotype effect, F (1, 10) = 1.0, P = 0.33; time, F (21, 210) = 17.4, P < 0.0001;
genotype x time, F (21, 210) = 0.73, P = 0.80.
In another behavioral paradigm elicited by repeated psychostimulant administration—
conditioned place preference (CPP), which measures the ‘rewarding’ properties of drugs
(Tzschentke, 2007)—we observed no differences in the effects of either AMPH or cocaine
in RGS12-null vs wild type mice (Figure 3G-H). CPP as induced by 2 mg/kg doses of
AMPH was analyzed by two-way, repeated-measures ANOVA: genotype effect, F (1,12)
= 0.23, P = 0.64; time, F (1,12) = 54.1, P < 0.0001; genotype x time, F (1,12) = 0.04, P =
0.84. CPP as induced by 10 mg/kg doses of cocaine was analyzed by two-way, repeatedmeasures ANOVA: genotype effect, F (1,14) = 3.43, P = 0.09; time, F (1, 14) = 41.4, P <

60
0.0001; genotype x time, F (1, 14) = 0.04, P = 0.84. All CPP data are presented as the
mean ± SEM (n = 6-9 per group).

2.4.4 - AMPH-elicited neuronal excitation is reduced in the NAc upon RGS12 loss
In light of the locomotor data and RGS12 expression data, we suspected that RGS12 loss
might affect psychostimulant-dependent neuronal activation in at least one locus within
the ventral striatum: namely, the nucleus accumbens (NAc). Therefore, we addressed
this hypothesis by measuring c-Fos induction in AMPH-treated RGS12-null and wild type
mice. c-Fos immunoreactivity (measured as c-Fos-positive nuclei per field; Figure 4A)
was pronounced in the NAc (i.e., ventro-lateral to the anterior commissure [ac]) after an
acute dose of 3 mg/kg AMPH. Consistent with the reduced hyperlocomotion of RGS12null mice to acute, low-dose AMPH, c-Fos immunoreactivity was significantly reduced in
the NAc of AMPH-treated RGS12-null mice compared with wild type littermates (Figure
4B). Conversely, in the dorsal striatum, the number of c-Fos-positive nuclei was not
different between AMPH-treated RGS12-null mice and wild type littermates (Figure 4B).
c-Fos immunoreactivity data are presented as the mean ± SEM (n = 3-4 mice per group)
and were analyzed by two-way ANOVA with Sidak’s multiple comparisons: vSTR, P <
0.0001 (****); dSTR, P = 0.85.

2.4.5 - Dopamine uptake is enhanced in ventral striatal synaptosomes from RGS12-null
mice
The reduced effects of psychostimulants on RGS12-null mice could be explained by
increased dopamine transporter (DAT)-mediated uptake in the ventral striatum of
dopamine, the major neurotransmitter affected by AMPH and cocaine (Ciccarone, 2011).
Thus, to test this hypothesis, we next prepared ventral and dorsal striatal synaptosomes
from RGS12-null mice to measure [3H]dopamine uptake. A significant increase in the Vmax
(maximal rate of [3H]dopamine uptake) of RGS12-null ventral striatal synaptosomes was
observed as compared with wild type ventral striatal synaptosomes (Figure 5A and 5B
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inset); however, no genotype-specific differences in Vmax were observed for dorsal striatal
synaptosomes (Figure 5B). Km values were equivalent between genotypes in both ventral
and dorsal striatal synaptosomes (Figure 5A-B). [3H]Dopamine uptake Vmax data are
presented in Fig. 5B as the mean ± SEM (n = 9-12 per group) and were analyzed by
genotype using two-way ANOVA with Sidak’s multiple comparisons: vSTR, P = 0.0054
(**); dSTR, P = 0.91 (ns, no significant difference). [3H]Dopamine uptake Km values were
as follows: vSTR, wild type mice = 0.36 ± 0.16 µM, RGS12-null mice = 0.33 ± 0.16 µM;
dSTR, wild type mice = 0.86 ± 0.32 µM, RGS12-null mice = 0.80 ± 0.32 µM; two-way
ANOVA with Sidak’s multiple comparisons: vSTR, P = 0.99; dSTR: P = 0.49.
To evaluate whether the observed increase in [3H]dopamine uptake in the ventral
striata of RGS12-null mice was mediated specifically by DAT, we also performed
[3H]dopamine uptake studies using RGS12-null ventral striatal synaptosomes in the
presence of the DAT-selective re-uptake inhibitor GBR12935 in order to quantify (and
subtract out) non-specific uptake. A significant increase in the Vmax of DAT-specific
[3H]dopamine uptake was observed in RGS12-null vSTR synaptosomes as compared
with those derived from wild type littermates (Figure 5C). DAT-specific [3H]dopamine
uptake data are presented as the mean ± SEM (n = 6 per group) and were analyzed by
unpaired t-test: P = 0.001 (**).

2.4.6 - DAT binding sites are significantly elevated in the ventral striatum
Data indicating increased dopamine uptake by ventral striatal synaptosomes
prompted us next to probe the expression levels of DAT in striatal tissue from RGS12null mice. Radioligand saturation binding assays were performed with [3H]WIN 35428 (a
DAT-selective radioligand) to determine the maximal number of DAT binding sites in wild
type and Rgs12-null crude membrane fractions of ventral and dorsal striatal tissue. A
marked increase was seen in [3H]WIN 35428 binding to ventral striatal membrane
fractions from Rgs12-null mice compared with wild type mice (Figure 5D and 5E inset).
Although unable to accurately determine Bmax given the absence of saturation binding,
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we were able to establish relative expression levels of DAT by comparing the binding of
wild type and RGS12-null ventral and dorsal striatal crude membrane fractions at the
maximal concentration of [3H]WIN 35428 tested (52.5 nM). As shown in the bar graph
inset within Figure 5E, [3H]WIN 35428 binding to RGS12-null ventral striatal crude
membrane fractions was markedly greater than radioligand binding to wild type ventral
striatal crude membrane fractions; however, there was no statistically significant,
genotype-specific effect on [3H]WIN 35428 binding to dorsal striatal crude membrane
fractions. Data for [3H]WIN 35428 binding in Fig. 5E (inset) are presented as the mean ±
SEM (n = 6-9 per group) and analyzed by genotype using two-way ANOVA with Sidak’s
multiple comparisons: vSTR, P = 0.0051 (**); dSTR, P = 0.11 (ns).
To assess whether the observed increase in vSTR DAT binding sites in Rgs12Δ5-8/Δ5-8
mice was recapitulated in an independent mouse strain lacking RGS12 expression, we
next performed [3H]WIN 35428 binding assays on crude membrane fractions from Crerecombinase dependent RGS12-null (Rgs12Δ5-6/Δ5-6) mice (Figure 1C and Figure S1E;
i.e., Rgs12fl/fl mice expressing an ubiquitously-expressed, CMV-driven Cre transgene).
We found that maximal DAT binding sites are also elevated in this Rgs12 Δ5-6/Δ5-6 mouse
strain relative to wild type (Rgs12+/+; CMV::Cre) littermate controls (Figure 5F). Data for
[3H]WIN 35428 binding in Fig. 5F are presented as the mean ± SEM (n = 6 per group)
and were analyzed by genotype using unpaired t-test: P < 0.0001 (****).
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2.5 - Discussion
Our major finding from these analyses is that the loss of RGS12 engenders reduced
acute responses (hyperlocomotion and c-Fos induction) in response to the psychoactive
drugs AMPH or cocaine. This reduction is likely caused by increased dopamine uptake in
the ventral striatum—in particular, the nucleus accumbens—due to elevated levels of
surface-exposed (and, hence, functional) DAT. The presence of RGS12, in one (or more)
brain region(s), must in some way negatively regulate DAT expression levels and/or
activity, given that RGS12 loss has been observed in this study to increase DAT
expression and activity, at least in the ventral striatum.
The expression pattern of Rgs12 mRNA compared with the distribution of RGS12
protein renders it tempting to speculate that RGS12 is being synthesized in the
dopaminergic projections from the midbrain (i.e., the VTA and SNc; e.g., Figure 1D) and
trafficked to striatal terminals (e.g., Figure 1F) Put another way, RGS12 appears to be a
pre-synaptic protein in the striatum. Furthermore, the lack of genotype-dependent
differences in locomotor responses to a post-synaptically active dopaminergic agonist
(i.e., SKF 81927; Figure 2G) suggests RGS12 acts pre-synaptically. Biochemical data
are also in line with this notion: the expression and function of DAT, a pre-synaptic protein
(Torres and Amara, 2007), are both increased upon RGS12 loss (Figure 5). However,
baseline dopamine levels in the ventral and dorsal striatum of wild type and RGS12-null
mice are identical, as measured by HPLC with dual-cell electrochemical detection
(Supplementary Figure S2). In addition, no changes were observed in the levels of
tyrosine hydroxylase, the rate-limiting enzyme for dopamine synthesis (Daubner et al.,
2011) (Supplementary Figure S2). Thus, the observed changes in DAT expression levels
and function are likely a direct result of RGS12 loss, and not necessarily caused indirectly
by a compensatory upregulation (Kimmel et al., 2001; Jakowec et al., 2004; Salvatore et
al., 2016) in response to altered dopamine synthesis or basal levels upon RGS12 loss
per se.
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Despite reduced locomotor responses to acute administration of AMPH and cocaine,
RGS12-null mice developed locomotor sensitization and CPP to each drug in a manner
similar to wild type mice. Although these latter behaviors are mediated by mesolimbic
dopamine (Steketee and Kalivas, 2011; Henry et al., 1989; Baik, 2013), their expression
is found to be dependent on neuroplastic changes (i.e., increased VTA excitability and
firing rate) to postsynaptic NMDA glutamate and dopamine receptor signaling/expression
levels, as well as to somatodendritic dopamine autoreceptors located on VTA neurons
(Henry et al., 1989; White and Wang, 1984; Neisewander et al., 1998; Tanabe et al.,
2004; Ramsey et al., 2008). These findings also support the notion that RGS12 is acting
pre-synaptically and thus why only acute behavioral responses to AMPH and cocaine are
affected.
Biochemical assays revealed no significant differences in DAT levels or activity in the
dorsal striatum. Thus, the phenomenon of RGS12 regulation of DAT appears to be region
specific; i.e., RGS12 affects DAT in the mesolimbic system (i.e., VTA to the nucleus
accumbens -- a major effector of locomotor behavior). Notably, the levels of RGS12 are
greater

in

the

ventral

striatum

than

in

the

dorsal

striatum

(Figure

1).

One possible explanation for this enrichment could be a functional and/or physical
interaction with pre-synaptic GPCR(s) in the ventral striatum that is not expressed or
relevant in the dorsal striatum. For example, striatal DAT expression and function are
potently regulated by two Gai-coupled GPCRs expressed on striatal presynaptic
membranes: D2 dopamine receptors and -opioid receptors (KORs). Activation of these
receptors serves as a negative feedback mechanism upon elevated striatal dopamine
tone, thus augmenting dopamine uptake and increasing surface DAT expression (Bolan
et al., 2007; Kivell et al., 2014) in a region-specific manner. Acute administration of KOR
agonists increases dopamine uptake in ventral, but not dorsal, striatum (Thompson et al.,
2000). Additionally, D2 receptor agonists decrease DAT expression in the dorsal striatum,
but increase DAT expression in the ventral striatum (Kimmel et al., 2001). Thus, removal
of RGS12 as a negative regulator of G protein-mediated signaling downstream of either
GPCR may feasibly lead to augmented pre-synaptic D2 receptor and/or KOR-mediated
signaling, resulting in elevated DAT surface expression and dopamine uptake.
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There are several possible mechanisms by which RGS12 could impact DAT trafficking
and/or function, given the multiple protein-protein interaction domains present within
RGS12 (Kimple et al., 2002; Snow et al., 1998; Willard et al., 2007). One simple
explanation for involvement of RGS12 in curtailing DAT function evokes the C-terminal
GoLoco motif of RGS12 -- a guanine nucleotide dissociation inhibitor (GDI) activity that
results in the sequestration of inactive Ga subunits (Kimple et al., 2002), which normally
re-associate with Gbg subunits. This re-association blocks any signaling that is mediated
by Gbg. Thus, by sequestering inactive Ga subunits, the GoLoco motif of RGS12 may
extend the lifetime of free Gbg subunits, which are known to, among other things, inhibit
DAT activity (Garcia-Olivares et al., 2013).
Another plausible explanation for RGS12 affecting DAT function in the ventral striatum
lies in the ability of RGS12 to interact with components of the MAPK/MEK/ERK cascade,
the activity of which supports DAT trafficking to the cell surface (Moron et al., 2003; Willard
et al., 2007). We speculate that RGS12, as a MAPK/MEK/ERK scaffold, diverts this
signaling cascade from facilitating the trafficking of DAT to the synaptic plasma
membrane in the ventral striatum. Another possibility that cannot be excluded is that
RGS12, through its established interactions with Ras, Raf, MEK, and/or other as-yet
unidentified proteins, regulates transcription factors that negatively modulate the
transcription of DAT. To explore this possibility, we performed immunoblot analyses on
whole lysates of ventral striatum using a validated DAT antibody (Garcia-Olivares et al.,
2013; Chen et al., 2006; Foster et al., 2012; Steinkellner et al., 2012); total DAT levels
were seen to be comparable in wild type and RGS12-null ventral striatum (Supplemental
Figure S2), arguing against any transcriptional effect (e.g., in VTA-to-NAc projection
neurons). Thus, we are currently assessing whether RGS12 regulates the trafficking of
DAT to the synaptic membrane in the ventral striatum.
There is a clear dose dependence to the differences seen in acute responses to AMPH
and cocaine between RGS12-null and wild type mice (Figure 2). We suspect that this is
due to a saturation of DAT by the uptake inhibitors AMPH and cocaine at higher
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concentrations. We propose that, at lower doses of DAT inhibitor (1 and 3 mg/kg AMPH;
10 mg/kg cocaine), the excess DAT that is expressed in RGS12-null ventral striatum is
available to clear more synaptic dopamine, reducing the acute locomotor responses of
RGS12-null mice vs those of wild type mice. However, at higher doses of DAT inhibitor
(5 mg/kg AMPH; 20 mg/kg and 40 mg/kg cocaine), even the extra DAT expressed in
RGS12-null mice becomes saturated by drug, so all DAT molecules in the ventral striatum
of both genotypes are blocked, thereby eliminating any difference in acute locomotor
responses between RGS12-null and wild type mice.
This hypothesis of extra, unsaturated DAT in RGS12-null mice would suggest that
DAT levels would become saturated at lower doses in wild type mice. Yet, in both
genotypes, locomotor response is seen to increase with 20 mg/kg cocaine over that of 10
mg/kg, and again with 40 mg/kg cocaine over that of 20 mg/kg (Figure 2F). Therefore, an
additional possibility is that RGS12 loss affects the regulation of autoreceptors on DATpositive terminals, thereby lowering the threshold for pre-synaptic feedback by synaptic
dopamine and resulting in curtailed DA release at low drug concentrations. On the other
hand, it has been reported that 20 mg/kg cocaine increases locomotor response even in
mice lacking vesicular monoamine transporter 2 (VMAT2), critical for dopamine transport
into synaptic vesicular stores (Wang et al., 1997). Thus, another possibility to consider is
a role for RGS12 in VMAT2 function affecting DA release - a role absent in RGS12-null
mice but dependent on DAT inhibitor dose for full elaboration and observation in
behavioral outcomes.
It is also notable that AMPH acts not only as an antagonist of DAT, but also as a
releaser of dopamine. This dual effect explains the increased locomotor activity elicited
by AMPH compared with cocaine, which is solely a DAT antagonist (Figure 2D vs 2F,
note the difference in y-axis scales). We propose that, at higher doses of AMPH (5 mg/kg),
due to saturation of DAT, the maximum quantity possible of dopamine is released (i.e., at
5 mg/kg, dopamine is completely depleted from the pre-synaptic terminals of both wild
type and RGS12-null mice), potentially explaining why there is no difference between the
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genotypes. Moreover, in ventral striatal synaptosomal preparations, the ability of AMPH
to enhance the release of [3H]dopamine is not markedly different between wild type and
RGS12-null mice (Supplemental Figure S3). This latter observation suggest that RGS12
somehow modulates the uptake functionality – but not the release functionality – of DAT.
Molecular studies to address this issue are currently underway.
In summary, our studies have uncovered a novel regulator of ventral striatal DAT
expression and activity: namely, RGS12. The neuroanatomical site(s) of RGS12 action
and the mechanism(s) by which it regulates ventral striatal DAT expression and function
remain to be identified. However, the observed functional interaction between RGS12 and
DAT clearly impacts acute mesolimbic-dependent responses to dopaminergic
psychostimulants. Future work is required to establish the molecular determinants within
both proteins that underlie this regulation, be it direct (e.g., via possible RGS12/DAT
interactions) or indirect via the presynaptic regulation of G protein subunits or other
intermediates.
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2.6 - Figures
2.6.1 - Targeting sites for Rgs12 gene locus deletion and expression patterns of
Rgs12 mRNA and protein in the adult mouse brain.
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Figure 1. Independent targeting of two separate ablations to the mouse Rgs12 locus.
(A) Multiple, protein-protein interaction domain architecture of the encoded RGS12
protein, including a PSD-95/Dlg/ZO-1 (PDZ; orange) domain capable of binding the
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C-termini of the MAPK middle-tier kinase MEK2 and the interleukin-8 receptor CXCR2
(Willard et al., 2007; Snow et al., 1998), a phosphotyrosine-binding (PTB; pink) domain
thought to bind the NGF receptor TrkA (Willard et al., 2007), an RGS domain (yellow) which
binds and inactivates heterotrimeric G protein Ga subunits of the Gi/o subfamily (Snow
et al., 1998), a tandem repeat of Ras-binding domains (RBDs; cyan) that bind indicated
members of the Ras GTPase and MAPK first-tier (Raf) kinases (ref. (Willard et al., 2007)),
a GoLoco motif which binds inactive Ga subunits of the Gi subfamily (ref. (Kimple et al.,
2002)), and regions of predicted low complexity (rose). Vertical lines indicate exon-exon
junctions within the open-reading frame encoded by the Rgs12 mRNA. (B) Mice lacking
functional RGS12 (Rgs12D5-8/D5-8) were obtained from the Texas A&M Institute of Genomic
Medicine (TIGM) in a 129/Sv x C57BL/6 mixed background. Because congenic C57BL/6
mice are standard for neuropsychopharmacological behavioral assays, we back-crossed
the TIGM Rgs12D5-8/D5-8 mice with C57BL/6J mice for more than ten generations.
Henceforth, Rgs12D5-8/D5-8 mice will refer to congenic Rgs12D5-8/D5-8 mice on the C57BL/6J
background. Exons 5-8, encoding the entire polypeptide sequence of the RGS domain of
RGS12 (yellow; panel A), were targeted for replacement with a neomycin resistance,
drug-selectable marker. (D) Coronal in situ hybridization (Allen Brain Atlas) reveals
marked Rgs12 mRNA labeling in the ventral tegmental area (VTA) and substantia nigra
pars compacta (SNc), beds of the mesolimbic and nigrostriatal dopaminergic soma.
Analyses also reveal hippocampal (HPC) Rgs12 mRNA, particularly in the dentate gyrus.
(E) Coronal in situ hybridization from our group shows sparse Rgs12 mRNA in dorsal
(dSTR) and ventral (vSTR) striatum and cortex (CTX). Marked labeling was observed in
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the claustrum (CLA). (F) Immunoblotting for RGS12 protein levels in microdissected
frontal cortex, dorsal striatum (dSTR), ventral striatum (vSTR), and midbrain in WT and
RGS12-null mice. b-actin immunoreactivity served as a loading control. (G) Densitometric
analysis demonstrates that RGS12 in vSTR is higher than frontal cortex, dSTR, and
midbrain and, specifically is 157% more abundant than in dSTR. Data are the mean ±
SEM (n = 6 mice per group) relative to dSTR set to 100%. One-way ANOVA with Tukey’s
multiple comparisons: dSTR vs frontal cortex P = 0.018 (*, P < 0.05), dSTR vs vSTR P =
0.0014 (**, P < 0.01), dSTR vs midbrain P = 0.724 (not significant [ns], P > 0.05).
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2.6.2 - RGS12-null mice exhibit reduced hyperlocomotor responses to the
presynaptically-acting psychostimulants d-amphetamine (AMPH) and cocaine.
A 1200

Saline
600
400
200

0

10

20

30

40

50

Rgs12 +/+ ; CMV::Cre
Rgs12 fl/fl ; CMV::Cre

1000

800

0

1200

Horizontal activity
(sum X,Y beam breaks)

1000

Horizontal activity
(sum X,Y beam breaks)

B

Rgs12 +/+ ; CMV::Cre
Rgs12 fl/fl ; CMV::Cre

60

70

80

90

800

AMPH
(3 mg/kg)

600
400
200
0

100 110

0

10

20

30

40

Time (min)

D

Rgs12 +/+
Rgs12 Δ5-8/Δ5-8

1200

Horizontal activity
(sum X,Y beam breaks)

C

800

200

0

10

20

30

40

50

60

Time (min)

70

80

90

400

200
100
0

0

10

20

30

40

50

60

70

80

90

100 110

Time (min)

G

7000

Total X,Y beam breaks
(over 60 min)

6000

80

90

100 110

****

12000
8000
p = 0.057
4000
0

F

Cocaine
(10 mg/kg)

300

70

Rgs12 +/+
Rgs12 Δ5-8/Δ5-8

16000

100 110

Rgs12 +/+
Rgs12 Δ5-8/Δ5-8

500

60

ns
20000

10000

Total X,Y beam breaks
(over 60 min)

Horizontal activity
(sum X,Y beam breaks)

AMPH
(3 mg/kg)

400

0

E

Total X,Y beam breaks
(over 80 min)

1000

600

50

Time (min)

8000

ns

Saline

1

3
5
AMPH (mg/kg)

Rgs12 +/+
Rgs12 Δ5-8/Δ5-8

6000

*

4000
2000
0

Saline

10
20
40
Cocaine (mg/kg)

Rgs12 +/+
Rgs12 Δ5-8/Δ5-8

5000
4000
3000
2000
1000
0

Saline

1

3
SKF 81927 (mg/kg)

5

Figure 2. Acute psychostimulant-induced locomotion in Rgs12-null mice. (A) Locomotor
activity in Rgs12 D5-6/D5-6 mice (i.e., conditional Rgs12fl/fl mice cross-bred with an ubiquitous
CMV::Cre transgene) following 30 min acclimation to activity chambers and then saline
(at a final volume of 10 mL/kg) administration. Data are the mean ± SEM (n = 7-8 per
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group). (B) AMPH (3 mg/kg)-induced hyperlocomotion in Rgs12 D5-6/D5-6 mice for 80 min
following 30 min acclimation to activity chambers. Data are the mean ± SEM (n = 7-8 per
group). (C) AMPH (3 mg/kg)-induced hyperlocomotion in constitutive Rgs12 D5-8/D5-8 mice
for 80 min following 30 min acclimation to activity chambers. Data are the mean ± SEM
(n = 9-23 per group). (D) Cocaine (10 mg/kg)-induced hyperlocomotion in constitutive
Rgs12 D5-8/D5-8 mice for 60 min following 30 min acclimation to activity chambers. Data are
the mean ± SEM (n = 9-10 per group). (E) Total locomotion by constitutive Rgs12 D5-8/D58

mice over 80 min following ip injection of saline or various doses of AMPH after 30 min

acclimation to activity chambers. Data are the mean ± SEM (n = 8-23 per group). (F) Total
locomotion by constitutive Rgs12 D5-8/D5-8 mice over 60 min following ip injection of saline
or various doses of cocaine after 30 min acclimation to activity chambers. Data are the
mean ± SEM (n = 7-20 per group). (G) Total locomotion by constitutive Rgs12 D5-8/D5-8
mice over 60 min following ip injection of saline or indicated doses of SKF 81927 after 30
min acclimation to activity chambers. Data are the mean ± SEM (n = 8 per group).
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2.6.3 - RGS12-null mice display normal locomotor sensitization and conditioned
place preference to AMPH and cocaine.
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Figure 3. Psychostimulant-induced locomotor sensitization and conditioned place
preference in RGS12-null mice. Total locomotion over 80 min following AMPH (2 mg/kg;
A-B) or 60 min following cocaine (20 mg/kg; D-E). Total locomotion normalized to day 1
total locomotion plotted as fold change across drug treatment days (C, F). Data are the
mean ± SEM (n = 6-9 per group). Psychostimulant-induced conditioned place preference
in Rgs12-null mice. Data shown are the difference in the time spent between AMPH (2
mg/kg) (panel G)- or cocaine (10 mg/kg) (panel H)-paired and saline-paired chamber for
pre-conditioning (day 2) and post-conditioning (day 9). Data are the mean ± SEM (n = 78 per group).

74
2.6.4 - AMPH-induced c-Fos immunoreactivity is reduced in the nucleus
accumbens (NAc), but not dorsal striatum (dSTR), of RGS12-null mice.
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(A)

Immunohistochemical analysis of c-Fos in the NAc of RGS12-null and WT mice injected
with AMPH (3 mg/kg). (B) Quantification of the number of c-Fos-positive neurons per field
in RGS12-null vs wild type dSTR and vSTR (3-4 matched sections per genotype). Data
are the mean ± SEM. (n = 3-4 mice per group).
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2.6.5 - The number of DAT binding sites and [3H]dopamine (DA) uptake are
increased in the ventral (vSTR), but not dorsal (dSTR), striatum of RGS12-null mice.
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Figure 5. Analysis of DAT function and expression in RGS12-null mice. [3H]Dopamine
uptake in ventral (A) and dorsal (B) striatal synaptosomes prepared from RGS12-null and
wild type mice. (B, inset) Uptake rates (Vmax) of [3H]dopamine in ventral and dorsal striatal
synaptosomes derived from data in panels A and B; non-specific uptake determined in
the presence of 10 µM cocaine. Data are the mean ± SEM (n = 9-12 per group). (C)
Uptake rates (Vmax) by DAT of [3H]dopamine in ventral striatal synaptosomes derived from
data in Supplementary Figure S4; non-specific uptake determined in the presence of 10
µM GBR12935 (a selective dopamine reuptake inhibitor). Data are the mean ± SEM (n =
6 per group). (D, E) Levels of DAT determined from [3H]WIN 35428 saturation binding
analysis of ventral (D) and dorsal (E) striatal crude membrane fractions. Non-specific
binding was determined in the presence of 10 µM GBR12935. (E, inset) Maximal DAT
binding sites at 52.5 nM [3H]WIN 35428 in ventral and dorsal striatal membranes derived
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from data in D and E. Data are the mean ± SEM (n = 6-9 per group). (F) Maximal DAT
binding sites at 52.5 nM [3H]WIN 35428 in ventral striatal membranes derived from data
in Supplementary Figure S4. Data are the mean ± SEM (n = 6 per group).
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2.8 - Supplementary Information
2.8.1 - Supplementary Figures
2.8.1a - Validation of two independent RGS12-null mouse strains.

Supplementary Figure S1. Validation of the independent targeting of two separate
ablations to the mouse Rgs12 locus. (A, A') Southern blot analyses using 5’ and 3’
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external probes that flank the Rgs12 gene region targeted for homologous recombination
(see Figure 1B), indicating that embryonic stem cell clone 1A7 harbors the predicted
homologous

recombination

event.

(B)

Immunoblotting

for

RGS12

and

b-actin expression within lysates of brain cortex (CTX), hippocampus (HPC), and striatum
(STR) from wild type (+/+) and RGS12-null (Rgs12D5-8/D5-8) mice, indicating the loss of
RGS12 expression in the latter mouse strain. (C) Mice engineered to harbor a loxP- and
FRT-site flanked Rgs12 gene were obtained from genOway (France) in the C57Bl/6
background. Exons 5-6, encoding the initial third of the RGS domain of RGS12 (see
Figure 1A), were targeted for replacement with a FRT-flanked neomycin resistance, drugselectable marker and flanking loxP recombination sites. (C, C') Southern blot analyses
using 5’ external (panel C) and 3’ internal (panel C') probes that flank the Rgs12 gene
region targeted for homologous recombination (see Figure 1C), indicating that embryonic
stem cell clone #99-1G harbors the predicted homologous recombination event. (D)
Southern blot analysis using 5’ external probe to verify that mice #1365, #1366, #1370,
#1371, and #1372, derived from breeding germ-line transmitted mice from clone #99-1G
with an ubiquitous Flp recombinase-expressing driver strain, have the correct Rgs12 gene
locus (Rgs12fl) lacking the FRT-site flanked neo cassette but retaining the loxP sites
flanking exons 5 and 6. (E) Immunoblotting for RGS12 and b-actin expression within
whole brain lysates of wild type mice (+/+), RGS12-null (Rgs12D5-8/D5-8) mice, and both
wild type mice and Rgs12fl/fl mice bred to a ubiquitously-expressed Cre recombinase
driver strain, leading the latter mouse to be deleted in exons 5 and 6 of Rgs12 (i.e.,
Rgs12D5-6/D5-6). (F) Sagittal sections of wild type (Rgs12+/+) and RGS12-null (Rgs12D5-8/D5-
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8)

mouse brain sections probed by in situ hybridization. Note the dense expression

of Rgs12 mRNA in the claustrum in the wild type section. Also notable is the labeling in
the hippocampus (Hpc), which is denser in the dentate gyrus than in the CA regions in
the wild type section. In addition, sparse labeling was observed in the caudate putamen
(CPu) and the cortex (Ctx) in the wild type section. Also notable is the absence of labeling
in the Rgs12D5-8/D5-8 section in all of these regions. (G) i. (Left half) Frontal coronal section
demonstrating dense Rgs12 mRNA labeling in the claustrum and sparse labeling in the
ventral and dorsal striatum (vSTR, dSTR) and cortex (Ctx). (Right half) Note the absence
of labeling in these regions in the Rgs12D5-8/D5-8 section. (G) ii. (Left half) Marked labeling
of the deep, lateral layers of the cortex (Ctx) and sparse labeling in the dorsal striatum
(dSTR) and hippocampus (Hpc) are shown. (Right half) Note the absence of labeling in
these regions in the Rgs12D5-8/D5-8 section.
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2.8.2 - Baseline levels of dopaminergic markers are normal in RGS12-null mice.
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Supplementary Figure S2. Baseline dopamine levels and dopaminergic marker
expression in RGS12-null mice. (A) Immunoblot analysis of DAT and tyrosine hydroxylase
(TH) immunoreactivity in dorsal striatum (dSTR) and ventral striatum (vSTR) of RGS12null and wild type mice. Densitometric analysis of (B) DAT and (C) TH immunoreactivity
normalized to average DAT or TH levels detected in wild type mice. Data are the mean ±
S.E.M (n = 6 per group). Data were analyzed by two-way ANOVA with Sidak’s multiple
comparisons. (D) Total tissue levels of dopamine detected by HPLC with dual-cell
electrochemical detection in dorsal striatal and ventral striatal homogenates from RGS12-null and wild type mice. Data were analyzed by two-way ANOVA with Sidak’s multiple
comparisons.
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2.8.3 - AMPH-induced [3H]dopamine (DA) efflux is only mildly affected in ventral
(vSTR), but not dorsal (dSTR), striatal synaptosomes.
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Supplementary Figure S3. AMPH-stimulated [3H]dopamine release in preloaded
synaptosomes. Release assays were performed as previously described (Rothman et al.,
2001) with minor modifications. Briefly, dorsal and ventral striatal synaptosomes were
prepared as described in the main text but with ice-cold sucrose buffer supplemented with
1 μM reserpine. Synaptosomes were then incubated to steady-state with 5 nM
[3H]dopamine (30 min) in Krebs-Ringer buffer supplemented with 1 μM reserpine.
Following incubation, 900 μL of preloaded synaptosomes were added to 12 x 75 mm
polystyrene tubes containing (+)-amphetamine (1 x 10-8.5 to 1 x 10-5 M) in Krebs-Ringer
buffer. The release reaction proceeded for 5 min, and was then terminated by rapid
filtration over 0.5% PEI-soaked Whatman GF/B filters with ice-cold Krebs-Ringer buffer,
washed three times, and remaining radioactivity in the filtered synaptosomes was
measured via liquid scintillation counting.
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2.8.4 - Increased DAT binding sites and [3H]dopamine (DA) uptake are recapitulated
in an independent, Cre-dependent RGS12-null mouse strain.
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Supplementary Figure S4. DAT-specific [3H]dopamine uptake in vSTR-derived
synaptosomes of Rgs12D5-8/D5-8 mice and DAT binding in striatal tissue samples from Cre
recombinase-dependent Rgs12D5-6/D5-6 mice. (A) [3H]Dopamine uptake in ventral striatal
synaptosomes prepared from Rgs12D5-8/D5-8 and wild type mice. Non-specific uptake was
determined in the presence of 10 µM GBR12935 (a selective dopamine reuptake
inhibitor). (B, C) Levels of DAT determined from [3H]WIN 35428 saturation binding
analysis of ventral (E) and dorsal (F) striatal crude membrane fractions from Rgs12D5-6/D56

and wild type mice (i.e., Rgs12fl/fl and Rgs12+/+ mice additionally expressing the CMV-

driven Cre recombinase transgene). Non-specific binding was determined in the presence
of 10 µM GBR12935.
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2.8.2 - Supplemental Reference:
Rothman RB, Baumann MH, Dersch CM, et al. (2001) Amphetamine-type central nervous
system stimulants release norepinephrine more potently than they release
dopamine and serotonin. Synapse 39(1): 32-41.
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3.1 - Abstract
Kappa opioid receptor (KOR) agonists show promise in ameliorating disorders, such
as addiction and chronic pain, but are limited by dysphoric and aversive side effects.
Clinically beneficial effects of KOR agonists (e.g., analgesia) are predominantly mediated
by heterotrimeric G protein signaling, whereas b-arrestin signaling is considered central
to their detrimental side effects (e.g., dysphoria/aversion). Here we show that Regulator
of

G protein

Signaling-12 (RGS12), via

independent signaling

mechanisms,

simultaneously attenuates G protein signaling and augments b-arrestin signaling
downstream of KOR, exhibiting considerable selectivity in its actions for KOR over other
opioid receptors. We previously reported that RGS12-null mice exhibit increased
dopamine transporter-mediated dopamine (DA) uptake in the ventral (vSTR), but not
dorsal striatum (dSTR), as well as reduced psychostimulant-induced hyperlocomotion; in
the current study, we found that these phenotypes are reversed following KOR
antagonism. Fast-scan cyclic voltammetry studies of dopamine (DA) release and
reuptake suggest that striatal disruptions to KOR-dependent DAergic neurotransmission
in RGS12-null mice are restricted to the nucleus accumbens. In both ventral striatal tissue
and transfected cells, RGS12 and KOR are seen to interact within a protein complex.
Ventral striatal-specific increases in KOR levels and KOR-induced G protein activation
are seen in RGS12-null mice, as well as enhanced sensitivity to KOR agonist-induced
hypolocomotion and analgesia -- G protein signaling-dependent behaviors; a ventral
striatal-specific increase in KOR levels was also observed in b-arrestin-2-deficient mice,
highlighting the importance of b-arrestin signaling to establishing steady-state KOR levels
in this particular brain region. Conversely, RGS12-null mice exhibited attenuated KORinduced conditioned place aversion (considered a b-arrestin signaling-dependent
behavior), consistent with the augmented KOR-mediated b-arrestin signaling seen upon
RGS12 over-expression. Collectively, our findings highlight a role for RGS12 as a novel,
differential regulator of both G protein-dependent and -independent signaling
downstream of KOR activation.
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3.2 - Introduction
KOR is highly expressed in mood- and pain-related CNS regions and is involved in
such pathologies as addiction, depression, anxiety, and chronic pain (Crowley and
Kash, 2015; Chavkin and Koob, 2016). During stress, KOR activation by endogenous
dynorphins results in analgesia, depressive / anxiety-like behaviors, and altered drug
reward (Chavkin and Koob, 2016; Schindler et al., 2012; Van't Veer and Carlezon,
2013; Schenk et al., 1999; Chartoff et al., 2016). KOR antagonists have shown promise
in preclinical models of stress-related psychiatric diseases including addiction
(Chavkin, 2011; Carlezon and Krystal, 2016). In contrast, acute administration of KOR
agonists has been shown to exert utility specifically in reducing pain and drug reward - behavioral outcomes particularly relevant to the current United States opioid epidemic
(Kolodny et al., 2015; Koh, 2015; Volkow and Collins, 2017; Kaski et al., 2019).
However, the advantageous effects of KOR agonists are limited by dysphoric sideeffects (Van't Veer and Carlezon, 2013; Chavkin and Koob, 2016; Bohn and Aube,
2017). Behaviors produced by KOR agonists depend upon which signaling cascade(s)
is/are activated (Ehrich et al., 2015; White et al., 2015; Brust et al., 2016; Liu et al.,
2018) – an example of biased agonism (a.k.a. functional selectivity) (Urban et al., 2007;
Rankovic et al., 2016). Agonists induce KOR conformational change (Che et al., 2018),
driving G protein dissociation (Siderovski and Willard, 2005). Freed G protein subunits
then induce biological responses, including cAMP reduction, potassium channel
activation, and inhibition of calcium influx (Karkhanis et al., 2017; Schoffelmeer et al.,
1988; Tallent et al., 1994; Henry et al., 1995). KOR activation also recruits GPCR
kinases (GRKs) and b-arrestin to trigger desensitization, internalization, and activation
of other pathways (McLaughlin et al., 2003; Bruchas et al., 2006). Pharmacological or
genetic inhibition of the KOR-stimulated b-arrestin signaling pathway abolishes KOR
agonist-induced conditioned place aversion (CPA) - a metric of dysphoria (Ehrich et
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al., 2015; Chavkin et al., 2014). Thus, KOR-induced CPA is considered b-arrestindependent. Conversely, KOR-mediated analgesia is considered G protein-dependent
and b-arrestin-independent (Brust et al., 2016; Hernandez et al., 1995; Chavkin, 2011;
Schattauer et al., 2017).
GPCR signaling is tightly controlled by Regulators of G protein Signaling, which
contain an RGS domain (Soundararajan et al., 2008), serving as a GTPase-accelerating
protein (GAP) for Ga (Snow et al., 1998a) and thereby inhibiting G protein signaling
(Lambert et al., 2010). Loss of RGS expression increases GPCR sensitivity to agonist
stimulation (e.g., (Han et al., 2010; Traynor, 2012)). Some RGS proteins contain
additional domains that modulate signaling independent of GAP activity (Anderson et al.,
2009; Shu et al., 2010). For example, RGS12 contains a PDZ domain, a phosphotyrosine
binding (PTB) domain, Ras binding domains (RBDs) (Willard et al., 2007), and a GoLoco
motif, which sequesters inactive Ga·GDP and thereby serves as a GDP dissociation
inhibitor (GDI) (Webb et al., 2005).
We recently found (Gross et al., 2018) that RGS12 is enriched in the ventral striatum
(vSTR) of the mesolimbic dopamine (DA) system which contributes to reward and affect
(Chao and Nestler, 2004; Russo and Nestler, 2013). RGS12 loss reduces
psychostimulant-induced hyperlocomotion and elevates dopamine transporter (DAT)
expression and DA uptake in the vSTR, but not dorsal striatum (dSTR) (Gross et al.,
2018). We hypothesized that RGS12 loss could elevate vSTR KOR activity/sensitivity, as
KOR is highly expressed in the mesolimbic DA system and enriched on presynaptic
terminals of the nucleus accumbens (NAc) (terminals that originate from ventral tegmental
area (VTA) DAergic projections (Crowley and Kash, 2015; Bruijnzeel, 2009)). Mesolimbic
KOR activation reduces extracellular DA – an action proposed to underlie dysphoric
effects (Knoll and Carlezon, 2010; Chefer et al., 2013). KOR-mediated DA decrease
occurs by inhibition of exocytotic DA release (Di Chiara and Imperato, 1988; Donzanti et
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al., 1992) and increased DAT-mediated DA reuptake via Gai/o- and MAPK-dependent
signaling (Thompson et al., 2000; Kivell et al., 2014). Here, we examined whether
augmented vSTR DA uptake and reduced psychostimulant-induced hyperlocomotion in
RGS12-null mouse strains (Gross et al., 2018) results from enhanced KOR action, given
that RGS12 is an established inhibitor of Gai/o signaling (Snow et al., 1998a). Our
investigation revealed that RGS12 more robustly affects KOR-mediated signaling than it
does other opioid receptors, RGS12 differentially modulates G protein-dependent
versus -independent KOR signaling, and RGS12 loss differentially affects KOR-mediated
behaviors, likely contingent upon which KOR-initiated signaling cascade is required to
elicit the particular behavioral outcome.
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3.3 - Materials and Methods
3.3.1 - Drugs and radioligands
The opioid receptor agonists U50,488 hydrochloride (Cat. no. 0495), DAMGO (Cat. no.
1171), and DADLE (Cat. no. 3790) were purchased from Tocris Bioscience (Minneapolis,
MN). For all in vitro experiments with opioid receptor agonists, 10 mM stocks were
prepared with dimethyl sulfoxide (DMSO), then diluted to the appropriate final working
concentrations in assay buffer. The KOR antagonist nor-Binaltorphimine dihydrochloride
(nor-BNI; Cat. no. 0347) was also purchased from Tocris Bioscience, and was dissolved
in sterile 0.9% sodium chloride (saline) for all experiments. D-Amphetamine hemisulfate
salt and morphine sulfate salt pentahydrate were both purchased from Sigma Aldrich (St.
Louis, MO) and dissolved in sterile saline for all experiments. For all animal experiments,
drugs

were

administered

intraperitoneally

(ip).

[3H]Dihydroxyphenylethylamine

([3H]dopamine; Cat. no. NET673250UC), [3H]WIN35593 (Cat. no. NET1033250UC), and
[3H]U-69,593 (Cat. no. NET952250UC) were purchased from Perkin-Elmer (Waltham,
WA).

3.3.2 - Subjects
Rgs12Δ5-8/Δ5-8 mice (a.k.a. Rgs12-/- or RGS12-null) (Gross et al., 2018) and wildtype
(Rgs12+/+) littermates, both C57BL/6J and of both sexes, were housed under
conventional lighting (12 hours light / 12 hours dark), humidity, and temperature, with food
and water ad libitum. Behaviors were tested within the light cycle. All mice used were 812 weeks of age. Experiments were in accordance with WVU Animal Care and Use
Committee and NIH guidelines.
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3.3.3 - Synaptosomal [3H]DA uptake
Synaptosomal [3H]DA uptake was performed as described (Gross et al., 2018), with
modifications described in Supplementary Methods.
3.3.4 - Locomotor activity
AMPH-induced locomotor activity was measured as described (Gross et al., 2018) with
modifications denoted in Supplementary Methods.
3.3.5 - Fast-scan cyclic voltammetry (FSCV)
RGS12-null and wildtype littermates were injected with 10 mg/kg nor-BNI or saline (i.p.).
24 hours later, brain slices were prepared and FSCV performed as described (Schmidt
et al., 2018), with modifications detailed in Supplementary Methods.
3.3.6 - Radioligand binding assays
3.3.6a - [3H]WIN35428 binding to DAT
DAT binding sites were quantified as described (Gross et al., 2018), with modifications
detailed in Supplementary Methods.
3.3.6b - [3H]U69,593 binding to KOR and [35S]GTPgS incorporation upon KOR activation
KOR saturation binding and GTPgS incorporation assays were performed as described
(Zhou et al., 2015), with modifications detailed in Supplementary Methods.
3.3.7 - Co-immunoprecipitations
Co-immunoprecipitations (co-IPs) from brain tissue were performed with the Pierce co-IP
Kit (Waltham, MA) according to manufacturer’s instructions, with modifications described
in Supplementary Methods. Co-IP analyses in HEK293T cells were performed with the
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Pierce HA-Tag IP/Co-IP Kit according to manufacturer’s instructions, with modifications
detailed in Supplementary Methods.

3.3.8 - cAMP inhibition
HEK293T cells were transfected via CaPO4 (Jordan et al., 1996) with GloSensor-22F
cAMP biosensor (Promega) and HA-tagged opioid receptor (3XHA-hKOR, 3XHA-hMOR,
or 3XHA-hDOR; www.cdna.org), with or without wildtype human RGS12, RGS domain
loss-of-function RGS12 (Rgs12E740K), or GoLoco motif loss-of-function RGS12
(Rgs12R1206F). Additional procedures are detailed in Supplementary Methods.

3.3.9 - b-arrestin recruitment
Agonist-induced b-arrestin recruitment was determined using ‘Tango’ assay (Barnea et
al., 2008; Allen et al., 2011). HTLA cells expressing b-arrestin-TEV protease fusion and
tetracycline transactivator-driven luciferase reporter (Barnea et al., 2008) were
transfected via CaPO4 (Jordan et al., 1996) with opioid receptor-Tango vectors (FLAGKOR-Tango, FLAG-MOR-Tango, or FLAG-DOR-Tango; contributed to Addgene by Dr.
Bryan Roth) with or without WT hRGS12, Rgs12E740K, or Rgs12R1206F vectors. Additional
procedures are detailed in Supplementary Methods.

3.3.10 - Hot plate analgesia and conditioned place aversion (CPA) tests
To detect sensitivity to painful stimuli, the hot plate test of nociception was performed as
previously described (Bohn et al., 1999) with modifications detailed in Supplementary
Information. CPA was performed as described (Schindler et al., 2012) with modifications
denoted in Supplemental Methods.
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3.4 - Results
3.4.1 - vSTR DAT dysfunction in RGS12-null mice is KOR-dependent
Rgs12 mRNA is detected in multiple Oprk1-expressing neuronal populations in the
mouse brain (Fig. S1), including the VTA and substantia nigra pars compacta (SNc), the
anatomical loci of DAergic projection neurons; within the striatum, RGS12 protein is seen
(Gross et al., 2018) to be particularly enriched within the ventral striatum. To evaluate
whether increased KOR activity is responsible for elevated DAT-mediated DA uptake
observed (Gross et al., 2018) in the vSTR of RGS12-null mice, [3H]DA uptake by vSTR
synaptosomes was measured following systemic pretreatment with the KOR-selective
antagonist nor-BNI (Fig. 1A). Omnibus analyses revealed an effect of genotype,
antagonist treatment, and a genotype x treatment interaction (genotype, F(1,9) = 13.5, p
= 0.005; treatment, F(1,9) = 13.4, p = 0.005; interaction, F(1,9) = 7.0, p = 0.026).
Synaptosomes from saline-pretreated RGS12-null mice exhibited increased DATmediated [3H]DA uptake compared with wildtype mice (p = 0.001) (Fig. 1A). nor-BNI
pretreatment (10 mg/kg, ip) reversed this effect (p = 0.002); nor-BNI pretreatment did not
affect [3H]DA uptake in wildtype controls (p = 0.768). All data from [3H]DA uptake analyses
are the mean ± SEM and analyzed by two-way ANOVA followed by Sidak's post hoc test
(n = 4-8 mice/group).
To test whether increased DAT binding sites in the vSTR of RGS12-null mice
(Gross et al., 2018) was due to increased KOR expression/sensitivity, we systemically
pretreated RGS12-null and wildtype mice with nor-BNI (10 mg/kg, ip) or saline over 14
days and assessed [3H]WIN35428 binding to DAT (Fig. 1B). Omnibus analyses revealed
an effect of genotype and a genotype x antagonist treatment interaction (genotype,
F(1,16) = 19.5, p < 0.001; treatment x genotype interaction, F(1,16) = 8.0, p = 0.011).
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Multiple comparisons analysis showed that saline-treated RGS12-null mice display
increased [3H]WIN35428 binding to DAT relative to saline-treated wildtype mice (p <
0.001). Prolonged nor-BNI pretreatment reversed this effect (p = 0.048) to levels
comparable to saline-treated wildtype mice (p = 0.149). nor-BNI treatment did not
significantly affect DAT binding in wildtype mice (p = 0.673). All data from DAT binding
analyses are the mean ± SEM and analyzed by two-way ANOVA followed by Sidak's post
hoc test (n = 6 mice/group).
Augmented DA uptake and DAT binding sites in RGS12-null mice were previously
correlated

with

decreased

hyperlocomotor

response

to

the

DA-dependent

psychostimulant d-amphetamine (AMPH) (Gross et al., 2018). To assess whether this
blunted hyperlocomotion is due to increased KOR activity, RGS12-null mice were
pretreated with nor-BNI (10 mg/kg, ip) 24 hours prior to AMPH treatment. Omnibus
analyses revealed an effect of genotype and antagonist treatment (genotype, F(1,44) =
7.5, p = 0.009; treatment, F(1,44) = 7.0, p = 0.011). Attenuated AMPH-induced
hyperlocomotion in RGS12-null mice (p = 0.039) was reversed following nor-BNI
pretreatment (p = 0.045) (Fig. 1C); in contrast, nor-BNI pretreatment did not affect AMPHinduced hyperlocomotion of wildtype mice (p = 0.305). Hyperlocomotion data are the
mean ± SEM and analyzed by two-way ANOVA followed by a Sidak's post hoc test (n =
10-13 mice/group).
FSCV analyses of DA release and reuptake revealed significant effects of
genotype and nor-BNI treatment within the NAc core, but not the NAc shell nor dSTR, in
mice lacking RGS12 expression (Fig. 1D-G and Fig. S2). Examining peak DA release in
the NAc core, we found significant main effects of stimulation amplitude (F(62,2) = 34.439,
p < 0.001) and genotype (F(1,31) = 4.875, p = 0.035), and a non-significant genotype x
antagonist treatment interaction (F(1,31) = 3.206, p = 0.083) (Fig. 1D). Furthermore, a
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significant main effect of antagonist treatment (F(1,31) = 6.089, p = 0.019) was seen on
DA reuptake dynamics (Fig. 1F) as measured by t1/2 (Yorgason et al., 2011). Within the
NAc shell (Fig. 1E), a significant main effect of stimulation amplitude was observed
(F(1.4,43.3) = 38.2, p < 0.0001), as well as a non-significant stimulation x genotype x
antagonist treatment interaction (F(2,62) = 2.5, p = 0.089); however, there was no
significant effect of genotype, antagonist treatment, or genotype x treatment interaction
(p > 0.05) regarding peak DA concentration. In the dSTR, we observed only an effect of
stimulation amplitude (F(1.2,38.3) = 2, p < 0.0001) and no effect of genotype, antagonist
treatment, nor any interaction (p > 0.05) (Fig. S2A). There were no significant effects, in
the NAc shell or the dSTR, on t1/2 measures of DA reuptake (p > 0.05) (Shell: Fig. 1G;
dSTR: Fig. S2B). All data are mean ± SEM and were analyzed by general linear mixed
model with stimulation amplitude as a repeated factor and genotype and antagonist
treatment as between-subject factors (n = 6 - 11 mice/group). It is important to note that
electrical stimulation of striatal brain slices during FSCV also recruits local microcircuitry,
including cholinergic interneurons, which can strongly influence DA release magnitude
via acetylcholine release and subsequent activation of nicotinic cholinergic receptors
expressed on DA terminals (Threlfell et al., 2012; Melchior et al., 2015). Given high Rgs12
expression in ChAT+ (cholinergic) interneurons, yet relatively low expression of KOR in
these neurons (e.g., Fig. S1C), it is possible that the KOR-independent reductions in
accumbal DA release seen in RGS12-null mice may be due, in part, to RGS12 loss within
ChAT+ striatal interneurons. Future studies will be required to parse out the relative
contributions of this specific interneuron population.
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3.4.2 - RGS12 forms a protein complex with KOR in brain tissue and transfected
cells
Endogenous KOR co-immunoprecipitates with endogenous RGS12 in vSTR tissue
from wildtype mice (Fig. 2). KOR immunoreactivity was absent in immunoprecipitated
samples from RGS12-null vSTR (Fig. 2A), suggesting that KOR immunoreactivity from
the wildtype mouse vSTR sample was not due to non-specific KOR binding. Consistent
with this finding from vSTR (Fig. 2A), we found robust RGS12 immunoreactivity in
immunoprecipitates of HA-tagged KOR expressed in transfected HEK293T cells (Fig.
2B). Notably, co-expression of RGS12 with the mu opioid receptor (3XHA-MOR) resulted
in only a weak, non-specific signal (relative to RGS12 alone-transfected cells; Fig. 2B),
supporting the notion of a selective interaction of RGS12 with KOR and not MOR.

3.4.3 - KOR sensitivity and binding sites are increased in vSTR of RGS12-null mice
Given the effect of KOR antagonism in reversing the DAT-mediated DA dysfunction
of RGS12-null mice, we probed for changes in KOR signaling and/or levels upon RGS12
loss. Systemic administration of KOR agonists, including U50,488, reduces mouse
locomotion (Castellano et al., 1988) -- an index of KOR sensitivity in vivo. Following 2.5
mg/kg U50,488, RGS12-null, but not wildtype, mice displayed hypolocomotion relative to
vehicle-treated controls (Fig. 2C; RGS12-null: p = 0.012; wildtype: p = 0.892), indicating
increased KOR sensitivity in RGS12-null mice. A higher dose (5 mg/kg) significantly
reduced locomotion in both genotypes (Fig. 2C; RGS12-null: p = 0.000; wildtype: p =
0.0007). All data are the mean ± SEM and analyzed by two-way ANOVA (n = 7-13
mice/group). Omnibus analyses of summed data (Fig. 2C) revealed an effect of genotype,
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U50,488 treatment, and a trend for a genotype x treatment interaction (genotype, F(1,55)
= 4.4, p = 0.040; treatment, F(2,55) = 20.1, p < 0.0001; interaction, F (2,55) = 2.8, p =
0.072). Multiple comparisons were analyzed by a Sidak's post hoc test and performed
with each dose of U50,488 statistically compared to saline-treated controls.
We also measured [35S]GTPgS incorporation upon U50,488-elicited G protein
activation in vSTR and dSTR membranes. At 1 µM U50,488, RGS12-null, but not
wildtype, mice displayed significant GTPgS incorporation in vSTR membranes (Fig. 2D)
relative to vehicle control (RGS12-null [1 µM]: p = 0.015; wildtype [1 µM]: p = 0.996),
supporting the notion of enhanced KOR-stimulated G protein activation in the vSTR upon
RGS12 loss. A two-way ANOVA of the data across multiple U50,488 dosings (Fig. 2D)
revealed omnibus effects of genotype, U50,488 treatment, and a genotype x treatment
interaction (genotype: p = 0.005; treatment: 0.004, interaction: p = 0.015).
vSTR and dSTR preparations from wildtype mice, as well as dSTR preparations from
RGS12-null mice, only displayed significant [35S]GTPgS incorporation at the highest
concentration tested (Fig. 2D: e.g., vSTR of wildtype mice at 100 µM U50,488: p = 0.028).
Low signal window (e.g., ~0.2-fold max) in assays of [35S]GTPgS binding to endogenous
receptors in native brain tissue has been previously noted (Bohn et al., 2015). U50,488induced [35S]GTPgS binding was not differentially elevated in dSTR preparations from
RGS12-null vs wildtype mice (Fig. 2D inset: Student’s t-test t(7) = 0.06; p = 0.946). All
data from [35S]GTPgS incorporation are the mean ± SEM (n = 13-19 mice/group).
We next assessed whether increased KOR levels/binding sites, in addition to
augmented KOR signaling, could account for KOR antagonism-mediated reversal of
increased DA uptake in RGS12-null mice. We performed saturation binding with the KOR-
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selective agonist [3H]U69,593 on vSTR and dSTR membranes from RGS12-null mice vs
wildtype controls. With loss of RGS12, KOR binding sites (Bmax) were increased in vSTR
(Fig. 2E) (F(1,87) = 12.9, p = 0.0005), but not dSTR (F(1,62) = 0.3, p = 0.618;); in contrast,
Kd values were equivalent between RGS12-null and wildtype mice in both vSTR (F(1,87)
= 0.008, p = 0.931) and dSTR (F(1,62) = 0.3, p = 0.610) preparations. All data from
[3H]U69,593 saturation binding are the mean ± SEM, and the inset of Fig. 2E was
analyzed by two-way ANOVA (n = 9-12 mice/group), revealing an effect of genotype,
brain region, and a genotype x brain region interaction (genotype, F(1,24) = 10.0, p =
0.004; region, F(1,24) = 4.6, p = 0.043 ; interaction, F (1,24) = 6.1, p = 0.021); multiple
comparisons were analyzed by Sidak's post hoc test (multiple comparisons: vSTR,
RGS12-null vs wildtype, p < 0.0001; dSTR, RGS12-null vs wildtype, p = 0.879). To
ascertain whether increased KOR protein levels/binding sites in RGS12-null mice was
due to KOR (Oprk1) transcriptional upregulation, we performed qRT-PCR on vSTR and
midbrain tissue. RGS12-null and wildtype mice exhibited similar Oprk1 mRNA levels in
both regions (Fig. S3A), suggesting that enhanced KOR activation observed in RGS12null mice is not likely due to elevated KOR expression.

3.4.4 - RGS12 differentially regulates G protein and b-arrestin signaling downstream of
KOR

KOR belongs to the GPCR family that includes mu- (MOR) and delta- (DOR) opioid
receptors – also Gi/o-coupled, but with separate neuroanatomical distributions and
functions relative to KOR (Pan, 1998; Al-Hasani and Bruchas, 2011). To determine
whether RGS12 regulates G protein signaling downstream of opioid receptor activation,
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we used a cAMP-based readout in HEK293T cells (Allen et al., 2011) to measure
receptor-mediated, Gai/o-dependent inhibition of isoproterenol-induced cAMP increases
(Fig. 3A-F). PTX pretreatment abolished KOR agonist-stimulated cAMP inhibition (Fig.
3A inset: t(3) = 18.1, p < 0.001), validating the luciferase assay as a measure of Gi/omediated signaling. Wildtype (WT) RGS12 expression reduced U50,488 potency by at
least 20-fold (Fig. 3A: F(1,245) = 56.8, p < 0.0001; also Fig. S4A), but only affected
agonism of MOR by ~3-fold (Fig. 3B: F(1,216) = 13.1, p = 0.0004; also Fig. S4B) and
DOR by 2.5-fold (Fig. 3C: F(1,136) = 7.6, p = 0.007). The effect of RGS12 expression on
KOR-mediated G protein signaling relied on both the GAP and GDI activities of RGS12,
as loss-of-function mutations to either element within RGS12 curtailed the observed
decrease in pIC50 from 20-fold (RGS12 WT) to less than 4-fold (Fig. 3A: RGS12E740K: F(1,
205) = 7.1, p = 0.008; RGS12R1206F: F(1, 173) = 5.7, p = 0.018). We previously established
that the E740K charge-reversal mutation to RGS12 eliminates RGS domain GAP activity
(Sambi et al., 2006), whereas the R1206F mutation eliminates GoLoco motif GDI activity
(Kimple et al., 2002; Sambi et al., 2006).
The PDZ domain of RGS12 exhibits a high degree of similarity (Snow et al., 1998a)
to the first PDZ domain of NHERF1 (“Na+/H+ exchanger regulatory factor-1”). NHERF1
is known (Li et al., 2002) to employ its first PDZ domain to bind directly to a PDZ docking
site at the KOR C-terminus (aa 376-380: -NKPV-cooh), but does not bind MOR nor DOR
(which both lack this C-terminal sequence). As RGS12 co-immunoprecipitates with KOR,
but not MOR, in transfected cells (Fig. 2B), we tested whether such binding specificity
was determined by a potential PDZ domain / GPCR C-terminal tail interaction. We
mutated the last four amino acids of the KOR C-terminus (i.e., NKPV) to four alanine
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residues and, conversely, mutated the last four amino acids of the MOR C-terminus to
that found in the wildtype KOR sequence (i.e., NKPV) (Fig. 3D). Co-expression of
hRGS12-WT with hKORAAAA diminished the RGS12-mediated reduction in U50,488
potency from 20-fold down to 4-fold (Fig. 3A vs E: F(1, 272) = 5.0, p = 0.024). Conversely,
substitution of the last four amino acids of MOR to the C-terminal PDZ docking site of
KOR (i.e., MORNKPV) was seen to enhance the RGS12-mediated reduction of DAMGO
potency from 3-fold to 6-fold (Fig. 3B vs F: F(1, 271) = 32.1, p < 0.0001), constituting a 2fold gain-of-function from the effect of RGS12 on wildtype MOR. Together, these data
suggest that the PDZ docking site of KOR is necessary, but not sufficient in its entirety,
to account for the selectivity RGS12 exerts on opioid agonist potency for KOR over the
other opioid receptors.
To determine whether RGS12 also regulates G protein-independent signaling from
opioid receptors, we examined b-arrestin recruitment following receptor activation (Allen
et al., 2011; Barnea et al., 2008). Expression of wildtype RGS12 augmented KOR
agonist-dependent b-arrestin recruitment by 3-fold (Fig. 3G: F(1,410) = 211, p < 0.0001),
but only mildly elevated MOR agonist-dependent b-arrestin recruitment (Fig. 3I: 1.2-fold;
F(1,314) = 11.5, p = 0.0008) and DOR agonist-dependent b-arrestin recruitment (Fig. 3J:
1.1-fold; F(1,250) = 17.6, p < 0.0001); no potency changes (EC50) were observed for any
opioid receptor agonist used: KOR/U50,488: F(1,410) = 0.3, p = 0.598; MOR/DAMGO:
F(1,314) = 0.3, p = 0.561; and DOR/DADLE: F(1,250) = 1.6, p = 0.205) (Fig. 3G,I,J).
RGS domain and GoLoco motif loss-of-function mutants did not reverse the RGS12dependent increase in b-arrestin recruitment downstream of KOR activation (Fig. 3G).
RGS12E740K elicited no change in the maximal efficacy (Emax) of KOR agonist-dependent
b-arrestin recruitment relative to wildtype RGS12 (RGS12E740K: F(1,410) = 2.1, p = 0.148),
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whereas RGS12R1206F co-transfection resulted in a slight, but statistically significant,
increase in KOR agonist-dependent b-arrestin recruitment relative to wildtype protein
(RGS12R1206F: F(1,410) = 20.9, p < 0.0001). Together, these data indicate that RGS12
requires a functional RGS domain and GoLoco motif for its full effects on KOR-mediated
G protein signaling (Fig. 3A), but not for enhancing b-arrestin translocation to activated
KOR (Fig. 3G), suggesting that RGS12 increases b-arrestin recruitment in a G proteinindependent manner. To confirm this idea, we evaluated KOR agonist-stimulated barrestin translocation following PTX pretreatment. Overnight PTX pretreatment had no
effect on the RGS12-mediated increase in b-arrestin recruitment to activated KOR (Fig.
3H; p = 0.696) nor an effect on U50,488-induced b-arrestin recruitment efficacy in control
cells expressing KOR-only (Fig. 3H; p = 0.540). Omnibus analyses revealed only an effect
of RGS12 expression (RGS12, F(1,8) = 1160.0, p < 0.001). Data in Fig. 3H are the mean
± SEM (N = 3 independent experiments) and were analyzed by two-way ANOVA with
Sidak's post hoc test.
We hypothesized that the increased KOR binding sites seen in the vSTR of RGS12null mice (Fig. 2E) might be due to attenuated b-arrestin-2-dependent internalization
and/or downregulation of KOR in the absence of RGS12 expression. To test this idea, we
performed [3H]U69,593 saturation binding assays in vSTR and dSTR membranes of barrestin-2 knockout (barr2KO) (Bohn et al., 1999) and wildtype control mice. b-arrestin-2
knockout mice exhibited increased KOR Bmax in the vSTR compared to wildtype controls
(Fig. 3K,L: F(1,66) = 4.1, p = 0.044); in contrast, Kd values for KOR radioligand binding
were equivalent between barr2KO and wildtype mice in both vSTR (F(1,66) = 0.1, p =
0.701) and dSTR (F(1,68) = 0.1, p = 0.678) preparations (Fig. 3K,L). Analysis of KOR
binding Bmax revealed that KOR levels were increased in the vSTR, but not the dSTR (Fig.
3L: F(1,68) = 0.018, p = 0.6674). Omnibus analysis revealed effects of genotype, brain
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region, and a trend for a genotype x brain region interaction (genotype, F(1,20) = 5.8, p
= 0.025; treatment, F(1,20) = 14.9, p = 0.001; interaction, F(1,20) = 4.0, p = 0.057). These
findings support the notion that increased KOR levels/binding sites in RGS12-null mice is
related to reduced KOR-mediated b-arrestin-2 function upon RGS12 loss. All data are the
mean ± SEM (n = 12 mice per group); data displayed in Fig. 3K-L were analyzed by twoway ANOVA with Sidak's post hoc test.

3.4.5 - RGS12 differentially regulates G protein- and b-arrestin-dependent
behaviors mediated by KOR
RGS12 expression selectively reduces KOR agonist-induced cAMP inhibition via its
RGS domain and GoLoco motif (Fig. 3); these data are consistent with findings of KOR
antagonism-mediated reversal of elevated DA uptake and DAT binding sites (Fig. 1A,B)
and attenuated AMPH-induced hyperlocomotion (Fig. 1C), increased KOR-stimulated
[35S]GTPgS

binding

(Fig.

2D),

and

increased

sensitivity

to

KOR-stimulated

hypolocomotion (Fig. 2C) upon RGS12 loss. Together, these findings suggest that
RGS12 normally reduces G protein-dependent KOR signaling, and RGS12 loss results
in hypersensitivity of KOR-mediated G protein signaling. To assess this hypothesis with
an integrated, behavioral output, we interrogated supraspinal nociception using the hot
plate assay (Sora et al., 1997); prior studies have determined that KOR-induced
analgesia represents a G protein-dependent and b-arrestin-independent outcome of KOR
agonism (Chavkin, 2011; White et al., 2015; Schattauer et al., 2017). Here, we tested
whether RGS12-null mice exhibit enhanced sensitivity to the analgesic effect of U50,488
(Fig. 4A-C). RGS12-null mice displayed significantly increased analgesia by U50,488 at
5 mg/kg (within-subjects comparisons: RGS12-null saline vs U50,488: p = 0.033) and
22.5 mg/kg (RGS12-null saline vs U50,488: p = 0.005), whereas wildtype littermates
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exhibited no statistically significant analgesia to either dose (within-subjects comparisons:
WT saline vs 5 mg/kg U50,488: p = 0.815; WT saline vs 22.5 mg/kg U50,488: p = 0.199).
Omnibus ANOVA revealed only a significant effect of treatment at these two doses of
U50,488 (5 mg/kg treatment, F(1,18) = 5.2, p = 0.036; 22.5 mg/kg treatment, F(1,15) =
13.8, p = 0.002). These results suggest that RGS12-null mice have enhanced sensitivity
to the analgesic output of KOR agonism. Following 30 mg/kg U50,488, there was no
difference in analgesia between genotypes (Fig. 4C: RGS12-null saline vs U50,488: p <
0.0001; WT saline vs U50,488: p = 0.0003); omnibus ANOVA revealed only a significant
effect of treatment at this 30 mg/kg dose of U50,488 (treatment, F(1,16) = 57.6, p <
0.0001). RGS12-null and wildtype mice pretreated with the KOR antagonist nor-BNI (10
mg/kg, ip) 24 hours prior to U50,488 administration exhibited no analgesic responses
(Fig. S5), indicating that the supraspinal anti-nociceptive effects of U50,488 (Fig. 4A-C)
are mediated by KOR activation. Supporting a selective function of RGS12 on KOR
signaling over that of other opioid receptors, RGS12-null mice were seen to exhibit normal
analgesia to morphine (Fig. S6) – a response dependent on MOR activation (Sora et al.,
1997; Pasternak, 2010). All data from hot plate analgesia experiments are the mean ±
SEM (n = 7-14 mice per group) and analyzed by two-way ANOVA followed by Sidak's
post hoc test.
While RGS12 is known to suppress G protein-dependent signaling (Snow et al.,
1998a; Kimple et al., 2002), RGS12 expression was also seen to augment b-arrestin
recruitment independent of its heterotrimeric G protein-modulating domains (Fig. 3G).
These data suggest that RGS12 loss may lead to decreased G protein-independent (i.e.,
b-arrestin) signaling downstream of KOR activation. Therefore, we examined conditioned
place aversion (CPA) to U50,488, given that aversion to KOR-induced dysphoria is
considered a b-arrestin-dependent behavior (Land et al., 2009; Chavkin et al., 2014;
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Ehrich et al., 2015). Wildtype mice exhibited CPA following 2.5 mg/kg U50,488 (p =
0.011); in contrast, RGS12-null mice did not express aversion at this dose (p = 0.548).
Omnibus ANOVA analysis revealed only an effect of U50,488 treatment (F(1,25) = 7.7, p
= 0.010) (Fig. 4D). These data suggest that RGS12 loss reduces the ability of KOR
agonism to produce aversion/dysphoria. At 5 mg/kg U50,488, both RGS12-null and
wildtype mice exhibited aversion (Fig. 4E) (within-subjects comparison: RGS12-null mice:
p = 0.021; WT mice: p < 0.0001); the aversion exhibited by RGS12-null mice was
attenuated relative to that of wildtype littermates (between-subjects comparison: RGS12null vs WT: p = 0.006). Omnibus ANOVA analysis revealed an effect of treatment at this
higher U50,488 dose (treatment, F(1,22) = 44.7, p < 0.0001) and a genotype X treatment
interaction (F(1,22) = 10.7, p = 0.004). All data from CPA experiments are the mean ±
SEM (n = 9-15 mice per group) and analyzed by two-way ANOVA followed by a Sidak's
post hoc test.
A summary of the interpretation of all these findings, derived from our interrogations
of adult RGS12-null mice, is presented in Figure 5. Constitutive loss of RGS12 may
alternatively (or additionally) engender disruptions to KOR signaling in the vSTR via
perturbation of neurodevelopmental processes. In response to neonatal or early life
stress, the KOR/dynorphin system becomes hypersensitive to endogenous and
exogenous activation, resulting in mesolimbic hypodopaminergia and behavioral
disruption in adulthood, including altered psychostimulant responsiveness (Van't Veer
and Carlezon, 2013; Vien et al., 2009; Karkhanis et al., 2016; Yorgason et al., 2016).
Thus, loss of RGS12 from birth may increase pre- and/or post-natal stress susceptibility
such that the KOR system becomes upregulated. This hypothesis is supported by
previous work from our group and others demonstrating that (i) RGS12 is strongly
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expressed throughout CNS regions integral to the early embryonic stages of
neurodevelopment (Martin-McCaffrey et al., 2005), (ii) RGS12 is required for
neurodevelopmental processes such as nerve growth factor-stimulated axonogenesis by
sensory neurons (Willard et al., 2007), and (iii) RGS12 levels are altered during
synaptogenesis by sensory deprivation (Butko et al., 2013) and in transgenic models of
neurodevelopmental diseases such as schizophrenia (Sialana et al., 2018). Future
studies will be required to elucidate whether RGS12 loss early in neurodevelopment
contributes to the disruptions of KOR signaling and behavior observed in constitutive
RGS12-null adult mice.
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3.5 - Discussion
RGS12 as an important regulator of vSTR DA homeostasis via KOR signaling
effects on DAT
RGS12 exhibits selective effects on KOR signaling in at least one region of the CNS
– the ventral striatum – via a mechanism dependent on an interaction with KOR that is at
least functional and likely direct. Single cell RNAseq data (Saunders et al., 2018) reveals
that Rgs12 is expressed in several Oprk1 (KOR)-expressing neuronal populations within
the corticostriatal circuit (Fig. S1C). Thus, disruptions to KOR signaling and behavior upon
global Rgs12 deletion may, at least in part, reflect an integrated response across several
corticostriatal brain regions and may not necessarily be restricted to abrogated functional
interaction solely within the vSTR. For example, loss of Rgs12 in striatal dopamine
receptor D1R+ and/or D2R+ medium spiny neurons (MSNs) seen to co-express Oprk1
and Rgs12 in wildtype mice (e.g., Fig. S1C) could contribute to the RGS12-null mouse
phenotypes observed, especially given the known roles these MSNs play in rewarding
and aversive responses (e.g., to psychostimulant-drugs) (Calipari et al., 2016; Tejeda et
al., 2017).
KOR activation results in hypodopaminergia in the vSTR/NAc by (i) decreasing DA
release (Di Chiara and Imperato, 1988; Donzanti et al., 1992) and (ii) increasing DATmediated DA reuptake (Thompson et al., 2000; Kivell et al., 2014) in a G proteindependent manner. As RGS12-null mice exhibit augmented DAT-mediated DA uptake
reversible by KOR blockade, and display increased KOR-mediated G protein signaling
(Figs. 1, 2), we hypothesized that RGS12 loss would also reduce DA release in the
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vSTR/NAc due to increased KOR-mediated G protein signaling. Indeed, RGS12-null mice
exhibited attenuated DA release in the NAc core (Fig. 1); in addition, a notable trend
towards reduced DA release was also observed in the NAc shell, but this latter result was
not statistically different from wildtype controls. Evoked DA release is considerably lower
in the NAc shell than the core (Melchior and Jones, 2017), which may account for our
inability to attain statistically significant differences between genotypes when performing
FSCV in the shell. No differences of DA release nor in nor-BNI pretreatment effects were
detected in the dSTR (Fig. S2), further supporting that RGS12 selectively exerts DAmodulatory effects in the vSTR, but not dSTR.
KOR blockade via nor-BNI pretreatment did not rescue the deficient DA release seen
in the NAc core of RGS12-null mice (Fig. 1), suggesting that this release defect is KORindependent or reliant on long-term neurodevelopmental maladaptation to RGS12 loss
rather than acute KOR signaling upregulation per se. We identified a trend for nor-BNI
pretreatment to increase DA release in RGS12-null, but not wildtype, mice within the NAc
shell at select stimulation amplitudes (Fig. 1), although this did not reach statistical
significance. KOR agonists have been reported to reduce DA release more potently in
the NAc shell than the core (Melchior and Jones, 2017), and this effect may relate to the
higher level of KOR expression in the NAc shell relative to the core seen in rodents
(Mansour et al., 1995a; Resendez et al., 2016). Therefore, the observed trend for
increased DA release by nor-BNI in the NAc shell, but not NAc core, of RGS12-null mice
may have emerged given enhanced expression and function of KOR in the NAc shell over
the core.
Wildtype mice did not exhibit altered DA reuptake in the NAc core, NAc shell, nor
dSTR following nor-BNI pretreatment (Fig. 1 and S2); these observations support the
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notion that, under normal conditions, there is a lack of basal KOR tone (i.e., the presence
of dynorphin-stimulated and/or constitutive activity of KOR) in these regions. However,
augmented [3H]DA-uptake in the vSTR synaptosomes of RGS12-null-mice was reversed
by systemic nor-BNI pretreatment (Fig. 1); moreover, RGS12-null mice display a trend for
enhanced sensitivity to the effect of nor-BNI on DA reuptake in the NAc-core relative to
wildtype controls (Fig. 1). Together, these data support the idea that KOR
sensitivity/activity in the vSTR is enhanced in the absence of RGS12-expression. This
effect is unlikely to be related to elevated dynorphin tone, given normal Prodyn mRNA
expression in RGS12-null mice (Fig. S3B). RGS12-null mice may not exhibit KORdependent effects on DA reuptake in the NAc shell given that this region expresses
considerably less DAT than the NAc core (Nirenberg et al., 1997). Moreover, the minimal
levels of extracellular DA that arise following evoked DA release in the NAc shell,
especially in RGS12-null mice, may be insufficient to drive DAT-mediated DA reuptake at
thresholds sufficient to engage KOR, thereby masking any modulatory effects that RGS12
may have on KOR-dependent processes. Irrespective of the relative paucity of
engagement within the NAc shell leading to a lack of observable signal, our data from
brain-slice FSCV and synaptosomal [3H]DA uptake support that (i) RGS12 loss affects
DAergic neurotransmission in vSTR, but not the dSTR, and (ii) RGS12 modulates vSTRKOR signaling that affects DAT function, but does not appreciably affect KOR signaling
that specifically regulates DA release.
vSTR synaptosomes derived from RGS12-null mice exhibit elevated Vmax of [3H]DA
uptake (Gross et al., 2018). In contrast, DA reuptake in the NAc is similar in saline-treated
RGS12-null mice and saline-treated wildtype controls (Fig. 1). Such differences between
measurements of endogenous DA reuptake (e.g., via FSCV) vs exogenous DA uptake
(e.g., via synaptosomal [3H]DA-uptake) have been demonstrated previously (Chen and
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Reith, 2007). FSCV evaluates DA reuptake by quantifying the clearance rate (t1/2) of
endogenous DA released into the extracellular space following stimulation of release
(e.g., electrical) (Robinson et al., 2003; Yorgason et al., 2011). Thus, FSCV-derived
reuptake rates are predicated, in part, on the absolute quantity of DA released from
presynaptic DA neurons. Given that RGS12-null mice exhibit markedly reduced DA
release in the NAc following electrical stimulation (Fig. 1), these mice may consequently
display lower rates of DA reuptake than expected (relative to observed synaptosomal
[3H]DA-uptake rates) simply due to the considerably lower levels of extracellular DA
present during the experiment. Unlike in brain-slice FSCV (Phillips et al., 2002; McGinnis
et al., 2016), in vitro synaptosomal [3H]DA-uptake experiments employ high levels of both
[3H]-labeled and unlabeled DA to achieve DAT saturation (e.g., refs. (Bermingham and
Blakely, 2016; Gross et al., 2018)). Consequently, this high load of exogenous DA
produces a distinctly different measure of DA uptake capacity relative to FSCV
(Richardson et al., 2016; Gowrishankar et al., 2018) given that it drives activation of
endogenously expressed receptors and thereby engages negative feedback systems
(e.g., ref. (Gowrishankar et al., 2018)). Thus, RGS12-null mice may require elevated DA
tone in the vSTR/NAc to manifest observable differences in DAT-mediated DA uptake.
Our finding that RGS12 modulates KOR function (this study) and DAT function (Gross
et al., 2018) in the vSTR, but not dSTR, supports previous findings that KOR effects on
DAT function and AMPH-induced neuronal activation are restricted to the vSTR (Gray et
al., 1999; Thompson et al., 2000). Regio-specific RGS12 action on KOR and DAT function
might be, at least in part, related to the greater RGS12 expression seen in vSTR relative
to dSTR (Gross et al., 2018). An alternative (or additive) explanation might be differential
expression of some G-protein-signaling element(s) between the vSTR and dSTR. For
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example, DA signaling via the dopamine D2 receptor is reported as being more potent in
the NAc (vSTR) than the dSTR (Marcott et al., 2018), given preferential coupling of D2R
to Gao, which is more highly expressed in the NAc than dSTR relative to Gai (Lein et al.,
2007). While the RGS12 RGS domain increases the GTPase activity of both Gao and
Gai1 proteins (Snow et al., 1998a), the GoLoco-motif binds only to Gai1/i2/i3 subunits and
not to Gao (Kimple et al., 2002). Such differential engagement of Gai vs Gao by RGS12
might thereby underlie a vSTR specific action of RGS12 on KOR signaling and,
consequently, on DAT function.

RGS12 as a potential target for inhibition to help direct KOR agonism toward
beneficial analgesia and away from anti-therapeutic aversion/dysphoria?
Neuroanatomical loci mediating supraspinal opioid-induced analgesia are located
throughout the brain (Lipp, 1991; Jensen, 1997), with the mesolimbic dopamine-system
playing an integral role (Altier and Stewart, 1999; Gear et al., 1999). Thus, the enhanced
analgesic effect of U50,488 in RGS12-null mice (Fig. 4) is consistent with the augmented
KOR agonist potency and KOR levels observed in the vSTR of these mice (Fig. 2).
RGS12 may also regulate KOR-mediated spinal analgesia via similar mechanisms:
RGS12 and KOR are both expressed in spinal neurons that mediate analgesia (Willard
et al., 2007; Hylden et al., 1991; Cai et al., 2016). Dorsal root ganglion (DRG) neurons
located adjacent to the spinal cord, as well as the dorsal horns, represent key nociceptive
loci as they contain neurons responsible for receiving and transmitting nociceptive signals
(Todd, 2010). Both KOR and RGS12 are highly expressed in DRGs (Tsai et al., 2010;
Willard et al., 2007), and KOR is known to mediate analgesic responses within this
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anatomical region (Xu et al., 2004). Thus, the effects of RGS12 loss on KOR-mediated
analgesia may also rely, at least in part, on augmented KOR-mediated G protein signaling
at the level of the spinal cord. RGS12-null mice exhibited normal morphine-induced
analgesia (Fig. S6), supporting the idea that RGS12 functions selectively on KORsignaling relative to that of other opioid receptors, especially given the receptor-selectivity
of morphine’s analgesic actions (i.e., the anti-nociceptive effects of morphine are
completely lost in MOR knockout mice (Sora et al., 1997; Pasternak, 2010) yet preserved
in mice lacking KOR (Simonin et al., 1998)).
Prior evidence suggests that the DA-lowering effects of KOR agonists in the vSTR
underlie their aversive/dysphoric properties (Knoll and Carlezon, 2010; Shippenberg et
al., 1993); thus, attenuated U50,488-induced CPA in RGS12-null mice might be related
to a constitutively elevated DA reuptake in the vSTR of these mice (Gross et al., 2018),
resulting in reduced extracellular DA and causing a 'floor effect' whereby KOR-mediated
reductions in vSTR DA are unable to manifest aversion in the absence of RGS12
expression. However, this possibility is unlikely, as even DA-deficient mice display KORinduced CPA (Land et al., 2009). Reduced KOR-induced CPA in RGS12-null mice is also
unlikely to reflect a learning deficit given that these mice exhibit normal conditioned-placepreference to both amphetamine and cocaine (Gross et al., 2018).
RGS12 over-expression was seen to reduce G protein-dependent signaling and
increase b-arrestin recruitment downstream of KOR activation (Fig. 3). Consistent with
these findings, Rgs12 ablation enhances KOR-stimulated G protein activation and
sensitivity to U50,488-induced hypolocomotion (Fig. 2). KOR-induced hypolocomotion is
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unaffected by b-arrestin-2 knockout (White et al., 2015), suggesting that reduced
locomotion upon KOR activation is G protein-dependent. RGS12-null mice also exhibit
increased KOR binding sites (a measure of protein expression) (Fig. 2) despite normal
Oprk1-mRNA levels (Fig. S3), suggesting that elevated KOR levels/binding sites are not
due to Oprk1 transcriptional upregulation. Increased KOR-protein levels and/or
sensitivity, and not dynorphin expression levels (Fig. S3), likely underlie the increased
vSTR

DAT-mediated

DA-uptake

and

resultant

reduction

in

AMPH-stimulated

hyperlocomotion seen in RGS12-null mice (Gross et al., 2018), given that these two
effects are reversed by KOR inhibition (Fig. 1).
In light of augmented b-arrestin-recruitment to activated KOR upon RGS12 overexpression (Fig. 3), we speculated that RGS12 loss reduces b-arrestin-dependent
internalization and/or downregulation of KOR -- a hypothesis strongly-supported by our
observation of increased vSTR, but not dSTR, KOR-binding in b-arrestin-2 knockouts
(Fig. 3). In contrast, [3H]DA-uptake is unaffected in b-arrestin-2 knockouts (Fig. S7); as
others have demonstrated that KOR-mediated increases in [3H]DA-uptake are sensitive
to PTX (Kivell et al., 2014), these findings collectively suggest that basal and KORstimulated DA uptake are b-arrestin-independent and G protein-dependent, respectively.
Enhanced KOR-dependent [3H]DA-uptake in the vSTR of RGS12-null-mice (Fig. 1) is
thus likely mediated by increased G-protein-signaling downstream of KOR (Fig. 5). Under
conditions of low accumbal DA tone, RGS12-null mice displayed an exaggerated
response to KOR antagonist-mediated reductions in DA reuptake in the NAc core, but not
dSTR (Figs. 1 & S2), further supporting that RGS12 loss engenders hypersensitivity to
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the effects of KOR on DAT function selectively in the mesolimbic DA system. Augmented
KOR-mediated G protein signaling upon RGS12-loss is further supported by increased
sensitivity of RGS12-null mice to U50,488-induced supraspinal analgesia (Fig. 4),
considered a G protein-dependent outcome of KOR agonism (Schattauer et al., 2017;
White et al., 2015). Conversely, RGS12-null mice display reduced aversion to U50,488
(Fig. 4), a behavioral outcome of KOR activation considered to be reliant on b-arrestin
signaling (Chavkin et al., 2014; Ehrich et al., 2015), consistent with observations that
RGS12 over-expression augments KOR-mediated b-arrestin-recruitment (Fig. 3).
Together, our data demonstrate that (i) RGS12 and KOR functionally interact in the vSTR,
but not dSTR, (ii) RGS12 exerts specificity for KOR over other opioid receptors, (iii)
RGS12 differentially regulates signaling cascades downstream of KOR via independent
mechanisms, and (iv) RGS12 is a critical determinant of KOR-mediated behavioral
outcomes.
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3.6 - Figures
3.6.1 - Ventral striatal dopamine transporter (DAT) dysfunction in RGS12-null mice
is kappa opioid receptor (KOR)-dependent.
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Figure 1. Ventral striatal DAT dysfunction in RGS12-null mice is KOR-dependent. (A)
Uptake of [3H]dopamine (8 nM) and (B) the number of DAT binding sites are increased in
vSTR synaptosomes derived from RGS12-null (Rgs12-/-) mice vs WT (Rgs12+/+) littermate
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controls; this increase is lost upon prior administration to the mice of the KOR-selective
antagonist nor-BNI. Mice were administered vehicle (saline) or nor-BNI (10 mg/kg, ip) 24
hours (A) or over 14 days (B) prior to sacrifice and synaptosome or membrane
preparation, respectively. Non-specific binding was determined in the presence of 10 µM
GBR12935 (a selective DA reuptake inhibitor). Data are the mean ± SEM and tested by
two-way ANOVA with Sidak’s post hoc test (n = 4-8 mice) (*, p < 0.05, **, p < 0.01, ***, p
< 0.001). (C) Suppression of AMPH-induced hyperlocomotion by RGS12-null mice is
reversed upon prior administration of nor-BNI. AMPH (3 mg/kg, ip)-induced changes to
locomotion behavior are shown in RGS12-null mice (open symbols) and WT littermate
controls (closed symbols) following 30 min acclimation to activity chambers. Mice were
treated with either vehicle (saline; circles) or nor-BNI (10 mg/kg delivered ip; triangles) 24
hours prior to the experiment. Data are the mean ± SEM (n = 10-13 mice per group). (C,
inset) Total locomotion (over 80 min) by RGS12-null mice and WT littermate controls
(derived from data in panel C) treated with saline or nor-BNI following injection of AMPH
(3 mg/kg, ip). Data are the mean ± SEM and tested by two-way ANOVA with Sidak’s post
hoc test (n = 10-13 mice per group) (*, p < 0.05). (D) Electrically-stimulated DA release
(peak DA current, nA) is attenuated in the NAc core of RGS12-null mice. (E) Electricallystimulated DA release in the NAc shell. RGS12-null mice exhibit a trend towards altered
nor-BNI-dependent DA release at select stimulation amplitudes (stimulation x genotype x
antagonist treatment interaction). (F) nor-BNI treatment reduces DA reuptake (t1/2) in
RGS12-null, but not wildtype, mice. (G) Baseline and nor-BNI-dependent DA reuptake in
the NAc shell is not altered in RGS12-null mice relative to wildtype mice. All FSCV data
are mean ± SEM (n = 6 - 11 mice per group) and were analyzed by general linear mixed
model ANOVA (*, p < 0.05).
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3.6.2 - RGS12 interacts with KOR and RGS12 loss results in elevated KOR
sensitivity and binding sites in the vSTR.
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Figure 2. RGS12 interacts with KOR and RGS12 loss results in elevated KOR sensitivity
and binding sites in the vSTR. (A) Representative immunoblots indicating that KOR and
RGS12 co-immunoprecipitate in the vSTR of wildtype mice (N = 2 experiments).
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Subpanel (i) indicates loss of RGS12 immunoreactivity within whole lysates of ventral
striatum from Rgs12-null mice. Subpanel (ii) demonstrates that endogenous KOR protein
is co-immunoprecipitated from ventral striatal lysate upon immunoprecipitation of
endogenous RGS12 protein. Subpanels (ii) and (iii) indicate that immunoblots probed
with a mixture of anti-KOR and an anti-KOR blocking peptide yield no KOR
immunoreactivity, confirming antibody specificity. Immunoprecipitation of RGS12 in
RGS12-null vSTR results in greatly reduced signal of KOR immunoreactivity (see
densitometric quantitation below immunoblot of subpanel (ii)), supporting that KOR
immunoreactivity in wildtype IP samples is not due to non-specific pull down. (B)
Co-immunoprecipitation analyses of HEK293T cells transiently transfected with human
opioid receptor (with N-terminal HA-tag) and/or full-length RGS12 vector DNA. Robust
content of RGS12 is seen in the anti-HA antibody immunoprecipitate when RGS12 is coexpressed with KOR, whereas co-expression of the related opioid receptor MOR yields
only non-specific binding signal (i.e., compare first vs last lanes). Parallel immunoblots
containing whole cell lysates resolved by SDS-PAGE demonstrate the presence or
absence of RGS12, KOR, and/or MOR expression in appropriate conditions. (C) Total
locomotion (over 30 min) by RGS12-null mice and wildtype littermate controls following
administration of U50,488. RGS12-null, but not wildtype, mice exhibit a hypolocomotor
effect to 2.5 mg/kg U50,488 relative to vehicle controls. At 5 mg/kg U50,488, RGS12-null
and wildtype controls both display reduced locomotor activity relative to vehicle controls.
Data are the mean ± SEM and tested by two-way ANOVA with Dunnet’s post hoc test (n
= 7-13 mice per group) (ns, p > 0.05; *, p < 0.05, ***, p < 0.001, ****, p < 0.0001). (D)
[35S]GTPgS incorporation into vSTR membranes from RGS12-null mice and wildtype
littermate controls upon activation with KOR agonist U50,488. Data are normalized to
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vehicle (saline) control (expressed as fold change). vSTR membranes from RGS12-null
mice exhibit increased sensitivity to U50,488 relative to wildtype controls. Inset,
[35S]GTPgS binding (at 100 µM U50,488) by dSTR membranes from RGS12-null mice
and wildtype littermate controls. All data are the mean ± SEM and tested by two-way
ANOVA with Sidak’s post hoc test (n = 13-19 mice per group) (*, p < 0.05, *** p < 0.001).
(E) [3H]U69,593 saturation binding analysis of vSTR membranes from RGS12-null
(Rgs12-/-) mice and wildtype (Rgs12+/+) littermate controls. Non-specific binding was
determined in the presence of 10 µM nor-BNI (KOR antagonist). Inset, As derived from
data in panel B and parallel binding data from dSTR membrane samples, Bmax was
quantified and seen to be increased in vSTR (but not dSTR) of RGS12-null mice (RGS12null vSTR Bmax = 62.5 ± 3.9 fmol/mg protein vs wildtype vSTR Bmax = 42.1 ± 3.3 fmol/mg
protein). The KD for [3H]U69,593 did not differ across genotypes (RGS12-null vSTR: 1.8
± 0.4 nM; WT vSTR: 1.8 ± 0.4 nM). Data are the mean ± SEM and tested by two-way
ANOVA with Sidak’s post hoc test (n = 9-12 mice per group) (***, p < 0.001).
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2.6.3 - RGS12 differentially regulates KOR agonist-mediated G protein versus barrestin signaling cascades and exerts considerable selectivity for KOR over other
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Figure 3. RGS12 expression reduces potency of the KOR agonist U50,488, yet
augments agonist-stimulated recruitment of b-arrestin to KOR via independent
mechanisms. (A-C) RGS12 expression reduces potency of the KOR agonist U50,488 to
a greater extent than for the MOR agonist DAMGO or the DOR agonist DADLE.
GloSensor-22F (Promega) luciferase-based measurements of cAMP levels within
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HEK293T cells stimulated with 100 nM isoproterenol and simultaneously treated with
opioid receptor-selective agonists following transient co-expression of (A) KOR cDNA
plus indicated RGS12 expression plasmids, (B) MOR cDNA with or without wildtype (WT)
RGS12, or (C) DOR cDNA with or without WT RGS12. (A, inset) PTX (200 ng/mL)
pretreatment abolished KOR agonist-driven cAMP inhibition, confirming that the assay is
dependent on Gi/o-mediated signaling. Wildtype RGS12 expression reduced U50,488
potency by 20-fold, i.e. 6- to 8-fold more than its effects on DAMGO (3-fold) and DADLE
(2.5-fold) potency. Loss-of-function point mutants of RGS12 curtailed U50,488 potency
reductions from 20-fold down to 3-to-4-fold. Data were normalized to vehicle control
conditions and are expressed as the mean ± SEM from multiple experiments (N = 3).
Concentration-response curves were fit by four-parameter non-linear regression (Prism
7). (D-F) The PDZ domain docking site of KOR (-NKPV-c) is necessary, but not sufficient,
to completely account for the specificity of RGS12 for KOR over MOR in assays of GPCRmediated G protein signaling. (D) Schematic representing creation of KOR expression
cDNA containing mutation to the C-terminus (-NKPV-c to -AAAA-c) and MOR expression
cDNA containing mutation of its wildtype C-terminus (MOR: -APLP-c) to KOR’s wildtype
C-terminus (-NKPV-c). (E) Mutation to the C-terminus of KOR curtailed RGS12-mediated
U50,488 potency reductions from 20-fold (e.g., panel A) to 4-fold. (F) RGS12 reduced
MOR agonist potency by 6-fold following substitution of the MOR C-terminus with the
wildtype KOR C-terminus, relative to a 3-fold potency reduction observed with wildtype
MOR (e.g., panel B). Data are normalized to vehicle control and expressed as mean ±
SEM from N = 3 experiments. Dose-response curves fit by four parameter non-linear
regression (Prism). (G-J) RGS12 expression augments agonist-stimulated recruitment of
b-arrestin to KOR, but not MOR nor DOR, in a G protein-independent manner. Tango

125
assays of b-arrestin recruitment within HTLA cells (Barnea et al., 2008; Allen et al., 2011)
stimulated with indicated agonists following transient co-expression of (G) KOR cDNA
plus indicated RGS12 expression plasmids, (H) KOR cDNA with or without WT RGS12
following pretreatment with PTX or vehicle, (I) MOR cDNA with or without WT RGS12, or
(J) DOR cDNA with or without WT RGS12. Agonist potency (pEC50 values) did not differ
between conditions. U50,488-induced b-arrestin recruitment efficacy was ~3-fold greater
when either WT RGS12, or loss-of-function point mutants of RGS12, was co-expressed
with KOR, whereas WT RGS12 only increased b-arrestin recruitment to MOR by 1.2-fold
and DOR by 1.1-fold. PTX pretreatment did not affect U50,488-induced b-arrestin
recruitment to KOR (panel H) in the presence or absence of WT RGS12. Data were
normalized to vehicle control conditions (fold change) and are expressed as the mean ±
SEM from multiple experiments (N = 3). Curves were analyzed by three-parameter nonlinear regression and panel H was analyzed by two-way ANOVA with Sidak's post hoc
test. (K) [3H]U69,593 saturation binding analysis of vSTR membranes from b-arrestin-2
knockout (barr2KO) mice and wildtype (WT) controls. (L) As derived from data in panel K
and parallel binding data from dSTR membrane samples, Bmax was increased in vSTR
(but not dSTR) of b-arrestin-2 knockout (barr2KO vSTR Bmax = 150.1 ± 17.1 fmol/mg
protein vs wildtype vSTR Bmax = 93.1 ± 14.6 fmol/mg protein; barr2KO dSTR Bmax = 74.5
± 9.8 fmol/mg protein vs wildtype dSTR Bmax = 69.3 ± 7.7 fmol/mg protein). The KD for
[3H]U69,593 did not differ across genotypes (barr2KO vSTR: 7.1 ± 1.8 nM; WT vSTR: 8.4
± 2.9 nM; barr2KO dSTR: 7.8 ± 2.3 nM; WT dSTR: 6.6 ± 1.7 nM;). Data are the mean ±
SEM and panel L was analyzed by two-way ANOVA with Sidak’s post hoc test (n = 12
mice per group) (*, p < 0.05).
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3.6.4 - RGS12-null mice display differential behavioral responses to KOR agonists.
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Figure 4. RGS12-null mice exhibit a heightened sensitivity to the analgesic effect of
U50,488 administration but attenuated conditioned place aversion (CPA) to the aversive
effects of U50,488. U50,488-induced analgesia at a dose of (A) 5 mg/kg, (B) 22.5 mg/kg,
or (C) 30 mg/kg was measured in RGS12-null (Rgs12-/-) mice vs WT (Rgs12+/+) littermate
controls using a hot plate latency test. Data are the mean ± SEM and tested by two-way
repeated-measures (within-subjects design) ANOVA followed by Sidak’s post hoc test (n
= 8-10 mice per group) (ns, not significantly different; *, p < 0.05; **, p < 0.01; ***, p <
0.001; ****, p < 0.0001). (D-E) RGS12-null mice exhibit attenuated conditioned place
aversion (CPA) to the aversive effects of U50,488. 2.5 mg/kg (D) or 5.0 mg/kg (E) of
U50,488 was administered to RGS12-null (Rgs12-/-) mice and WT (Rgs12+/+) littermate
controls to test for conditioned place aversion (a measure of the dysphoric property of
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KOR agonism). Data are the mean ± SEM and tested by two-way repeated-measures
ANOVA (for within-subjects comparisons) and between-subjects ANOVA (for betweensubjects comparisons) each followed by Sidak’s post hoc test (n = 8-15 mice per group;
*, p < 0.05; **, p < 0.01; ****, p < 0.0001).
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3.6.5 - Proposed model of RGS12 action in the differential outputs of KOR-activated
signaling.
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Figure 5. Proposed model of RGS12 action in the differential outputs of KOR-activated
signaling. (A) Agonist-induced activation of KOR dissociates Gi/o-coupled heterotrimers
into free G protein subunits, evokes G protein-dependent signal transduction (thick grey
arrow) and, ultimately, produces analgesia and regulates DAT function. RGS12
expression is seen to reduce KOR-mediated G protein signaling via its central RGS
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domain (by accelerating GTP hydrolysis of Gai/o·GTP) and its C-terminal GoLoco motif
(by binding Gai·GDP). RGS12 also contains an N-terminal PDZ domain that interacts with
MEK2 (Willard et al., 2007) and findings from this study suggest interaction with the
C-terminal PDZ domain docking site of KOR (NKPV-c). RGS12 also contains tandem
Ras-binding domains (RBDs) that interact with activated H-Ras and A-/B-Raf to enable
MAPK/ERK scaffolding properties (Willard et al., 2007). Agonist-stimulated KOR
activation is also known to drive GRK3-dependent b-arrestin-2 recruitment (Bruchas and
Chavkin, 2010), resulting in receptor internalization, b-arrestin-dependent signal
transduction (thick black arrow) and, ultimately, aversive behavior. RGS12 expression is
seen to augment KOR agonist-stimulated b-arrestin recruitment independent of its GAP
and GDI activity, suggesting that RGS12 may modulate GRK3 activity on activated KOR
(KOR*) and/or enhance b-arrestin-2 recruitment and/or function by as yet undetermined
molecular mechanisms (represented by question marks over dashed arrows). (B) Loss
of RGS12 in mice results in concomitant increases in KOR-mediated G protein signaling
and decreases in b-arrestin-2 recruitment, thus resulting in enhanced KOR agoniststimulated analgesia and disrupted DAT function (thicker black arrow), as well as an
attenuation of KOR-stimulated aversion (thinner grey arrow), respectively.
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3.8 - Supplementary Information
3.8.1 - Supplementary Methods
3.8.1a - b-Arrestin-2 deficient animals
Male and female b-arrestin-2 knockout (barr2KO) (JAX Stock 023852) and wildtype
C57BL/6 control mice (JAX Stock 000664) were purchased from The Jackson Laboratory
(Bar Harbor, ME) and housed under identical conditions to RGS12-null and wildtype
littermates.
3.8.1b - Synaptosomal [3H]DA uptake
Synaptosomal [3H]DA uptake was performed as described (Gross et al., 2018) with minor
modifications. Briefly, RGS12-null mice and wildtype littermates were administered
vehicle (0.9% NaCl) or nor-BNI (10 mg/kg, ip) 24 hours prior to dissection. Ventral striata
were then extracted and synaptosomes prepared as described (Gross et al., 2018).
Synaptosomal fractions were incubated with 0.8 µM DA (with [3H]DA content diluted to 8
nM final concentration) in Krebs-Ringer buffer (Gross et al., 2018) for 10 minutes. Nonspecific uptake was determined in the presence of DAT-selective reuptake inhibitor
GBR12935. Uptake reactions were terminated by filtration over Whatman GF/B filters with
ice-cold Krebs-Ringer buffer, washed three times, and measured via liquid scintillation
counting. [3H]DA uptake analyses in tissue samples from barr2KO and wildtype control
mice were performed identically to RGS12-null and wildtype littermates, except that these
mice did not receive vehicle or nor-BNI pretreatment before testing.

3.8.1c - Locomotor activity
AMPH-induced locomotor activity was measured as described (Gross et al., 2018) with
the following modifications: RGS12-null mice and wildtype littermates received vehicle
(0.9% NaCl) or nor-BNI (10 mg/kg, ip) 24 hours prior to quantification of AMPH-induced
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hyperlocomotion. For U50,488-induced locomotion, RGS12-null mice and wildtype
littermates were administered vehicle (0.9% saline, ip) or U50,488 (2.5 or 5 mg/kg, ip),
immediately placed into open-field chambers (San Diego Instruments), and X,Y
coordinate beam breaks measured in five-min bins for 30 minutes.

3.8.1d - Fast-scan cyclic voltammetry (FSCV)
RGS12-null and wildtype littermates were injected with 10 mg/kg nor-BNI or saline (i.p.).
24 hours later, brain slices were prepared and FSCV performed as described (Schmidt
et al., 2018). Briefly, mice under deep anesthesia were decapitated, and brain tissue was
submerged in oxygenated ice-cold sucrose. 300 µm slices were cut with a Leica VT1000
vibratome and placed in oxygenated artificial cerebral spinal fluid (aCSF) (Schmidt et al.,
2018) for at least 30 min prior to electrochemical testing. Striatal slices were transferred
to an electrochemistry rig and perfused at 2 mL/min with oxygenated aCSF. Slices were
stimulated at 100, 200, and 300 µA with a bipolar nichrome electrode (single pulse, 4 ms
duration). DA signals were recorded with an in house fabricated 100 μm x 7 μm carbon
fiber microelectrode placed ~ 100 um from the stimulating electrode (Kile et al., 2012); a
custom built potentiostat (University of Washington, Seattle) and TarHeel CV written in
LabVIEW (National Instruments) were used to apply a triangle waveform (-0.4 to 1.3 V)
cycling at 10 Hz. Cyclic voltammograms (CVs) were analyzed with HDCV (UNC Chapel
Hill) to create IvT (current vs time) plots that were analyzed with Clampfit 10.6 software
(Molecular Devices, Sunnyvale, CA).

3.8.1e - Radioligand binding assays
[3H]WIN35428 binding to DAT
Evaluation of DAT binding sites was performed as described (Gross et al., 2018), with
minor modifications. As KOR-mediated changes to DAT levels requires prolonged drug
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treatment (Thompson et al., 2000), mice were treated with vehicle or the long-lasting,
irreversible KOR antagonist nor-BNI (10 mg/kg, saline, ip) for 14 days (Patkar et al., 2013)
before DAT binding was assessed. Mice received two injections of nor-BNI, first on day
0 and then on day 7. On day 14, mice were sacrificed, vSTR microdissected, and extracts
frozen on dry ice. Crude membrane fractions were prepared and incubated with
[3H]WIN35428 (52.5 nM) in the presence or absence of 10 µM GBR12935 to determine
DAT-specific binding; as we previously found that RGS12-null mice do not exhibit
complete DAT saturation in assays of vSTR DAT binding (Gross et al., 2018), therefore,
the relative number of DAT binding sites was determined using a single, high
concentration of [3H]WIN35428 (52.5 nM), as previously described (Gross et al., 2018).
Binding reactions proceeded for 1 hour at RT and then terminated by rapid filtration over
PEI (0.5%)-soaked Whatman GF/B filters with ice-cold Tris buffer. Protein contentadjusted data (in fmol/mg protein) were normalized to the wildtype vehicle condition and
expressed as fold change to control for variability in the efficacy of [3H]WIN35428 binding
to DAT across experiments. Data are displayed as mean ± SEM across multiple
experiments and statistical analyses performed with two-way ANOVA followed by Sidak's
post-hoc test (n = 6 mice per group).
[3H]U69,593 binding to KOR and [35S]GTPgS incorporation upon KOR activation
KOR saturation binding and GTPgS incorporation assays were performed as described
(Zhou et al., 2015) with modifications. Ventral and dorsal striatal brain regions were
dissected, immediately frozen on dry ice, homogenized with a polytron homogenizer in
10 volumes of buffer (10 mM Tris-HCl pH 7.4, 100 mM NaCl, 5 mM MgCl2, 1 mM DTT),
and passed through a 27-gauge needle eight times. Homogenates were centrifuged twice
at 20,000 x g for 30 min; pellets were resuspended in KOR assay buffer: either 50 mM
Tris-HCl pH 7.4 for [3H]U69,593 binding, or 50 mM Tris-HCl pH 7.4, 100 mM NaCl, 5 mM
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MgCl2, 1 mM EDTA, 20 μM GDP, 1 mM DTT for GTPgS incorporation. For saturation
binding, resuspensions were added to [3H]U69,593 (from 0.63 - 20 nM) and incubated for
2 hr at room temperature. Nonspecific binding was determined in the presence of 10 µM
nor-BNI. For GTPgS incorporation, resuspensions were added to [35S]GTPgS (0.1 nM)
and several independent concentrations of the KOR agonist U50,488 (0.0001, 0.01, 1,
and 100 µM; dissolved in saline). Binding was terminated by filtration over Whatman GF/B
filters with ice-cold deionized water (washed three times) and measured via liquid
scintillation counting after overnight drying.

3.8.1f - Co-immunoprecipitations
Co-immunoprecipitation (co-IP) analyses in brain tissue were performed with the
Pierce co-IP Kit (Waltham, MA) according to manufacturer’s instructions with minor
modifications. Briefly, anti-RGS12 (UNC60-26.2.1; DSHB, Iowa City, IA) was immobilized
on the kit’s AminoLink Plus-coupled resin. Ventral striata were dissected, immediately
frozen on dry ice, and then homogenized with a polytron homogenizer in co-IP lysis buffer
(Pierce), followed by addition of CHAPS detergent (1% final concentration).
Homogenates were incubated for 1 hr at 4°C (with rotation) to facilitate KOR solubilization
(Xia et al., 2003). Solubilized lysates were precleared with quenched resin and then
added to the anti-KOR-immobilized resin for overnight incubation (4°C with rotation).
Immunoprecipitates were washed, eluted, and denatured with Laemmli buffer containing
100 mM DTT (Pierce) for 30 minutes at 37°C. IP and whole lysate (input) samples were
then subjected to SDS-PAGE, transferred to nitrocellulose, and incubated overnight at
4°C with anti-KOR (#AOR-012; Alomone Labs, Jerusalem, Israel), a control mixture of
anti-KOR plus blocking peptide (AOR-012 immunizing peptide/control antigen; Alomone),
or anti-RGS12. Immunoblots were then washed, incubated with the appropriate HRP-
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conjugated secondary antibodies for 1 hr at RT, and visualized with enhanced
chemiluminescence.
Co-IP analyses in HEK293T cells were performed with the Pierce HA-Tag IP/CoIP Kit according to manufacturer’s instructions with minor modifications. Briefly, HEK293T
cells were transiently transfected (via CaPO4 (Jordan et al., 1996)) with wildtype human
RGS12 (hRGS12-WT) alone or co-transfected with hRGS12-WT and 3XHA-hKOR or
3XHA-hMOR HA-tagged human opioid receptors (www.cdna.org). Forty-eight hours later,
transfected cells were lysed with co-IP lysis buffer (Pierce), CHAPS added (1% final
concentration), and lysates solubilized for 1 hr (4°C with rotation). Solubilized lysates
were then added to pre-coupled anti-HA agarose spin columns and incubated overnight
(4°C with rotation) to immunoprecipitate 3XHA-KOR or 3XHA-MOR proteins.
Immunoprecipitates were washed, eluted, and denatured in 2X Sample Buffer with 100
mM DTT (Pierce). IP and whole lysate (input) samples were then subjected to SDSPAGE, transferred to nitrocellulose, and incubated overnight at 4°C with anti-RGS12 (sc398545, Santa Cruz, Dallas, TX) or anti-HA (Cat. 3725, Cell Signaling Technology,
Danvers, MA). Immunoblots were then washed, incubated with the appropriate HRPconjugated secondary antibodies for 1 hr at RT, and visualized with enhanced
chemiluminescence.

3.8.1g - cAMP inhibition
HEK293T cells were transfected via CaPO4 (Jordan et al., 1996) with vectors expressing
GloSensor-22F cAMP biosensor (Promega) and HA-tagged human opioid receptor
(3XHA-hKOR, 3XHA-hMOR, or 3XHA-hDOR; www.cdna.org), with or without wildtype
human RGS12, RGS domain loss-of-function RGS12 (Rgs12E740K), or GoLoco motif lossof-function RGS12 (Rgs12R1206F). Twenty-four hours later, transfected cells were seeded
onto white, clear bottom, 96-well plates (8 x 106 cells/plate). Next morning, cells were
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incubated with D-luciferin in buffer (20 mM HEPES, 140 mM NaCl, 5 mM KCl 250 µM
NaPO4, 0.1 mM glucose, 0.5 mM KH2PO4, 1.3 mM CaCl2, 1 mM MgSO4, 5 mM NaHCO3,
pH 7.4) for 2 hours at room temperature. Cells were then treated with various agonist
concentrations (U50,488 for KOR, DAMGO for MOR, and DADLE for DOR) for 15 minutes
at RT. Then, cells were treated with isoproterenol for 15 minutes to stimulate Gs signaling
and adenylyl cyclase activation. Luminescence was measured with a FlexStation3 platereader (Molecular Devices). In pertussis toxin (PTX) pre-treatment assays, to uncouple
Gi/o-coupled GPCRs via Ga ADP-ribosylation (Katada and Ui, 1982; Moss and Vaughan,
1988), cells were pretreated with 200 ng/mL PTX (or vehicle) for 24 hours (Pack et al.,
2018) prior to luminescence measurement.

3.8.1h - b-arrestin recruitment
Agonist-induced b-arrestin recruitment was determined using ‘Tango’ assay (Barnea et
al., 2008; Allen et al., 2011). HTLA cells, stably expressing b-arrestin-TEV protease fusion
and tetracycline transactivator-driven luciferase reporter (Barnea et al., 2008), were
transiently transfected via CaPO4 (Jordan et al., 1996) with opioid receptor-Tango vectors
(FLAG-KOR-Tango, FLAG-MOR-Tango, or FLAG-DOR-Tango; contributed to Addgene
by Dr. Bryan Roth) with or without WT hRGS12, Rgs12E740K, or Rgs12R1206F vectors.
Twenty-four hours later, transfected cells were seeded onto white, clear bottom, 384 well
plates (8 x 106 cells/plate). Next morning, cells were serum starved for 6 hours, then
stimulated with various agonist concentrations (U50,488 for KOR, DAMGO for MOR, or
DADLE for DOR). The following morning, cells were lysed with BrightGlo (Promega) and
luminescence measured with a FlexStation3. In Tango assays performed with PTX, cells
were pretreated with 200 ng/mL PTX or vehicle 24 hours prior to lysis and luminescence
measurement.
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3.8.1i - In silico single cell RNAseq analysis
The DropViz single cell RNAseq database (Saunders et al., 2018) was analyzed to
determine the mouse brain neuronal cell populations that co-express Rgs12 and Oprk1
mRNA. Data displayed are the output (Table) derived from a query with Rgs12 and Oprk1
(Gene) and Neuron (Limit by Class) set as query parameters. Results were sorted by the
neuronal single cell populations expressing the highest levels of Oprk1 (Oprk1 Amount)
and constrained to corticostriatal circuitry (frontal cortex, striatum, substantia nigra,
globus pallidus, and thalamus) given the relevance of these regions to the behavioral
effects of KOR agonism (Tejeda et al., 2017; Trifilieff and Martinez, 2013; Tejeda et al.,
2013).

3.8.1j - In situ hybridization
In situ hybridization on mouse brain slices was performed as previously described (Gross
et al., 2018); dual-label detection of Rgs12 and Oprk1 expression in the claustrum was
performed by the RNA In Situ Hybridization Core at Baylor College of Medicine, which is,
in part, supported by a Shared Instrumentation grant from the NIH (1S10OD016167).

3.8.1k - Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
Ventral striatum (vSTR) and midbrain were rapidly dissected, immediately frozen on dry
ice, and then homogenized on ice in TRIzole reagent (InvitrogenTM). RNA was extracted
according to manufacturer’s instructions (Direct-zol RNA MiniPrep, Zymo); genomic DNA
was eliminated with the QuantiTech Reverse Transcription Kit (Qiagen). RNA quantity
was assessed by QIAexpert bioanalyzer (Qiagen) and cDNA synthesized with
QuantiTech Reverse Transcription (Qiagen). Published primers (Du et al., 2016) for
Oprk1/KOR

(F:

5'-TCCCCAACTGGGCAGAATC-3',

R:

5'-

GACAGCGGTGATGATAACAGG-3') and Pdyn (F: 5'- CAGTGAGGATTCAGGATGGG3', R: 5'-CGTCAGGGTGAGAAAAGATGA-3') were obtained from Invitrogen. Data were
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normalized to averaged Ct values from three housekeeping genes: b-Actin (F: 5'GGCTGTATTCCCCTCCATCG-3', R: 5'-CCAGTTGGTAACAATGCCATGTT-3'), 18S
rRNA

(Qiagen),

and

b-Tubulin

(F:

5'-GGGAGGTGATAAGCGATGA-3',

R:

5'-

CCCAGGTTCTAGATCCACCA). Two µL of cDNA template was used in each qRT-PCR
reaction with SYBR Green PCR Master Mix (Qiagen). qRT-PCR was performed with a
Qiagen Rotor Gene-Q; melt curves were analyzed after each run to ensure primer
specificity.

3.8.1l - Hot plate analgesia test
To detect sensitivity to painful stimuli, the hot plate test of nociception was performed as
previously described (Bohn et al., 1999) with slight modifications. Mice were placed on a
hot plate (53 oC) and prevented from escape by a tall plastic cylinder. Latency to lick a
hindlimb, flinch/flick, jump, or other first sign of nociception was recorded. On day 1,
RGS12-null mice and wildtype littermates were administered saline (0.9% NaCl) 30
minutes prior to the test and nociceptive latency recorded. On day 2, all mice were
administered U50,488 (5, 22.5, or 30 mg/kg, ip) 30 minutes prior to the test and
nociceptive latency was recorded.

3.8.1m - Hot plate analgesia with KOR antagonist treatment
Hot plate analgesia assays with nor-BNI-treated mice were performed identically to all
other hot plate analgesia assays (Fig. 4A-C) except that mice were administered nor-BNI
(10 mg/kg, ip, dissolved in 0.9% NaCl) following their baseline measurement; thus, mice
underwent a 24 hour pretreatment of nor-BNI prior to the administration of 30 mg/kg
U50,488 (ip) and subsequent hot plate latency testing.

3.8.1n - Conditioned place aversion (CPA)
CPA was performed as described (Schindler et al., 2012) with modifications denoted
below. Mice were free to acclimate to a two-chambered place preference apparatus (Med
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Associates) on day 1 for 30 min; time spent in each compartment was recorded to
determine the most-preferred chamber (preconditioning). In the morning of days 2 and 3,
all RGS12-null mice and wildtype littermates were administered saline (0.9% NaCl) and
confined to their least-preferred chamber. In the afternoon of days 2 and 3, all mice
received U50,488 (2.5 or 5.0 mg/kg, ip) and were confined to their most-preferred
chamber for 30 min. On day 4 (postconditioning), CPA was determined by allowing mice
to freely explore. Pre- and post (U50,488)-conditioning were computed by subtracting the
time spent (seconds) in the most-preferred chamber (drug-paired during conditioning)
minus the least-preferred chamber (saline-paired during conditioning).
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3.8.2 - Supplementary Figures
3.8.2a - Rgs12 and Oprk1 (KOR) mRNAs show similar expression patterns in
mouse brain.
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Figure S1. Rgs12 and Oprk1 (KOR) mRNAs show similar expression patterns in mouse
brain. Coronal in situ hybridization (ISH) from the Allen Brain Atlas highlighting coincident
Oprk1 (A) and Rgs12 (B) mRNA expression in hippocampus (HPC), and the ventral
tegmental area (VTA) and substantia nigra pars compacta (SNc), with the latter two
regions being beds of mesolimbic and nigrostriatal dopaminergic soma, respectively.
(C) In silico analysis of a single cell RNAseq dataset (DropViz) shows co-expression of
Rgs12 with Oprk1 (KOR) in neuronal cell populations across several brain regions.
Data are sorted and displayed by the neuronal cell populations expressing the highest
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levels of Oprk1 (Oprk1 amount). Rgs12 exhibits co-expression with Oprk1 in many of
the top Oprk1-expressing neurons, particularly within brain regions composing the
corticostriatal circuit (e.g., frontal cortex, striatum, substantia nigra, globus pallidus,
thalamus). The highest expressing neuronal cell type for both Rgs12 and Oprk1 are
Nr4a2+ cells within the claustrum (a subregion of the frontal cortex), as observed in duallabel ISH below. (D-F) Epifluorescence images of dual-label ISH of a coronal brain slice
of a wildtype mouse with antisense RNA probes directed to Oprk1 mRNA (panel D, green)
and Rgs12 mRNA (panel E, red); overlay of both signals is presented in yellow in panel
F (CLA, claustrum; CTX, cortex; ec, external capsule; STR, striatum). Parallel dual-label
ISH of a brain slice from an RGS12-null (Rgs12-/-) mouse resulted in no signal in the red
channel (data not shown).
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3.8.2b - Baseline and KOR-dependent DA release and DA reuptake are normal in
the dSTR of RGS12-null mice.
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Figure S2. Baseline and KOR-dependent DA release and DA reuptake are normal in the
dSTR of RGS12-null mice. (A) Electrically-stimulated DA release (peak DA current, nA)
and (B) DA reuptake (t1/2) in the dSTR of brain slices from RGS12-null and wildtype mice
pretreated with vehicle (saline) or nor-BNI (10 mg/kg, ip) 24 hours prior to FSCV
measurements. Analyses reveal an effect of stimulation amplitude on DA release (p <
0.0001); however, no genotype, treatment, or interaction effects were observed in
measures of DA release or DA reuptake (p > 0.05). All FSCV data are mean ± SEM (n =
6 - 11 mice per group) and were analyzed by general linear mixed model ANOVA (ns, not
significantly different).
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3.8.2c - Oprk1 (KOR) and prodynorphin (Pdyn) mRNA levels are unchanged in the
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Figure S3. Oprk1 and prodynorphin mRNA levels are unchanged in the vSTR and
midbrain of RGS12-null mice. (A) Measurement of Oprk1 (KOR) mRNA levels in ventral
striatum (vSTR) and midbrain by qRT-PCR. RGS12-null and wildtype mice exhibited
similar Oprk1 mRNA levels in both regions (omnibus: genotype, F(1,20) = 0.2, p = 0.624;
region, F(1,20) = 0.4, p = 0.567; interaction, F (1,20) = 0.4, p = 0.536) (multiple
comparisons: Oprk1-vSTR: RGS12-null vs wildtype: p = 0.994, Oprk1-midbrain: RGS12null vs wildtype: p = 0.680). (B) Measurement of dynorphin precursor prodynorphin (Pdyn)
mRNA levels in vSTR and midbrain by qRT-PCR. Analysis revealed that prodynorphin
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mRNA levels in vSTR and midbrain were comparable between RGS12-null mice and
wildtype littermates (omnibus: genotype, F(1,19) = 0.02, p = 0.885; region, F(1,19) = 1.4,
p = 0.255; interaction, F (1,19) = 0.9, p = 0.351) (multiple comparisons: Pdyn-vSTR:
RGS12-null vs wildtype: p = 0.809, Pdyn-midbrain: RGS12-null vs wildtype: p = 0.703).
All data are the mean ± SEM and tested by two-way ANOVA with Sidak’s post hoc test (n
= 6 mice per group).
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3.8.2d - The selective effect of RGS12 on KOR-mediated G protein signaling is
preserved in rodent RGS12 variants.
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Figure S4. The selective effect of RGS12 on KOR-mediated G protein signaling is
preserved in rodent RGS12 variants. Glo-Sensor luciferase-based measurements of
cAMP levels in HEK293T cells stimulated with 100 nM isoproterenol and simultaneously
inhibited with indicated receptor-selective agonists following transient co-expression
(A) 3XHA-hKOR or (B) 3XHA-hMOR cDNA plus empty vector, untagged wildtype mouse
RGS12 (mRGS12), or myc-tagged wildtype rat RGS12 (rRGS12) expression plasmids.
Co-expression of mRGS12 or rRGS12 each reduced KOR agonist potency by ~30-fold
(Fig. S4A) (mRGS12: F(1, 56) = 14.1, p = 0.0004; KOR + mRGS12 pIC50 = 8.1 ± 0.2 vs
KOR only pIC50 = 9.6 ± 0.1) (rRGS12: F(1, 56) = 12.0, p = 0.001; KOR + rRGS12 pIC50 =
8.1 ± 0.2 vs KOR only pIC50 = 9.6 ± 0.1). In contrast, mRGS12 and rRGS12 each
attenuated MOR agonist potency by only ~6-fold (Fig. S4B) (mRGS12: F(1, 56) = 10.7, p
= 0.001; MOR + mRGS12 pIC50 = 7.1 ± 0.1 vs MOR only pIC50 = 7.9 ± 0.1) (rRGS12: F(1,
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56) = 7.5, p = 0.008; MOR + rRGS12WT pIC50 = 7.1 ± 0.2 vs MOR only pIC50 = 7.9 ± 0.1).
Data were normalized to vehicle control conditions and are expressed as the mean ±
SEM from multiple experiments. Concentration-response curves were fit by fourparameter non-linear regression (Prism 7).
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3.8.2e - The analgesic effect of 30 mg/kg U50,488 is lost, in both RGS12-null mice
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Figure S5. The analgesic effect of 30 mg/kg U50,488 is lost, in both RGS12-null mice
and wildtype littermate controls, following pretreatment with nor-BNI. U50,488 (30 mg/kg)induced supraspinal analgesia is KOR-dependent. Omnibus ANOVA analysis revealed
no effects of genotype, drug treatment (U50,488 + nor-BNI), or genotype x drug treatment
(p > 0.05). Data are the mean ± SEM (n = 8-10 mice per group) and tested by two-way
ANOVA.
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3.8.2f - Responses to morphine at doses of either 5 mg/kg (A) or 10 mg/kg (B) are
similar in RGS12-null mice and wildtype littermate controls.
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Figure S6. Responses to morphine at doses of either 5 mg/kg (A) or 10 mg/kg (B) are
similar in RGS12-null mice and wildtype littermate controls. (A) Omnibus ANOVA analysis
revealed no effects of genotype, morphine treatment, or genotype x drug treatment (p >
0.05). (B) Omnibus ANOVA analysis revealed only an effect of morphine treatment
(F(1,27) = 29.1, p < 0.001); multiple comparisons: RGS12-null saline vs 10 mg/kg
morphine: p = 0.0005; wildtype saline vs 10 mg/kg morphine: p = 0.004. Data are the
mean ± SEM (n = 7-14 mice per group) and tested by two-way ANOVA followed by Sidak’s
post hoc test (**, p < 0.01; ***, p < 0.001).
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3.8.2g - b-arrestin-2 is not required for [3H]DA uptake in the vSTR and dSTR.
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Figure S7. b-arrestin-2 is not required for [3H]DA uptake in the vSTR and dSTR. Uptake
of [3H]DA (8 nM) in synaptosomes prepared from vSTR and dSTR brain tissue from
barr2KO and wildtype mice. Non-specific binding was determined in the presence of 10
µM GBR12935. Data shown are the mean ± SEM (n = 4 mice per group) from a
representative experiment and tested by two-way ANOVA (p > 0.05). [3H]DA uptake in the
vSTR and dSTR of barr2KO and wildtype mice was performed twice (n = 8 mice per group
over 2 independent experiments).
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CHAPTER FOUR
Conclusions and Future Directions
4.1 - General Conclusions
The principal findings from this work support RGS12 as an important regulator of DAergic
and KOR-dependent signal transduction, neurotransmission, and behavior in mice. Moreover,
these studies identify a region-specific role for RGS12, particularly within the vSTR. Specifically,
this work highlights an integral role for RGS12 in constitutive and psychostimulant-dependent
DAT expression and function. We demonstrate that RGS12 mediates its effects on DAT
expression/function via a functional interaction with KOR. Further elucidation of this novel
functional interaction between RGS12 and KOR revealed that RGS12 is a key determinant of
proper KOR signaling (in vitro and in vivo) and behavior. Notably, our finding that RGS12
differentially modulates G protein versus barr signaling downstream of KOR is a relatively novel
concept for the GPCR signaling field. Namely, we reveal that interaction of a GPCR with an
intracellular signaling protein, rather than a pharmacological agent (e.g., a biased agonist) per se,
affects GPCR functional selectivity.
There are some limitations and unanswered questions remaining after this work,
particularly with respect to the physical and functional interaction(s) between RGS12 and KOR.
The Future Directions and Experimental Approaches section below is thus intended to provide a
roadmap for navigating at least some of the residual questions following the conclusion of my
dissertation work. Given that the functional interaction between RGS12 and KOR appears to
underlie the preponderance of biochemical and behavioral effects that I have identified in RGS12null mice, the experimental pursuits proposed below will be focused predominantly on further
elucidating the intricate biological relationship between these proteins.
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4.2 - Future Directions and Experimental Approaches
4.2.1 - Question 1: Does RGS12 affect KOR signaling and behaviors solely in KORexpressing neurons?
Rationale: mRNA and protein expression data (Gross et al., 2018) suggest that Rgs12 mRNA is
synthesized in DAergic projection neurons of the ventral tegmental area (VTA) and substantia
nigra pars compacta (SNc), and the protein trafficked to presynaptic terminals of the striatum.
Similar mRNA and protein distribution is observed with KOR: KOR-encoding Oprk1 mRNA is
enriched within DAergic VTA projections, and KOR is enriched on presynaptic terminals of the
NAc within the vSTR (Crowley and Kash, 2015; Britt and McGehee, 2008; Bruijnzeel, 2009).
These correlations suggest that RGS12 may be co-expressed with KOR in dopaminergic striatal
neurons, and RGS12 loss in these specific neurons engenders the observed disruptions of KOR
expression and function, and DA homeostasis, seen in global RGS12 knockout (RGS12-null)
mice.
Approach: We recently established (Gross et al., 2018) that CMV::Cre-driven Rgs12 excision
(Rgs12Δ5-6/Δ5-6) throughout the organism recapitulates the augmented DAT-mediated DA reuptake
and reduced hyperlocomotion to psychostimulants as observed in our global Rgs12Δ5-8/Δ5-8 strain.
Given this specific validation of our conditional RGS12 knockout (floxed) strain (Rgs12Δ5-6/Δ5-6)
(Gross et al., 2018), we are now positioned to cross it with strains expressing Cre downstream of
neuron subtype-specific promoters to identify those RGS12-expressing cell populations
necessary and sufficient to engender the KOR signaling dysfunction observed in constitutive
RGS12-null mice. We will first cross our Rgs12fl/fl mice with KOR::Cre C57BL/6 mice (which we
have obtained from Dr. Sarah Ross; (Cai et al., 2016; Snyder et al., 2018)) and initially assess for
Oprk1 promoter-driven Cre-mediated elimination of RGS12 expression in established KOR- and
RGS12-expressing brain regions (e.g., vSTR, dSTR, prefrontal cortex, midbrain, hippocampus)
by immunoblotting, as previously performed (Gross et al., 2018). We will quantify RGS12 levels
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within microdissected brain regions from Oprk1Cre/+;Rgs12fl/fl mice (tissue-restricted knockouts) as
compared with Oprk1Cre/+; Rgs12+/+ (wildtype control) mice. For example, if RGS12 is expressed
in non-KOR-expressing vSTR neurons in addition to KOR-expressing vSTR neurons, we are still
likely to observe significant (albeit incomplete) reductions in RGS12 levels relative to wildtype
controls, given the predominant expression of Oprk1 in this region, especially in the NAc (Mansour
et al., 1987; Svingos et al., 2001). Rgs12 loss from Cre-expressing tissue should also be assessed
using dual-label fluorescence in situ hybridization and validated Rgs12 riboprobes, as previously
performed (Fig. 3.8.2a).
Once significant reduction or loss of RGS12 is verified, we would need to perform many, if not
all, of the biochemical assays of KOR expression and function (e.g., KOR saturation binding with
[3H]U69,593, [35S]GTPgS binding, etc.) and DAergic neurotransmission (e.g., DAT saturation
binding with [3H]WIN35,438; [3H]DA uptake). We would also likely require the use of the tissuerestricted knockout strain in all behavioral assays previously performed with global RGS12-null
mice (e.g., hot plate analgesia and CPA elicited by multiple KOR agonists [Fig. 3.6.4]). If the
alterations to KOR signaling seen in global RGS12-null mice are due to loss of RGS12 function
within KOR-expressing neurons, we would expect that Oprk1Cre/+;Rgs12fl/fl mice should
recapitulate many, if not all, of the biochemical and behavioral phenotypes observed upon global
RGS12 loss.

4.2.2 - Question 2: Does RGS12 loss during neurodevelopment contribute to
the observed biochemical and behavioral disruptions in adult RGS12-null mice?
Rationale: If the biochemical and behavioral phenotypes observed in Oprk1Cre/+;Rgs12fl/fl mice do
not resemble those of global RGS12-null mice (or if only some phenotypes are recapitulated), we
would next need to probe whether alterations in KOR signaling and KOR activation-dependent
behaviors result from neurodevelopmental disruptions caused by RGS12 loss -- disruptions that
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may perturb the dynorphin/KOR system. This notion is supported by prior findings from the
Siderovski group that primary DRG neurons lacking RGS12 exhibit attenuated NGF-induced
axonogenesis (Willard et al., 2007), from the Tsien group that RGS12 levels are altered during
synaptogenesis by sensory deprivation (Butko et al., 2013), and from the Siderovski group that
Rgs12 is strongly expressed throughout CNS regions integral to early embryonic
neurodevelopment (Martin-McCaffrey et al., 2005).
Approach: To evaluate this hypothesis, we would cross Rgs12fl/fl mice with tamoxifen-inducible,
CAGG::Cre mice to induce Rgs12 excision conditionally in the adult mouse, obviating the
confound that pre- and/or post-natal neurodevelopmental adaptations and/or compensations may
occur across the lifespan in the absence of RGS12 within the global RGS12-null strains. In
another project within our laboratory, we demonstrated successful tamoxifen-induced, Cremediated homologous recombination at the adult stage of a different floxed Rgs allele, namely
that encoding RGS21, which is expressed in lingual chemosensory tissue (Schroer et al., 2018).
Thus, we are confident that we can successfully evaluate whether RGS12 loss produces KOR
dysfunction and altered DA homeostasis via a neurodevelopmental mechanism by crossing
tamoxifen-inducible Cre mice with our Rgs12fl/fl mice (i.e., inducing Cre-mediated Rgs12 excision
in adulthood). As an independent alternative approach (i.e., independent of either Oprk1Cre/+ or
tamoxifen-inducible driver lines), we could breed our Rgs12fl/fl mice with the DAT-iCre driver strain
(Turiault et al., 2007; Rocchetti et al., 2015), thereby restricting RGS12 loss to DAT-expressing
dopaminergic neurons.
Alternative IHC-based approach in parallel: Along with cross-breeding Rgs12fl/fl mice to tissueand temporally-restricted Cre drivers and phenotyping the resultant desired progeny, we could
quantify downstream signaling events in situ, beginning with the global RGS12-null mice, to help
establish the region-specific nature of RGS12 function(s) on KOR signaling in the brain. KOR
activation reportedly leads to phosphorylation of select kinases in the striatum, cortex,
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hippocampus, and amygdala (Robles et al., 2014; Bruchas et al., 2007a; Heinsbroek et al., 2018).
KOR-mediated pERK induction is preserved in GRK3-null mice (Bruchas et al., 2007a) and thus
likely a barr-independent, G protein-dependent output. Conversely, p38 MAPK phosphorylation
following KOR activation is lost in GRK3-null mice (Bruchas et al., 2007a); thus, p-p38 MAPK
induction is considered GRK3-/barr-dependent and G protein-independent (Bruchas et al., 2006).
Thus, we will perform IHC to test whether RGS12-deficient mice exhibit altered pERK and p-p38
induction upon KOR activation (and if this occurs in a region-specific manner). pERK and p-p38
content can be measured in brain slices of RGS12-deficient mice and matched wildtype
littermates treated systemically with unbiased/full KOR agonists (e.g., U50,488 in saline, ip) using
established IHC techniques (Gross et al., 2018) and validated anti-pERK / ERK and anti-p-p38 /
p38 MAPK antibodies (CST). pERK- and p-p38-positive cells will be counted and normalized to
ERK- and p38-positive cells (and expressed as fold induction) across multiple regions (e.g., vSTR
[in particular, NAc core & shell], dSTR, amygdala, hippocampus, prefrontal cortex,
claustrum/deep cortical layers) to determine if RGS12 loss (by global or tissue-restricted
knockout) perturbs outcomes of KOR-mediated G protein-dependent and -independent signaling.
If no IHC differences are seen in pERK and p-p38 levels between RGS12-deficient and wildtype
mice upon a single, high dose of KOR agonist, such a result may not preclude the possibility that
RGS12 loss produces a potency shift in KOR sensitivity upstream of ERK and p38
phosphorylation (i.e., any differences between genotypes may be masked by high drug dose); we
would then perform dose-response trials (e.g., U50,488 at 5, 10, 15, 20, 30 mg/kg). Moreover, in
vitro studies of KOR-stimulated ERK and p38 activation (Schattauer et al., 2017; Schattauer et
al., 2012) have shown that maximal kinase phosphorylation is achieved in a temporally distinct
fashion. Thus, we would begin by testing RGS12-deficient and wildtype mice at both 5 and 30
minutes to capture the predicted maximal activation of pERK and p-p38, respectively (Schattauer
et al., 2017; Schattauer et al., 2012); we will establish time-course data for phosphorylation of
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both kinases if required. We would also likely benefit by evaluating a 2-hour timepoint in later
analyses of KOR-stimulated pERK induction to assess whether RGS12 loss affects the late phase
(McLennan et al., 2008) of barr-dependent ERK phosphorylation following KOR activation.
KOR activation is reported to induce amygdala-related anxiogenesis (Crowley and Kash,
2015; Bruchas et al., 2009; Knoll et al., 2011), frontal cortex- and hippocampal-dependent
learning deficits (Carey et al., 2009; Paris et al., 2011), depression-like and stress-related
behaviors involving mesolimbic structures (VTA, NAc (Bruchas et al., 2008; Chartoff et al., 2009;
Berube et al., 2013)), and psychotomimesis and sensory gating deficits that may be related to
KOR action in the claustrum and/or deep layers of the cerebral cortex (Ruderman et al., 2009;
Stiefel et al., 2014; Patru and Reser, 2015). Given that RGS12 is expressed along with KOR in
virtually all of these brain regions (Gross et al., 2018) (Allen Brain Atlas), these planned IHC
studies for identifying particular CNS regions of RGS12 action should surely aid in selecting future
behavioral experiments to better understand the extent to which RGS12 modulates behavioral
outcomes of KOR signaling.

4.2.3 – Question 3: Does RGS12 play a role in KOR-mediated signaling and behavior
involving the spinal cord?
Rationale: Our findings show that global RGS12-null mice have increased sensitivity to the
analgesia elicited by KOR agonism in the hot plate assay (Fig. 3.6.4), a test of supraspinal
analgesia (Hull et al., 1994; Sora et al., 1997). RGS12 may also regulate KOR-mediated spinal
antinociception via similar mechanisms, especially with evidence that both RGS12 and KOR are
expressed in spinal neurons that mediate nociception ((Willard et al., 2007; Cai et al., 2016;
Hylden et al., 1991), and see also GENSAT strain Tg(Rgs12-EGFP)HW332Gsat/Mmucd). For
example, RGS12 is highly expressed in dorsal root ganglion (DRG) neurons, and the Siderovski
group has previously shown that RGS12 is a key regulator of NGF-stimulated axonogenesis in
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these neurons (Willard et al., 2007; Lewin and Mendell, 1993; Lewin et al., 2014). DRGs located
adjacent to the spinal cord, as well as the dorsal horns, represent key nociceptive loci (Todd,
2010). Notably, KOR is also highly expressed in DRG neurons and contributes to growth factorstimulated neurite extension (Tsai et al., 2010) and to anti-nociceptive responses via its action
within this anatomical region (Xu et al., 2004).
Hypotheses: RGS12 loss in the spinal cord drives altered nociception given KOR-mediated
G protein hypersensitivity and barr hyposensitivity; RGS12 loss increases sensitivity to the
antinociceptive and anti-pruritic effects of KOR agonism; RGS12 loss prevents the development
of tolerance to the antinociceptive effects of repeated KOR agonism (as elicited by either chronic
exogenous applications of KOR agonist or the induction of neuropathic injury).
Approaches:
4.2.3a - (i) Antinociception: To assess if RGS12 regulates KOR activity in the spinal cord, we
will perform the tail immersion test (McLaughlin et al., 2004) (i.e., spinal nociception to thermal
stimulus). Like antinociceptive behaviors in the hot-plate test, increased tail withdrawal latency
following acute KOR agonist administration is considered G protein-dependent but barrindependent (Schattauer et al., 2017; McLaughlin et al., 2004). If RGS12 regulates spinal KOR
signaling, we expect RGS12 deficiency to potentiate KOR agonist-induced antinociception
relative to wildtype controls. In the tail withdrawal test, the distal 1 cm of the tail is immersed in 55
°C water for up to 10 s, and tail withdrawal latency is monitored. Increased tail withdrawal latency
in drug-treated mice can be used to infer the drug’s antinociceptive efficacy. Dose ranges of full
KOR agonists (e.g., U50,488 at 1, 2.5, 7.5, 15, or 30 mg/kg, ip; (Schattauer et al., 2017)) or vehicle
will be separately administered to RGS12-deficient (global RGS12-null and tissue-restricted
knockout) mice and wildtype controls 30 min prior to testing. Initial data with the unbiased/full
KOR agonist U50,488 (Fig. 4.2.3a-1 below) suggest that global RGS12-null mice do have
augmented KOR-induced tail withdrawal latencies, albeit dose-dependently.

166

4.2.3a-1 - RGS12-null mice exhibit augmented spinal antinociception to the KOR agonist in
a dose-dependent manner.

Fig. 4.2.3a-1. RGS12-null mice exhibit augmented spinal antinociception to the KOR
agonist U50,488 at the 2.5 mg/kg dose. Indicated single doses of U50,488 were administered
to global RGS12-null and WT mice prior to the warm water tail immersion test. Data are the mean
± SEM; two-way repeated-measures ANOVA (for within-subjects comparisons) and betweensubjects ANOVA (for between-subjects comparisons) each followed by Sidak’s post hoc test were
performed (n = 5-10 mice/group; *, p < 0.05; **, p < 0.01; ****, p < 0.0001 vs baseline).
Unpublished preliminary data.
4.2.3b - (ii) Antinociceptive tolerance: Opioid-induced antinociception is limited by the
development of tolerance following repeated administration -- a process facilitated by barrdependent downregulation of opioid receptors (Raehal and Bohn, 2014). For example,
antinociceptive tolerance to the MOR agonist morphine is lost in barr-2 knockout mice (Bohn et
al., 2000). Similarly, tolerance to U50,488 is attenuated in GRK3 knockout mice (McLaughlin et
al., 2004), suggesting that KOR-mediated tolerance also relies on a GRK3-/barr-dependent
mechanism. Given our findings that acute KOR-stimulated analgesia (G protein-dependent) is
augmented, yet KOR-induced CPA (barr-dependent) is attenuated in RGS12-null mice (see
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Chapter 3), we hypothesize that RGS12-deficient and barr-2-deficient mouse strains will exhibit
reduced tolerance to repeated KOR agonism.
Approaches: To begin to assess this hypothesis, we would repeatedly administer an
unbiased/full KOR agonist to RGS12-deficient and barr-2-deficient mice (and wildtype littermate
controls), as previously described (McLaughlin et al., 2004). For example, mice will receive
escalating doses of U50,488 (in saline; ip) twice daily for days 1-4 (i.e., 10 & 15, 25 & 30, 50 &
60, and 70 & 75 mg/kg, AM/PM), then given a challenge dose of 25 mg/kg on day 5. Control
groups for both genotypes (gene-deficient and wildtype mice) will receive saline injections, then
acute saline or U50,488 on day 5. Tolerance will be evaluated by decreased nociceptive latency
per the tail immersion test (as above), performed 30 min after each day’s AM injection.
Potential Confounds and Future Pursuits for 4.2.3a and 4.2.3b: It would be advantageous to also
evaluate tolerance in the hot plate assay to assess barr-dependent supraspinal analgesia in light
of our initial data that RGS12-null mice exhibit enhanced sensitivity to acute KOR-induced
analgesia in this assay (Fig. 3.6.4). However, we anticipate that an ascending dose schedule of
an unbiased/full KOR agonist may acutely produce profound motoric dysfunction and lack of
coordination. In the hot plate assay, mice are placed on a 53 °C metal surface and latency to
nociception (licking/shaking of a hindlimb or jumping) recorded. In this way, the behavior indicative
of nociception relies upon motoric action. We have observed motor dysfunction in some mice
receiving 30 mg/kg U50,488; others report that KOR agonists produce dysfunction in coordination
tests, such as rotarod (White et al., 2015). Conversely, tail withdrawal is a spinal-mediated
(reflexive) response (Janssen et al., 1963; Bohn et al., 2002) and, thus, is unaffected by repeated
and/or high doses of KOR agonists (McLaughlin et al., 2004). It is possible that we may not see
differences in tail withdrawal tolerance between RGS12-deficient and wildtype mice if RGS12
regulates KOR-initiated signaling predominantly in supraspinal (e.g., vSTR), and not spinal,
regions. If this outcome manifests, it will be even more important to use data generated by planned
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IHC studies (see Question #2 - Alternative IHC-based approach in parallel) to better predict those
specific CNS regions in which RGS12 modulates KOR signaling, and then correlate those findings
to observed behaviors following KOR agonism relevant to the regions identified.

4.2.3c - Anti-pruritus:
Rationale: KOR activation produces anti-pruritic effects via action within DRG neurons of the
spinal cord (Ross et al., 2010; Kardon et al., 2014). Intractable itch can occur secondary to
disease (e.g., chronic renal failure (Simonsen et al., 2017)) or after neuraxial opioid administration
(Ko, 2015) and often requires clinical intervention. KOR agonists mitigate itch in humans and
rodents (Kumagai et al., 2012; Morgenweck et al., 2015). Conversely, KOR antagonists induce
itch (Kamei and Nagase, 2001; Inan et al., 2009), but this effect is only partially attenuated in
KOR-knockout

mice,

suggesting

that

KOR-independent

mechanisms

also

contribute

(Morgenweck et al., 2015). The KOR-selective G protein-biased (Schattauer et al., 2017) agonist
nalfurafine is approved in Japan to treat pruritus in hemodialysis patients (Kumagai et al., 2012);
the newer G protein-biased KOR agonist, triazole 1.1, also retains the anti-pruritic efficacy of
unbiased KOR agonists (Brust et al., 2016), underscoring the concept that KOR-induced antipruritus may be G protein-dependent and barr-independent.
Hypothesis: RGS12-deficient mouse strains will exhibit increased anti-pruritic responses to a
conventional (unbiased) KOR agonist relative to controls, given our findings that RGS12 loss
engenders KOR-mediated G protein signaling hypersensitivity and barr signaling hyposensitivity
(see Chapter 3)
Approach: We would evaluate KOR-induced anti-pruritus as previously described (Brust et al.,
2016; Schlosburg et al., 2009; Schlosburg et al., 2011). Briefly, RGS12-deficient and wildtype
control mice will be injected with an unbiased KOR agonist (see dose considerations below), and
injected 10 min later with either vehicle or the pruritus-inducing agent chloroquine phosphate (CP,
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40 mg/kg, sc midscapular (Kuraishi et al., 1995) or nape of neck (Morgenweck et al., 2015)).
Hindlimb scratching bout frequency and duration will be quantified in 5-min bins over 1 hr by a
genotype-blinded investigator. Given the potentially subjective nature of these scoring
procedures, a subset of videos will need to be re-scored by an independent investigator to ensure
intra- and inter-observer reliability.
Potential Confounds and Methods Considerations for Anti-Pruritus Testing: Studies of KOR
agonist-induced anti-pruritus often precipitate scratching with the KOR antagonists nor-BNI or
5'GNTI (Brust et al., 2016; Schattauer et al., 2017; Morgenweck et al., 2015). KOR antagonistinduced itch is preserved (albeit reduced) in KOR-deficient mice, and is attenuated in barr-2deficient mice (Morgenweck et al., 2015), suggesting that itch produced by KOR antagonists is,
at least in part, KOR-independent and barr-2-dependent. Conversely, CP-induced itch (KORindependent) is robustly inhibited by G protein-biased KOR agonists, and this effect of KOR
agonism is unaltered in barr-2-deficient mice (Brust et al., 2016), supporting the notion that the
anti-pruritic effect of KOR agonism on CP-stimulated itching is G protein-dependent. Thus, we will
evaluate (at least initially) KOR agonist-induced anti-pruritus to CP (i.e., not to KOR antagonism)
to assess whether RGS12-deficient mouse strains exhibit KOR-mediated G protein
hypersensitivity in this spinal-dependent behavior. We will also consider the polycationic mast cell
degranulator compound 40/80 to precipitate scratching behavior (via localized histamine release
(Schlosburg et al., 2009; Schlosburg et al., 2011), as an additional alternative to avoid using KOR
antagonists.
U50,488 administration prior to CP injection robustly suppresses CP-induced itch (Brust et al.,
2016) at doses as low as 1 mg/kg U50,488. Thus, 1 mg/kg will be the highest dose in initial
U50,488 dose-response trials, systematically decreased until we identify the lowest U50,488 dose
that does not affect wildtype littermate controls. We will then test whether matched RGS12deficient mice display reduced scratching at this lowest U50,488 dose, which would suggest that

170
RGS12 loss increases KOR-mediated G protein signaling sensitivity, as first seen in previous
experiments (Fig. 3.6.2 & Fig. 3.6.4). Future studies should seek to replicate the effect using
nalfurafine instead of U50,488, because nalfurafine is approved in Japan for treatment of pruritus
and is a G protein-biased KOR agonist (Schattauer et al., 2017; Kumagai et al., 2012).

4.2.3d - Neuropathic pain
Rationale: Peripheral nerve damage causes neuropathic pain (Zimmermann, 2001) by producing
hyperalgesia (increased pain response to noxious stimuli), allodynia (pain response to innocuous
stimuli), and spontaneous pain. Such neuropathic pain increases acute and prolonged dynorphin
release and increases KOR activation within the dorsal horn (Xu et al., 2004; Wagner et al., 1993;
Wang et al., 2001). Antagonism or genetic deletion of KOR enhances hyperalgesia (Xu et al.,
2004; Obara et al., 2003) and allodynia (Xu et al., 2004) following chronic constriction injury (CCI)
of the sciatic nerve, an established rodent model of neuropathic pain (Jaggi et al., 2011). These
data suggest that neuropathic injury-induced KOR activation in the spinal cord by endogenous
dynorphins helps mitigate increased nociception following damage.
Approach: To test whether RGS12 functions in the spinal cord to modulate dynorphin/KORrelated reductions of neuropathic pain, we will perform CCI surgeries (in collaboration with the
Kinsey lab) on RGS12-deficient mouse strains (both global and tissue-restricted knockouts), and
compare resultant hyperalgesia (e.g., Hargreaves’ plantar stimulator test), and mechanical (e.g.,
von Frey filament) and cold (acetone-induced) allodynia vs wildtype littermate controls using
established techniques in measuring rodent neuropathic pain (Crowe et al., 2017; Crowe et al.,
2015; Kinsey et al., 2010; Kinsey et al., 2013; Wilkerson et al., 2016). Unpublished pilot data (from
the Kinsey lab) suggest that global RGS12 deficiency indeed leads to reduced allodynia postCCI; this finding supports the notion that RGS12 loss may reduce sciatic nerve injury-induced
allodynia by augmenting KOR-mediated antinociception.
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Fig. 4.2.3d-1. RGS12-null mice exhibit attenuated allodynia after CCI.

Fig. 4.2.3d-1. RGS12-null mice exhibit attenuated allodynia after CCI. Wildtype mice (Rgs12+/+;
n = 16) and RGS12-null mice (Rgs12-/-; n = 20) each received a chronic constriction injury of the
right sciatic nerve. After the indicated elapsed time, resultant mechanical allodynia (paw
withdrawal threshold [PWT]) was assessed at the right hind paw using a series of von Frey
filaments as previously described (Kinsey et al., 2010; Kinsey et al., 2013; Crowe et al., 2015;
Crowe et al., 2017; Wilkerson et al., 2016); mean contralateral (left paw control) withdrawal
thresholds are graphically represented as the horizontal dotted line. *, p < 0.05, from unpaired ttest comparing right hind paw PWT between genotypes. Unpublished preliminary data produced
by Floyd Steele, PhD candidate in the Kinsey lab, using mice provided by the Siderovski and
Setola labs.
To first test KOR mediation of post-CCI nociception differences in RGS12-deficient mice, we
will pretreat mice with KOR antagonist (e.g., the long-lasting, irreversible KOR antagonist norBNI) prior to testing hyperalgesia (Hargreaves’ plantar stimulator test) and allodynia (e.g., as
performed in Fig. 4.2.3d-1 above) at 7, 11, and 14 days post CCI injury. Systemic nor-BNI is seen
to reverse KOR-mediated antinociception for up to 14-21 days post-injection (Bruchas et al.,
2007b; Patkar et al., 2013); thus, a single administration of nor-BNI (10 mg/kg, ip, dissolved in
saline) 24 hours prior (i.e., day 1) to CCI surgery (day 0) should suffice to ascertain whether any
effects engendered by RGS12 deficiency are dynorphin/KOR-mediated. As an alternative to the
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use of nor-BNI, we could also consider JDTic (Bruchas et al., 2007b; Munro et al., 2012); however,
we would avoid employing 5’-GNTI owing to its off-target PAM effect at the a1A-adrenergic
receptor (Munro et al., 2013).
CCI is reported (Xu et al., 2004) to reduce the ability of exogenous KOR agonists to attenuate
the hyperalgesia and allodynia that result after nerve injury; this phenomenon of reduced KOR
agonism affecting post-CCI is considered consistent with the development of tolerance to KOR
agonism-induced antinociception observed in the tail immersion test (McLaughlin et al., 2004).
Moreover, this reduced KOR agonism effect post-CCI is lost in GRK3-deficient mice and thus
considered barr-dependent (Xu et al., 2004). Therefore, our initial observation of reduced CCIinduced allodynia in global RGS12-null mice may be due, at least in part, to attenuated KORmediated barr signaling in the absence of RGS12 and, therefore, reduced development of
KOR tolerance that normally occurs in response to prolonged dynorphin release elicited by CCI
(Xu et al., 2004; Kajander et al., 1990; Malan et al., 2000; Gardell et al., 2004). This notion is
consistent with our observation that RGS12 deficiency attenuates KOR agonist-induced CPA
(considered a barr-dependent behavior; Fig. 3.6.4) and, conversely, RGS12 over-expression
greatly enhances barr recruitment to activated KOR in vitro (Fig. 3.6.3).
Thus, to evaluate whether global or tissue-restricted RGS12-deficient mice exhibit diminished
barr-dependent KOR tolerance related to neuropathic pain, we will perform CCI (and sham)
surgeries on RGS12-deficient and wildtype littermate mice, and then assess at 7, 11, and 14 days
post-CCI hyperalgesia and mechanical/cold allodynia following acute administration of KOR
agonists (e.g., U50,488 in escalating doses). We would suspect that RGS12 deficiency will
attenuate (or abolish) the potency reduction (rightward EC50 shift) normally seen in KOR agonistinduced antinociception post-CCI (i.e., as seen in GRK3-null mice (Xu et al., 2004)); such
observations would support a role for RGS12 in facilitating barr-dependent KOR tolerance.
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Potential Confounds and Future Directions for Neuropathic Pain Assessment: Peripheral nerve
injury can also lead to supraspinal KOR activation (Abraham et al., 2000; Narita et al., 2006; Cahill
et al., 2014), which may modulate spinally mediated nociceptive behaviors. For example, some
evidence (Cahill et al., 2014) suggests that chronic pain is regulated by KOR-dependent
modulation of mesolimbic DA, proposed to govern the negative affect experienced during pain
and thus contribute to nociceptive responsiveness following neuropathic injury. Because we have
evidence that the disrupted mesolimbic DAergic neurotransmission observed in RGS12-null mice
is KOR-mediated (Fig. 3.6.1), it is plausible that any behavioral effects observed in neuropathic
pain assays may be due, at least in part, to central effects of KOR (e.g., in the mesolimbic DA
system), rather than direct spinal cord effects. Thus, if systemically administered KOR antagonist
blocks the attenuation of CCI-induced nociceptive responses in RGS12-deficient mice (e.g., Fig.
4.2.3d-1 above), we will then test whether this reversal is due specifically, or in part, to changes
in KOR signaling in the ventral striatum caused by RGS12 loss. To test this, we would locally
deliver KOR antagonist (e.g., 100 nM nor-BNI) or saline into the vSTR by reverse dialysis, as
previously described (Gray et al., 1999; Yang et al., 2015; Virk et al., 2016). Briefly, we would
perform stereotaxic surgery on RGS12-deficient mice and wildtype littermates to implant dialysis
probes into the vSTR. Following surgical recovery, we would administer KOR antagonist or
vehicle via reverse dialysis 24 hours prior to CCI surgery. Following 7, 11, and 14 days post-CCI,
we would perform nociceptive testing of hyperalgesia (as above for experiments using
systemically administered KOR antagonist) and allodynia (e.g., as in Fig. 4.2.3d-1 above). Like
systemic administration, nor-BNI delivered directly into the CNS remains detectable (Patkar et al.,
2013) in mouse brain for up to 21 days. Thus, a single administration of nor-BNI by reverse
dialysis should be sufficient to antagonize KOR for the duration of the experiment.
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4.2.4 - Question 4: Do RGS12 and KOR associate via a PDZ-mediated interaction?
Rationale: An early paper on RGS12 from the Siderovski lab (Snow et al., 1998) described the
binding specificity of its PDZ domain and noted a high degree of sequence similarity between the
RGS12 PDZ domain and the first PDZ domain of NHERF1. Subsequent work (Li et al., 2002) has
shown that NHERF1 directly binds a PDZ-recognition site at the KOR C-terminus (amino acids
376-380: -NKPV), but does not bind MOR (which lacks this C-terminal sequence; e.g., Fig. 10);
furthermore, NHERF1 over-expression is reported (Li et al., 2002) to impact both KOR agonistinduced signaling and KOR trafficking/recycling. Thus, the first plausible candidate for
investigating the molecular determinant(s) of selectivity of RGS12 action on KOR is a PDZ
domain/C-terminal interaction, similar to that of the NHERF1/KOR interaction (Li et al., 2002). Our
initial evidence using a KOR mutant with the last four amino acids of the wildtype KOR C-terminus
mutated to alanines (NKPV à AAAA), as well as a gain-of-function MOR mutant containing KOR's
wildtype C-terminus in substitution of its native C-terminal sequence (MORAPLP>NKPV), supports
that the effects of RGS12 on KOR-mediated G protein signaling are PDZ-dependent (Fig. 3.6.3).
Approach: Bioluminescence resonance energy transfer (BRET): To help visualize potential
interactions between RGS12 and KOR in a real-time, cellular context, we would initiate BRET
analyses using Promega’s NanoBRET system (Machleidt et al., 2015), similar to prior studies
from the Siderovski lab (Giguere et al., 2012; Giguere et al., 2014) interrogating GPSM3
interactions with NLRP3, 14-3-3, and G protein subunits. The Siderovski group has previously
established (Willard et al., 2007) that RGS12 can be modified at either the N- or C-terminus with
a fusion protein (e.g., YFP or CFP) while retaining normal subcellular localization and cellular
function. To leave the KOR C-terminus unperturbed*, we would likely engineer the NanoLuc or
HaloTag fusion in the receptor’s third intracellular loop (Wu et al., 2012). We should also test
placing the NanoLuc or HaloTag fusion in the first or second intracellular loops, or within the Cterminus (prior to the final -NKPV sequence). To test interaction specificity, MOR, DOR, and D2R
would need to be tagged in the same fashion as the optimized KOR construct. Initial experiments
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will test whether RGS12 is located in close proximity to KOR under basal and/or KOR agoniststimulated conditions. Mutagenesis studies (subaim (i) above) will inform further BRET construct
development to elucidate those key determinants underlying any observed intracellular BRET
between RGS12 and KOR.
Potential Confounds and Future Pursuits: *Caveat: To facilitate the Tango assay (Barnea et al.,
2008) GPCR ORFs like that of KOR are cloned with C-terminal fusions: i.e., the vasopressin V2R
tail, a TEV protease cleavage site, and a tTa transcription factor; this C-terminal extension
prevents the KOR NKPV PDZ sequence from being displayed at the extreme C-terminus of the
resultant GPCR fusion protein. However, there is ample evidence (Gee et al., 1998; Penkert et
al., 2004; Wong et al., 2003; London et al., 2004) that PDZ domains also recognize internal
peptide sequences (e.g., PDZ domains of syntrophin, Par-6, and Dishevelled).
One possible outcome is that a PDZ-mediated interaction between RGS12 and KOR is
established that critically depends on the free -NKPV C-terminus of KOR and, thereby, only
affects G protein-dependent signaling and not barr interaction. RGS12 might augment barr
interaction with KOR through a PDZ domain-independent protein segment, or alternatively,
through regulating a specific signaling process (independent of the RGS domain and GoLoco
motif;

Fig.
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other

receptors.

barr recruitment can engage myriad kinases, including tyrosine kinases (e.g., c-Src (Fan et al.,
2001; Ribas et al., 2007)) and Ras-dependent MAPKs (Eishingdrelo and Kongsamut, 2013;
Claing, 2013). Thus, RGS12 may augment barr recruitment by enhancing tyrosine
phosphorylation- and/or Ras-dependent signaling events via its PTB domain and/or tandem
RBDs, respectively. Dissecting these particular molecular determinants would proceed in a similar
fashion to what is articulated above for the “PDZ domain hypothesis.” For example, the Siderovski
group previously characterized (Uhlik et al., 2005) the RGS12 PTB domain as belonging to a new
subclass with unique electrostatics, and also established (Willard et al., 2007) a loss-of-function
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mutation (H995L) to the first RBD of RGS12 that reduces binding to H-Ras without abrogating
Raf association. If required, unbiased determinations of previously unidentified RGS12-interacting
partners would be performed to generate additional hypotheses as to the nature of the selective
RGS12 / KOR interaction, similar to the proteomics and yeast two-hybrid screens that the
Siderovski group has successfully performed for RGS12 and GPSM3 interactants (Willard et al.,
2007; Giguere et al., 2012; Giguere et al., 2014).
If the effect of RGS12 on KOR-mediated signaling is dependent on a PDZ-mediated
interaction, we could consider using CRISPR / Cas9-based genome editing to induce a
quadruple-alanine mutation to the KOR C-terminus (KOR NKPV>AAAA) within the mouse Oprk1 gene
and thereby assess whether abrogating PDZ-dependent interactions with the KOR C-terminus
will reproduce the KOR signaling and DA homeostasis imbalance phenotypes observed upon
global loss of RGS12 (e.g., Figs. 7-9, 12, and other phenotypes as described (Gross et al., 2018)).
This pursuit would not be able to directly implicate RGS12 alone in any KOR- and/or DA-related
phenotypes we observe in KOR NKPV>AAAA mice, given that NHERF1 and GEC1 are also assumed
to bind KOR using this motif (Huang et al., 2004; Chen et al., 2006). However, if we were to
demonstrate that KOR NKPV>AAAA mice phenocopy some of the deficiencies/perturbations of one or
more RGS12-deficient mouse strains, it will nonetheless provide strong correlative evidence that
PDZ domain-dependent interactions between KOR and RGS12 account for at least some of the
behavioral and biochemical disruptions observed upon RGS12 loss.

4.2.5 - Question 5: Which specific brain regions and protein domains are responsible for
the disruptions to DA and KOR function observed with global RGS12-null mice?
Rationale: To make the case for RGS12 as a valid target for future drug discovery towards small
molecule-mediated modulation of KOR agonist functional selectivity, a demonstration of reversal
of mouse biochemical and behavioral deficits elicited by RGS12 deficiency is a required
milestone. To date, no validated chemical probe for RGS12 modulation has yet been established.
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Thus, a genetic rescue strategy is required for a proof-of-principle demonstration of the region
specificity of RGS12 in select biochemical and/or behavioral outcomes: i.e., viral transduction of
RGS12 into select CNS regions of RGS12-deficient mouse strains.
Hypothesis: (1) Targeted re-expression of wildtype RGS12 will reverse or attenuate one or more
of the behavioral deficits elicited by Rgs12 ablation; (2) re-expression of RGS12 loss-of-function
mutants will ascertain the importance of select protein-protein interactions to such function by
RGS12 in vivo.
Approach: Given the <5 kb packaging restriction of adeno-associated viruses (Shevtsova et al.,
2005) vs the >4 kb size of the Rgs12 open-reading frame (NCBI NM_173402), lentiviruses
expressing epitope-tagged, wildtype RGS12 will need to be constructed, purified, and titered.
The Siderovski group has previously found that fluorescent protein-tagging RGS12 at either N- or
C-termini has no effect on RGS12 expression or function (Willard et al., 2007); GFP onlyexpressing lentivirus will be used as a negative control. To evaluate RGS12 function in select
neuronal populations, lentivirus transducing Rgs12 from cell type-specific promoters (e.g., DAT
promoter for striatal DA neurons) will be constructed pending success in reversing behavioral
deficits with RGS12 expressed from a more global PGK or synapsin1A promoter.
Expectations and Future Pursuits - For one or more of the observed, CNS-centered, behavioral
deficits seen upon global RGS12 loss (see Chapter 2 & Chapter 3), we expect viral-mediated
restoration of vSTR RGS12 expression to normalize these behaviors. While we cannot overlook
the possibility that constitutive RGS12 loss causes aberrant mouse behavior owing to a pleiotropy
of dysfunctions (e.g., across multiple CNS regions and circuits; across a lengthy
neurodevelopmental time-span), our expectation above arises from the unique effects that
RGS12 loss (and barr-2 loss) is seen to engender for KOR specifically within the vSTR (Fig. 3.6.13.6.3). If reversal by viral-mediated RGS12 re-expression in the vSTR is seen for deficits
attributable to RGS12 deficiency, the mesolimbic circuitry and DAT-dependent functions of virally
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infected mice will then be assessed biochemically to test whether behavior reversal by RGS12
re-expression is correlated with normalization of mesolimbic DA neurotransmission (i.e.,
particularly DAT function and expression). Furthermore, evidence of reversal by wildtype RGS12
re-expression would allow subsequent delivery of loss-of-function point mutants of RGS12 in
head-to-head comparison with wildtype RGS12 to identify particular protein functions critical to
RGS12 action in this context. These loss-of-function mutants will come from results of the
experimental pursuits from Question 4 above, as well as prior studies of the Siderovski lab that
have validated several loss-of-function point mutations, including a charge reversal (E740K) that
eliminates RGS domain GAP activity (Sambi et al., 2006), an Arg-to-Phe change (R1206F) to the
GoLoco motif which eliminates Ga binding and endosomal targeting of RGS12 (Sambi et al.,
2006), and a His-to-Leu change (H995L) to the first Ras-binding domain that reduces RGS12
binding to activated H-Ras without abrogating Raf kinase association (Willard et al., 2007).

4.2.6 - Question 6: How does RGS12 regulate psychostimulant-evoked DA levels in vivo?
Rationale: Reduced hyperlocomotion in RGS12-null mice to psychostimulants (Fig. 2.6.2)
suggests that RGS12 is involved in drug-induced increases in extracellular DA levels in the live
organism. These behavioral outcomes are correlated with disruptions in DAT radioligand binding,
[3H]DA uptake, and [3H]DA efflux (Chapter 2) -- all measures of ex vivo transporter
function/activity. Although drug-induced [3H]DA release in synaptosomes provides valuable
information for ascertaining biochemical processes disrupted upon RGS12 loss, it cannot reflect
neurotransmission in the animal with intact neurocircuitry. Thus, future studies should employ in
vivo microdialysis -- continuous sampling of extracellular contents (e.g., monoaminergic
neurotransmitters such as DA, 5-HT, norepinephrine [NE]) in live, awake RGS12-null and wildtype
animals, rather than post-mortem preparations.
Approach: - Psychostimulant (e.g., AMPH, METH)-induced DA release should be assessed by in
vivo microdialysis as previously performed by members of our lab (Doly et al., 2008). Specifically,
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mice would undergo stereotaxic surgery to implant microdialysis probes in dSTR and vSTR with
coordinates from the Paxinos atlas. Upon recovery from surgery, mice would be injected with
releasing agents (e.g., AMPH, METH) and dialysate collected every 10 minutes over 190 minutes.
DA concentrations in dialysates would then be determined by HPLC with electrochemical
detection. Additional studies with other psychostimulants that produce deficient hyperlocomotor
responses in RGS12-null mice (e.g., cocaine) should also be examined.
Expectations and Future Plans: AMPH- and METH-induced DA release is likely significantly
attenuated in RGS12-null mice, given reduced hyperlocomotion to these drugs (Fig. 2.6.2 &
unpublished observations for METH). However, AMPH and METH-also exhibit appreciable affinity
for the 5-HT (SERT) and NE transporter (NET), and induce transport reversal through these
transporters (Steinkellner et al., 2011). To rule out any contribution of altered 5-HT or NE release
to reduced hyperlocomotion of RGS12-null mice, we would need to also employ the microdialysis
outlined here to evaluate SERT and NET function in RGS12-null mice (i.e., drug-induced changes
in 5-HT and NE levels in relevant brain regions) and thereby assess the possible contribution of
this molecular target to reduced AMPH-/METH--induced hyperlocomotion.
Potential Limitations and Control Experiment(s): Microdialysis is limited by poor temporal
resolution (10 min collection intervals are most often employed) vs other techniques like
voltammetry (Chefer et al., 2009). Thus, microdialysis may not fully reflect real-time monoamine
neurotransmitter dynamics. However, we have found RGS12-null mice have reduced
hyperlocomotion to AMPH-like drugs over an 80 min period (e.g., post-drug; Fig. 2.6.2).
Therefore, dialysate collection in 10-min intervals should still inform whether perturbations in
monoamine neurotransmitter dynamics are related to the reduced hyperlocomotion to AMPH-like
drugs of RGS12-null mice. Also, stereotaxic implantation of a probe is invasive and can damage
tissue, which could result in disrupted behavioral responses independent of drug-treatment. To
verify that behaviorally-salient damage has not occurred, spontaneous locomotor activity ought
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to be measured in probe implanted, saline-treated RGS12-null and wildtype mice and compared
to saline-treated mice that have not undergone stereotaxic surgery.

4.2.7 - Question 7: Does RGS12 modulate SERT expression/function and serotonergic
behaviors via KOR-dependent mechanism(s)?
Rationale: We have shown that increased DAT expression and DA uptake, as well as reduced
AMPH-induced hyperlocomotion, are reversed following antagonism of KOR (Fig. 3.6.1).
Similarly, RGS12-null mice exhibit increased SERT expression and 5-HT uptake in a regiondependent manner, and these effects correlate with disrupted MDMA-induced hyperlocomotion
(unpublished

observations)

and

several

other

5-HT-dependent

behaviors

(stress-

coping/depression-like behavior, anxiety, and social interaction -- unpublished observations).
Chronic stress (with concomitantly increased endogenous dynorphin release and KOR activation)
and KOR agonists have been shown to increase plasmalemmal SERT expression and SERTmediated 5-HT uptake in a region-dependent manner and these changes are proposed to underlie
a 'depression-like' phenotype (Schindler et al., 2012). Thus, it is reasonable to suspect that
augmented SERT function and expression in RGS12-null mice is related to increased KOR
expression/sensitivity and that these alterations to the serotonergic system underlies the
observed disruptions to 5-HT-dependent behaviors (i.e., MDMA-induced locomotor activity,
forced swim stress, tail suspension stress, elevated zero/plus maze, and social interaction).
Hypothesis: KOR blockade is sufficient to reverse or rescue SERT dysfunction and perturbation
of 5-HT-dependent behaviors in RGS12-null mice.
Approach: Experiments will be designed exactly as described for studies evaluating DAT
expression, [3H]DA uptake, and AMPH-induced hyperlocomotion (Fig. 3.6.1), except that KOR
antagonist (nor-BNI, 10 mg/kg, 24-hour pretreatment, ip)-treated RGS12-null and wildtype mice
will be evaluated for (1) [3H]citalopram saturation binding to SERT, (2) SERT-mediated [3H]5-HT
uptake, (3) MDMA-induced [3H]5-HT efflux, (4) MDMA (10 and 30 mg/kg)-induced locomotor
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activity, (5) forced swim stress, (6) tail suspension stress, (7) elevated zero and/or plus maze,
and (8) social interaction as per methods employed previously (Doly et al., 2008; Jin et al., 2017;
Bey et al., 2018). Additionally, future studies of serotonergic neurotransmission and behavior
should employ the use of the KOR::Cre-Rgs12 floxed mouse strain described above (in section
4.2.1), as this strategy could help determine whether RGS12 impacts serotonergic function via
action specifically within KOR-expressing neurons.
Expectations and Future Pursuits: Given our observations with the effect of RGS12 on DAT (Fig.
3.6.1) and prior work by others demonstrating that KOR induces similar effects on SERT
(Schindler et al., 2012), we would suspect that KOR antagonism would reverse the SERT
dysfunction (i.e., SERT radioligand binding, 5-HT uptake, 5-HT efflux, and MDMA-induced
locomotor activity) observed in RGS12-null mice (unpublished observations). Given that the
disruptions to 5-HT-dependent behavioral outcomes (i.e., forced swim stress, tail suspension
stress, elevated zero and/or plus maze, and social interaction) in RGS12-null mice (unpublished
observations) is drug-independent (i.e., these are basal phenotypes of the mouse strain absence
any drug application), it is reasonable to suspect that these phenotypes may manifest via one or
more different neurobiological perturbations, even if these behaviors all are strongly associated
with serotonergic neurotransmission. Thus, if KOR antagonism is not sufficient to reverse or
rescue any of these behavioral perturbations, future studies will require additional
pharmacological intervention, including (but not limited to) direct manipulation of the serotonergic
system (i.e., KOR-independent 5-HT neurotransmission) with selective serotonin reuptake
inhibitors (SSRIs) and/or specific 5-HT receptor agonists/antagonists. With respect to the latter,
initial studies should employ the use of agonists/antagonists selective for Gai/o-coupled 5-HT
receptors (e.g., 5-HT receptor 1A [HTR1A]), given the specificity of RGS12 for this Ga subunit
subtype.
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APPENDIX A
RGS12 and Prepulse Inhibition
Appendix A.1 - Deletion of schizophrenia-associated gene RGS12 in mice results in
baseline prepulse inhibition deficiencies that are not reversed by antipsychotics
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Figure Appx. A.1. Deletion of the schizophrenia-associated gene RGS12 (Xu et al., 2011;
Guipponi et al., 2014) in mice produces baseline deficiencies in prepulse inhibition that are not
reversed by several different antipsychotics. (A) Baseline prepulse inhibition of acoustic startle
(% PPI) in RGS12-null (Rgs12-/- - open bars) and wildtype littermate control (Rgs12+/+ - closed
bars) mice to four different prepulse intensities: 4 (PP4), 8 (PP8), 12 (PP12), and 16 (PP16)
decibels (dB) above background noise (65 dB). Data were analyzed by two-way ANOVA (n = 1419 mice per group). (B) Average baseline startle amplitude (millivolts, mV) (a measure of startle
reactivity) across three blocks of a complete PPI session in RGS12-null and wildtype littermate
controls. Block 1 consisted of 6 sequential startle pulse-only (120 dB) white noise bursts at the
beginning of the session, Block 2 consisted of 12 startle pulse-only exposures interspersed
pseudorandomly throughout the PPI session, and Block 3 consisted of 6 sequential startle pulseonly exposures at the end of the PPI session. Data were analyzed by two-way ANOVA (n = 18
mice per group) (C) PPI following vehicle, acute (0.1 mg/kg, 30-min pretreatment, ip), or repeated
(0.5 mg/kg, 14 consecutive days, once/day, ip) administration of the prototypical 1st generation
antipsychotic haloperidol (a dopamine D2 receptor antagonist) in wildtype (left panel) and RGS12null (right panel) littermate controls. Data were analyzed by two-way ANOVA (n = 8-10 mice per
group) (D) PPI following vehicle or acute administration of the prototypical 2nd generation
antipsychotic clozapine (a serotonin 5-HT2A and dopamine D2 receptor antagonist) at various
doses (0.5, 1.0, or 2.0 mg/kg, 30-min pretreatment, ip) in wildtype (left panel) and RGS12-null
(right panel) littermate controls. Data were analyzed by two-way ANOVA (n = 4-18 mice per group)
(E) PPI following vehicle or acute administration of the prototypical 3rd generation antipsychotic
aripiprazole (a serotonin 5-HT2A and dopamine D2 receptor partial agonist) at various doses (1.0
or 3.0 mg/kg, 30-min pretreatment, ip) in wildtype (left panel) and RGS12-null (right panel)
littermate controls. Data were analyzed by two-way ANOVA (n = 6-7 mice per group) All data are
the mean +/- SEM. * p < 0.05, ** p < 0.01, p < 0.0001.
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Appendix A.2 - Deletion of schizophrenia-associated gene RGS6 in mice does not alter
baseline prepulse inhibition or startle reactivity
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Figure Appx. A.2. Deletion of schizophrenia-associated gene RGS6 (Schizophrenia Working
Group of the Psychiatric Genomics, 2014) in mice does not alter prepulse inhibition or startle
reactivity. (A) Baseline prepulse inhibition of acoustic startle (% PPI) in constitutive RGS6-null
(Rgs12-/- - open bars) and wildtype littermate control (Rgs6+/+ - closed bars) mice to four different
prepulse intensities: 4 (PP4), 8 (PP8), 12 (PP12), and 16 (PP16) decibels (dB) above background
noise (65 dB). Analysis by two-way ANOVA revealed no significant differences between
genotypes (n = 10-12 mice per group; p > 0.05). (B) Average baseline startle amplitude (millivolts,
mV) (a measure of startle reactivity) across three blocks of a complete PPI session in RGS12null and wildtype littermate controls. Analysis by two-way ANOVA revealed no significant
differences between genotypes (n = 10-12 mice per group; p > 0.05).
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